<!DOCTYPE html>
<html lang="en" class="no-js">
    <head>
        <title>Myeloid malignancies: mutations, models and management | BMC Cancer | Full Text</title>

        
    
        
    


        
        
    
    <meta name="journal_id" content='12885'/>
    
    <meta name="dc.title" content='Myeloid malignancies: mutations, models and management'/>
    
    <meta name="dc.description" content='Myeloid malignant diseases comprise chronic (including myelodysplastic syndromes, myeloproliferative neoplasms and chronic myelomonocytic leukemia) and acute (acute myeloid leukemia) stages. They are clonal diseases arising in hematopoietic stem or progenitor cells. Mutations responsible for these diseases occur in several genes whose encoded proteins belong principally to five classes: signaling pathways proteins (e.g. CBL, FLT3, JAK2, RAS), transcription factors (e.g. CEBPA, ETV6, RUNX1), epigenetic regulators (e.g. ASXL1, DNMT3A, EZH2, IDH1, IDH2, SUZ12, TET2, UTX), tumor suppressors (e.g. TP53), and components of the spliceosome (e.g. SF3B1, SRSF2). Large-scale sequencing efforts will soon lead to the establishment of a comprehensive repertoire of these mutations, allowing for a better definition and classification of myeloid malignancies, the identification of new prognostic markers and therapeutic targets, and the development of novel therapies. Given the importance of epigenetic deregulation in myeloid diseases, the use of drugs targeting epigenetic regulators appears as a most promising therapeutic approach.'/>
    
    <meta name="dc.source" content='BMC Cancer 2012 12:1'/>
    
    <meta name="dc.format" content='text/html'/>
    
    <meta name="dc.publisher" content='BioMed Central'/>
    
    <meta name="dc.date" content='2012-07-23'/>
    
    <meta name="dc.type" content='ReviewPaper'/>
    
    <meta name="dc.language" content='En'/>
    
    <meta name="dc.copyright" content='2012 Murati et al.; licensee BioMed Central Ltd.'/>
    
    <meta name="dc.rights" content='http://creativecommons.org/licenses/by/2.0'/>
    
    <meta name="dc.rightsAgent" content='reprints@biomedcentral.com'/>
    
    <meta name="prism.issn" content='1471-2407'/>
    
    <meta name="prism.publicationName" content='BMC Cancer'/>
    
    <meta name="prism.publicationDate" content='2012-07-23'/>
    
    <meta name="prism.volume" content='12'/>
    
    <meta name="prism.number" content='1'/>
    
    <meta name="prism.section" content='ReviewPaper'/>
    
    <meta name="prism.startingPage" content='304'/>
    
    <meta name="prism.copyright" content='2012 Murati et al.; licensee BioMed Central Ltd.'/>
    
    <meta name="prism.rightsAgent" content='reprints@biomedcentral.com'/>
    
    <meta name="prism.url" content='https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-304'/>
    
    <meta name="citation_pdf_url" content='https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-12-304?site=bmccancer.biomedcentral.com'/>
    
    <meta name="citation_abstract_html_url" content='https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-304'/>
    
    <meta name="citation_fulltext_html_url" content='https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-304'/>
    
    <meta name="citation_journal_title" content='BMC Cancer'/>
    
    <meta name="citation_publisher" content='BioMed Central'/>
    
    <meta name="citation_issn" content='1471-2407'/>
    
    <meta name="citation_title" content='Myeloid malignancies: mutations, models and management'/>
    
    <meta name="citation_volume" content='12'/>
    
    <meta name="citation_issue" content='1'/>
    
    <meta name="citation_date" content='2012/07/23'/>
    
    <meta name="citation_publication_date" content='2012/07/23'/>
    
    <meta name="citation_firstpage" content='304'/>
    
    <meta name="citation_article_type" content='Review'/>
    
    <meta name="citation_fulltext_world_readable" content=''/>
    
    <meta name="dc.creator" content='Anne Murati'/>
    
    <meta name="dc.creator" content='Mandy Brecqueville'/>
    
    <meta name="dc.creator" content='Raynier Devillier'/>
    
    <meta name="dc.creator" content='Marie-Joelle Mozziconacci'/>
    
    <meta name="dc.creator" content='V&#233;ronique Gelsi-Boyer'/>
    
    <meta name="dc.creator" content='Daniel Birnbaum'/>
    
    <meta name="dc.subject" content='Cancer Research'/>
    
    <meta name="dc.subject" content='Oncology'/>
    
    <meta name="dc.subject" content='Surgical Oncology'/>
    
    <meta name="dc.subject" content='Health Promotion and Disease Prevention'/>
    
    <meta name="dc.subject" content='Biomedicine general'/>
    
    <meta name="dc.subject" content='Medicine/Public Health, general'/>
    
    <meta name="citation_author" content='Anne Murati'/>
    
    <meta name="citation_author_institution" content='Centre de Recherche en Canc&#233;rologie de Marseille, laboratoire d&#8217;Oncologie Mol&#233;culaire; UMR1068 Inserm, Institut Paoli-Calmettes, Marseille, France'/>
    
    <meta name="citation_author" content='Mandy Brecqueville'/>
    
    <meta name="citation_author_institution" content='Centre de Recherche en Canc&#233;rologie de Marseille, laboratoire d&#8217;Oncologie Mol&#233;culaire; UMR1068 Inserm, Institut Paoli-Calmettes, Marseille, France'/>
    
    <meta name="citation_author" content='Raynier Devillier'/>
    
    <meta name="citation_author_institution" content='Centre de Recherche en Canc&#233;rologie de Marseille, laboratoire d&#8217;Oncologie Mol&#233;culaire; UMR1068 Inserm, Institut Paoli-Calmettes, Marseille, France'/>
    
    <meta name="citation_author" content='Marie-Joelle Mozziconacci'/>
    
    <meta name="citation_author_institution" content='Centre de Recherche en Canc&#233;rologie de Marseille, laboratoire d&#8217;Oncologie Mol&#233;culaire; UMR1068 Inserm, Institut Paoli-Calmettes, Marseille, France'/>
    
    <meta name="citation_author" content='V&#233;ronique Gelsi-Boyer'/>
    
    <meta name="citation_author_institution" content='Centre de Recherche en Canc&#233;rologie de Marseille, laboratoire d&#8217;Oncologie Mol&#233;culaire; UMR1068 Inserm, Institut Paoli-Calmettes, Marseille, France'/>
    
    <meta name="citation_author" content='Daniel Birnbaum'/>
    
    <meta name="citation_author_institution" content='Centre de Recherche en Canc&#233;rologie de Marseille, laboratoire d&#8217;Oncologie Mol&#233;culaire; UMR1068 Inserm, Institut Paoli-Calmettes, Marseille, France'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Rev Cancer; citation_title=Leukaemogenesis: more than mutant genes; citation_author=J Chen; citation_author=O Odenike; citation_author=JD Rowley; citation_volume=10; citation_publication_date=2010; citation_pages=23-36; citation_id=CR1;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Lancet; citation_title=Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders; citation_author=EJ Baxter; citation_author=LM Scott; citation_author=PJ Campbell; citation_author=C East; citation_author=N Fourouclas; citation_author=S Swanton; citation_author=GS Vassiliou; citation_author=AJ Bench; citation_author=EM Boyd; citation_author=N Curtin; citation_author=MA Scott; citation_author=WN Erber; citation_author=AR Green; citation_volume=365; citation_publication_date=2005; citation_pages=1054-1061; citation_id=CR2;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera; citation_author=C James; citation_author=V Ugo; citation_author=JP Le Couedic; citation_author=J Staerk; citation_author=F Delhommeau; citation_author=C Lacout; citation_author=L Garcon; citation_author=H Raslova; citation_author=R Berger; citation_author=A Bennaceur-Griscelli; citation_author=JL Villeval; citation_author=SN Constantinescu; citation_author=N Casadevall; citation_author=W Vainchenker; citation_volume=434; citation_publication_date=2005; citation_pages=1144-1148; citation_id=CR3;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=A gain-of-function mutation of JAK2 in myeloproliferative disorders; citation_author=R Kralovics; citation_author=F Passamonti; citation_author=AS Buser; citation_author=SS Teo; citation_author=R Tiedt; citation_author=JR Passweg; citation_author=A Tichelli; citation_author=M Cazzola; citation_author=RC Skoda; citation_volume=352; citation_publication_date=2005; citation_pages=1779-1790; citation_id=CR4;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis; citation_author=RL Levine; citation_author=M Wadleigh; citation_author=J Cools; citation_author=BL Ebert; citation_author=G Wernig; citation_author=BJ Huntly; citation_author=TJ Boggon; citation_author=I Wlodarska; citation_author=JJ Clark; citation_author=S Moore; citation_author=J Adelsperger; citation_author=S Koo; citation_author=JC Lee; citation_author=S Gabriel; citation_author=T Mercher; citation_author=A D&#39;Andrea; citation_author=S Frohling; citation_author=K Dohner; citation_author=P Marynen; citation_author=P Vandenberghe; citation_author=RA Mesa; citation_author=A Tefferi; citation_author=JD Griffin; citation_author=MJ Eck; citation_author=WR Sellers; citation_author=M Meyerson; citation_author=TR Golub; citation_author=SJ Lee; citation_author=DG Gilliland; citation_volume=7; citation_publication_date=2005; citation_pages=387-397; citation_id=CR5;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Med; citation_title=Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells; citation_author=BJ Druker; citation_author=S Tamura; citation_author=E Buchdunger; citation_author=S Ohno; citation_author=GM Segal; citation_author=S Fanning; citation_author=J Zimmermann; citation_author=NB Lydon; citation_volume=2; citation_publication_date=1996; citation_pages=561-566; citation_id=CR6;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Adv Hematol; citation_title=Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy; citation_author=AT Fathi; citation_author=O Abdel-Wahab; citation_volume=2012; citation_publication_date=2012; citation_pages=469592; citation_id=CR7;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Hematol Oncol; citation_title=Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases; citation_author=V Gelsi-Boyer; citation_author=M Brecqueville; citation_author=R Devillier; citation_author=A Murati; citation_author=MJ Mozziconacci; citation_author=D Birnbaum; citation_volume=5; citation_publication_date=2012; citation_pages=12; citation_id=CR8;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Hematology Am Soc Hematol Educ Program; citation_title=Genetics of Myelodysplastic Syndromes: New Insights; citation_author=TA Graubert; citation_author=MJ Walter; citation_volume=1; citation_publication_date=2011; citation_pages=543-549; citation_id=CR9;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications; citation_author=G Marcucci; citation_author=T Haferlach; citation_author=H Dohner; citation_volume=29; citation_publication_date=2011; citation_pages=475-486; citation_id=CR10;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Biochim Biophys Acta; citation_title=TET2, a tumor suppressor in hematological disorders; citation_author=T Mercher; citation_author=C Quivoron; citation_author=L Couronne; citation_author=C Bastard; citation_author=W Vainchenker; citation_author=OA Bernard; citation_volume=1825; citation_publication_date=2012; citation_pages=173-177; citation_id=CR11;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F; citation_author=FX Schaub; citation_author=R Jager; citation_author=R Looser; citation_author=H Hao-Shen; citation_author=S Hermouet; citation_author=F Girodon; citation_author=A Tichelli; citation_author=H Gisslinger; citation_author=R Kralovics; citation_author=RC Skoda; citation_volume=113; citation_publication_date=2009; citation_pages=2022-2027; citation_id=CR12;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Hematol Oncol; citation_title=Current findings for recurring mutations in acute myeloid leukemia; citation_author=S Takahashi; citation_volume=4; citation_publication_date=2011; citation_pages=36; citation_id=CR13;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Mutations galore in myeloproliferative neoplasms: Would the real Spartacus please stand up?; citation_author=A Tefferi; citation_volume=25; citation_publication_date=2011; citation_pages=1059-1063; citation_id=CR14;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia; citation_author=F Thol; citation_author=F Damm; citation_author=A Ludeking; citation_author=C Winschel; citation_author=K Wagner; citation_author=M Morgan; citation_author=H Yun; citation_author=G Gohring; citation_author=B Schlegelberger; citation_author=D Hoelzer; citation_author=M Lubbert; citation_author=L Kanz; citation_author=W Fiedler; citation_author=H Kirchner; citation_author=G Heil; citation_author=J Krauter; citation_author=A Ganser; citation_author=M Heuser; citation_volume=29; citation_publication_date=2011; citation_pages=2889-2896; citation_id=CR15;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=New mutations and pathogenesis of myeloproliferative neoplasms; citation_author=W Vainchenker; citation_author=F Delhommeau; citation_author=SN Constantinescu; citation_author=OA Bernard; citation_volume=118; citation_publication_date=2011; citation_pages=1723-1735; citation_id=CR16;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood Cancer Journal; citation_title=Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms; citation_author=M Brecqueville; citation_author=N Cervera; citation_author=J Ad&#233;laide; citation_author=J Rey; citation_author=N Carbuccia; citation_author=M Chaffanet; citation_author=N Vey; citation_author=D Birnbaum; citation_author=A Murati; citation_volume=1; citation_publication_date=2011; citation_pages=e18; citation_id=CR17;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=Mutation in TET2 in myeloid cancers; citation_author=F Delhommeau; citation_author=S Dupont; citation_author=VV Della; citation_author=C James; citation_author=S Trannoy; citation_author=A Masse; citation_author=O Kosmider; citation_author=JP Le Couedic; citation_author=F Robert; citation_author=A Alberdi; citation_author=Y Lecluse; citation_author=I Plo; citation_author=FJ Dreyfus; citation_author=C Marzac; citation_author=N Casadevall; citation_author=C Lacombe; citation_author=SP Romana; citation_author=P Dessen; citation_author=J Soulier; citation_author=F Viguie; citation_author=M Fontenay; citation_author=W Vainchenker; citation_author=OA Bernard; citation_volume=360; citation_publication_date=2009; citation_pages=2289-2301; citation_id=CR18;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Res; citation_title=250&#8201;K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies; citation_author=AJ Dunbar; citation_author=LP Gondek; citation_author=CL O&#39;Keefe; citation_author=H Makishima; citation_author=MS Rataul; citation_author=H Szpurka; citation_author=MA Sekeres; citation_author=XF Wang; citation_author=MA McDevitt; citation_author=JP Maciejewski; citation_volume=68; citation_publication_date=2008; citation_pages=10349-10357; citation_id=CR19;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Genet; citation_title=Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders; citation_author=T Ernst; citation_author=AJ Chase; citation_author=J Score; citation_author=CE Hidalgo-Curtis; citation_author=C Bryant; citation_author=AV Jones; citation_author=K Waghorn; citation_author=K Zoi; citation_author=FM Ross; citation_author=A Reiter; citation_author=A Hochhaus; citation_author=HG Drexler; citation_author=A Duncombe; citation_author=F Cervantes; citation_author=D Oscier; citation_author=J Boultwood; citation_author=FH Grand; citation_author=NC Cross; citation_volume=42; citation_publication_date=2010; citation_pages=722-726; citation_id=CR20;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Br J Haematol; citation_title=Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia; citation_author=V Gelsi-Boyer; citation_author=V Trouplin; citation_author=J Ad&#233;laide; citation_author=J Bonansea; citation_author=N Cervera; citation_author=N Carbuccia; citation_author=A Lagarde; citation_author=T Prebet; citation_author=M Nezri; citation_author=D Sainty; citation_author=S Olschwang; citation_author=L Xerri; citation_author=M Chaffanet; citation_author=MJ Mozziconacci; citation_author=N Vey; citation_author=D Birnbaum; citation_volume=145; citation_publication_date=2009; citation_pages=788-800; citation_id=CR21;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Genet; citation_title=de WT, van der Reijden BA, Jansen JH: Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes; citation_author=G Nikoloski; citation_author=SM Langemeijer; citation_author=RP Kuiper; citation_author=R Knops; citation_author=M Massop; citation_author=ER Tonnissen; citation_author=A van der Heijden; citation_author=TN Scheele; citation_author=P Vandenberghe; citation_volume=42; citation_publication_date=2010; citation_pages=665-667; citation_id=CR22;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing; citation_author=L Ding; citation_author=TJ Ley; citation_author=DE Larson; citation_author=CA Miller; citation_author=DC Koboldt; citation_author=JS Welch; citation_author=JK Ritchey; citation_author=MA Young; citation_author=T Lamprecht; citation_author=MD McLellan; citation_author=JF McMichael; citation_author=JW Wallis; citation_author=C Lu; citation_author=D Shen; citation_author=CC Harris; citation_author=DJ Dooling; citation_author=RS Fulton; citation_author=LL Fulton; citation_author=K Chen; citation_author=H Schmidt; citation_author=J Kalicki-Veizer; citation_author=VJ Magrini; citation_author=L Cook; citation_author=SD McGrath; citation_author=TL Vickery; citation_author=MC Wendl; citation_author=S Heath; citation_author=MA Watson; citation_author=DC Link; citation_author=MH Tomasson; citation_author=WD Shannon; citation_author=JE Payton; citation_author=S Kulkarni; citation_author=P Westervelt; citation_author=MJ Walter; citation_author=TA Graubert; citation_author=ER Mardis; citation_author=RK Wilson; citation_author=JF DiPersio; citation_volume=481; citation_publication_date=2012; citation_pages=506-510; citation_id=CR23;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=DNMT3A mutations in acute myeloid leukemia; citation_author=TJ Ley; citation_author=L Ding; citation_author=MJ Walter; citation_author=MD McLellan; citation_author=T Lamprecht; citation_author=DE Larson; citation_author=C Kandoth; citation_author=JE Payton; citation_author=J Baty; citation_author=J Welch; citation_author=CC Harris; citation_author=CF Lichti; citation_author=RR Townsend; citation_author=RS Fulton; citation_author=DJ Dooling; citation_author=DC Koboldt; citation_author=H Schmidt; citation_author=Q Zhang; citation_author=JR Osborne; citation_author=L Lin; citation_author=M O&#39;Laughlin; citation_author=JF McMichael; citation_author=KD Delehaunty; citation_author=SD McGrath; citation_author=LA Fulton; citation_author=VJ Magrini; citation_author=TL Vickery; citation_author=J Hundal; citation_author=LL Cook; citation_author=JJ Conyers; citation_author=GW Swift; citation_author=JP Reed; citation_author=PA Alldredge; citation_author=T Wylie; citation_author=J Walker; citation_author=J Kalicki; citation_author=MA Watson; citation_author=S Heath; citation_author=WD Shannon; citation_author=N Varghese; citation_author=R Nagarajan; citation_author=P Westervelt; citation_author=MH Tomasson; citation_author=DC Link; citation_author=TA Graubert; citation_author=JF DiPersio; citation_author=ER Mardis; citation_author=RK Wilson; citation_volume=363; citation_publication_date=2010; citation_pages=2424-2433; citation_id=CR24;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia; citation_author=M Li; citation_author=R Collins; citation_author=Y Jiao; citation_author=P Ouillette; citation_author=D Bixby; citation_author=H Erba; citation_author=B Vogelstein; citation_author=KW Kinzler; citation_author=N Papadopoulos; citation_author=SN Malek; citation_volume=118; citation_publication_date=2011; citation_pages=5914-5917; citation_id=CR25;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=Recurring mutations found by sequencing an acute myeloid leukemia genome; citation_author=ER Mardis; citation_author=L Ding; citation_author=DJ Dooling; citation_author=DE Larson; citation_author=MD McLellan; citation_author=K Chen; citation_author=DC Koboldt; citation_author=RS Fulton; citation_author=KD Delehaunty; citation_author=SD McGrath; citation_author=LA Fulton; citation_author=DP Locke; citation_author=VJ Magrini; citation_author=RM Abbott; citation_author=TL Vickery; citation_author=JS Reed; citation_author=JS Robinson; citation_author=T Wylie; citation_author=SM Smith; citation_author=L Carmichael; citation_author=JM Eldred; citation_author=CC Harris; citation_author=J Walker; citation_author=JB Peck; citation_author=F Du; citation_author=AF Dukes; citation_author=GE Sanderson; citation_author=AM Brummett; citation_author=E Clark; citation_author=JF McMichael; citation_author=RJ Meyer; citation_author=JK Schindler; citation_author=CS Pohl; citation_author=JW Wallis; citation_author=X Shi; citation_author=L Lin; citation_author=H Schmidt; citation_author=Y Tang; citation_author=C Haipek; citation_author=ME Wiechert; citation_author=JV Ivy; citation_author=J Kalicki; citation_author=G Elliott; citation_author=RE Ries; citation_author=JE Payton; citation_author=P Westervelt; citation_author=MH Tomasson; citation_author=MA Watson; citation_author=J Baty; citation_author=S Heath; citation_author=WD Shannon; citation_author=R Nagarajan; citation_author=DC Link; citation_author=MJ Walter; citation_author=TA Graubert; citation_author=JF DiPersio; citation_author=RK Wilson; citation_author=TJ Ley; citation_volume=361; citation_publication_date=2009; citation_pages=1058-1066; citation_id=CR26;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=Somatic mutation of SF3B1 in myelodysplasia with ring sideroblasts and other cancers; citation_author=E Papaemmanuil; citation_author=M Cazzola; citation_author=J Boultwood; citation_author=L Malcovati; citation_author=P Vyas; citation_author=D Bowen; citation_author=A Pellagati; citation_author=JS Wainscoat; citation_author=E Hellstrom-Lindberg; citation_author=C Gambacorti-Passerini; citation_author=AL Godfrey; citation_author=JR Cross; citation_author=AR Green; citation_author=PA Futreal; citation_author=MR Stratton; citation_author=PJ Campbell; citation_volume=365; citation_publication_date=2011; citation_pages=1384-1395; citation_id=CR27;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Genet; citation_title=Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer; citation_author=G Van Haaften; citation_author=GL Dalgliesh; citation_author=H Davies; citation_author=L Chen; citation_author=G Bignell; citation_author=C Greenman; citation_author=S Edkins; citation_author=C Hardy; citation_author=S O&#39;Meara; citation_author=J Teague; citation_author=A Butler; citation_author=J Hinton; citation_author=C Latimer; citation_author=J Andrews; citation_author=S Barthorpe; citation_author=D Beare; citation_author=G Buck; citation_author=PJ Campbell; citation_author=J Cole; citation_author=S Forbes; citation_author=M Jia; citation_author=D Jones; citation_author=CY Kok; citation_author=C Leroy; citation_author=ML Lin; citation_author=DJ McBride; citation_author=M Maddison; citation_author=S Maquire; citation_author=K McLay; citation_author=A Menzies; citation_author=T Mironenko; citation_author=L Mulderrig; citation_author=L Mudie; citation_author=E Pleasance; citation_author=R Shepherd; citation_author=R Smith; citation_author=L Stebbings; citation_author=P Stephens; citation_author=G Tang; citation_author=PS Tarpey; citation_author=R Turner; citation_author=K Turrell; citation_author=J Varian; citation_author=S West; citation_author=S Widaa; citation_author=P Wray; citation_author=VP Collins; citation_author=K Ichimura; citation_author=S Law; citation_author=J Wong; citation_author=ST Yuen; citation_author=SY Leung; citation_author=G Tonon; citation_author=RA DePinho; citation_author=YT Tai; citation_author=KC Anderson; citation_author=RJ Kahnoski; citation_author=A Massie; citation_author=SK Khoo; citation_author=BT Teh; citation_author=MR Stratton; citation_author=PA Futreal; citation_volume=41; citation_publication_date=2009; citation_pages=521-523; citation_id=CR28;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts; citation_author=V Visconte; citation_author=H Makishima; citation_author=A Jankowska; citation_author=H Szpurka; citation_author=F Traina; citation_author=A Jerez; citation_author=C O&#39;Keefe; citation_author=HJ Rogers; citation_author=MA Sekeres; citation_author=JP Maciejewski; citation_author=RV Tiu; citation_volume=26; citation_publication_date=2011; citation_pages=542-545; citation_id=CR29;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Genet; citation_title=Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia; citation_author=XJ Yan; citation_author=J Xu; citation_author=ZH Gu; citation_author=CM Pan; citation_author=G Lu; citation_author=Y Shen; citation_author=JY Shi; citation_author=YM Zhu; citation_author=L Tang; citation_author=XW Zhang; citation_author=WX Liang; citation_author=JQ Mi; citation_author=HD Song; citation_author=KQ Li; citation_author=Z Chen; citation_author=SJ Chen; citation_volume=43; citation_publication_date=2011; citation_pages=309-315; citation_id=CR30;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=Frequent pathway mutations of splicing machinery in myelodysplasia; citation_author=K Yoshida; citation_author=M Sanada; citation_author=Y Shiraishi; citation_author=D Nowak; citation_author=Y Nagata; citation_author=R Yamamoto; citation_author=Y Sato; citation_author=A Sato-Otsubo; citation_author=A Kon; citation_author=M Nagasaki; citation_author=G Chalkidis; citation_author=Y Suzuki; citation_author=M Shiosaka; citation_author=R Kawahata; citation_author=T Yamaguchi; citation_author=M Otsu; citation_author=N Obara; citation_author=M Sakata-Yanagimoto; citation_author=K Ishiyama; citation_author=H Mori; citation_author=F Nolte; citation_author=WK Hofmann; citation_author=S Miyawaki; citation_author=S Sugano; citation_author=C Haferlach; citation_author=HP Koeffler; citation_author=LY Shih; citation_author=T Haferlach; citation_author=S Chiba; citation_author=H Nakauchi; citation_author=S Miyano; citation_author=S Ogawa; citation_volume=478; citation_publication_date=2011; citation_pages=64-69; citation_id=CR31;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Oncogene; citation_title=Array-based genomic resequencing of human leukemia; citation_author=Y Yamashita; citation_author=J Yuan; citation_author=I Suetake; citation_author=H Suzuki; citation_author=Y Ishikawa; citation_author=YL Choi; citation_author=T Ueno; citation_author=M Soda; citation_author=T Hamada; citation_author=H Haruta; citation_author=S Takada; citation_author=Y Miyazaki; citation_author=H Kiyoi; citation_author=E Ito; citation_author=T Naoe; citation_author=M Tomonaga; citation_author=M Toyota; citation_author=S Tajima; citation_author=A Iwama; citation_author=H Mano; citation_volume=29; citation_publication_date=2010; citation_pages=3723-3731; citation_id=CR32;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A; citation_author=AM Jankowska; citation_author=H Makishima; citation_author=RV Tiu; citation_author=H Szpurka; citation_author=Y Huang; citation_author=F Traina; citation_author=V Visconte; citation_author=Y Sugimoto; citation_author=C Prince; citation_author=C O&#39;Keefe; citation_author=ED Hsi; citation_author=A List; citation_author=MA Sekeres; citation_author=A Rao; citation_author=MA McDevitt; citation_author=JP Maciejewski; citation_volume=118; citation_publication_date=2011; citation_pages=3932-3941; citation_id=CR33;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis; citation_author=RL Levine; citation_author=C Belisle; citation_author=M Wadleigh; citation_author=D Zahrieh; citation_author=S Lee; citation_author=P Chagnon; citation_author=DG Gilliland; citation_author=L Busque; citation_volume=107; citation_publication_date=2006; citation_pages=4139-4141; citation_id=CR34;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera; citation_author=E Lippert; citation_author=M Boissinot; citation_author=R Kralovics; citation_author=F Girodon; citation_author=I Dobo; citation_author=V Praloran; citation_author=N Boiret-Dupre; citation_author=RC Skoda; citation_author=S Hermouet; citation_volume=108; citation_publication_date=2006; citation_pages=1865-1867; citation_id=CR35;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Br J Haematol; citation_title=ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia; citation_author=V Gelsi-Boyer; citation_author=V Trouplin; citation_author=J Roquain; citation_author=J Ad&#233;laide; citation_author=N Carbuccia; citation_author=B Esterni; citation_author=P Finetti; citation_author=A Murati; citation_author=C Arnoulet; citation_author=H Zerazhi; citation_author=H Fezoui; citation_author=Z Tadrist; citation_author=M Nezri; citation_author=M Chaffanet; citation_author=MJ Mozziconacci; citation_author=N Vey; citation_author=D Birnbaum; citation_volume=151; citation_publication_date=2010; citation_pages=365-375; citation_id=CR36;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Genes Chromosomes Cancer; citation_title=Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms; citation_author=M Brecqueville; citation_author=J Rey; citation_author=F Bertucci; citation_author=E Coppin; citation_author=P Finetti; citation_author=N Carbuccia; citation_author=N Cervera; citation_author=V Gelsi-Boyer; citation_author=C Arnoulet; citation_author=O Gisserot; citation_author=D Verrot; citation_author=B Slama; citation_author=N Vey; citation_author=MJ Mozziconacci; citation_author=D Birnbaum; citation_author=A Murati; citation_volume=51; citation_publication_date=2012; citation_pages=743-755; citation_id=CR37;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes; citation_author=F Damm; citation_author=O Kosmider; citation_author=V Gelsi-Boyer; citation_author=A Renneville; citation_author=N Carbuccia; citation_author=CH Curtis; citation_author=V Della-Valle; citation_author=L Couronne; citation_author=L Scourzic; citation_author=V Chesnais; citation_author=A Guerci-Bresler; citation_author=B Slama; citation_author=O Beyne-Rauzy; citation_author=A Schmidt-Tanguy; citation_author=A Stamatoullas-Bastard; citation_author=F Dreyfus; citation_author=T Prebet; citation_author=S De Botton; citation_author=N Vey; citation_author=M Morgan; citation_author=JR Cross; citation_author=C Preudhomme; citation_author=D Birnbaum; citation_author=O Bernard; citation_author=M Fontenay; citation_volume=119; citation_publication_date=2012; citation_pages=3211-3218; citation_id=CR38;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Genet; citation_title=Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes; citation_author=TA Graubert; citation_author=D Shen; citation_author=L Ding; citation_author=T Okeyo-Owuor; citation_author=CL Lunn; citation_author=J Shao; citation_author=K Krysiak; citation_author=CC Harris; citation_author=DC Koboldt; citation_author=DE Larson; citation_author=MD McLellan; citation_author=DJ Dooling; citation_author=RM Abbott; citation_author=RS Fulton; citation_author=H Schmidt; citation_author=J Kalicki-Veizer; citation_author=M O&#39;Laughlin; citation_author=M Grillot; citation_author=J Baty; citation_author=S Heath; citation_author=JL Frater; citation_author=T Nasim; citation_author=DC Link; citation_author=MH Tomasson; citation_author=P Westervelt; citation_author=JF DiPersio; citation_author=ER Mardis; citation_author=TJ Ley; citation_author=RK Wilson; citation_author=MJ Walter; citation_volume=44; citation_publication_date=2011; citation_pages=53-57; citation_id=CR39;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients; citation_author=TL Lasho; citation_author=CM Finke; citation_author=CA Hanson; citation_author=T Jimma; citation_author=RA Knudson; citation_author=RP Ketterling; citation_author=A Pardanani; citation_author=A Tefferi; citation_volume=26; citation_publication_date=2011; citation_pages=1135-1137; citation_id=CR40;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis; citation_author=H Makishima; citation_author=V Visconte; citation_author=H Sakaguchi; citation_author=AM Jankowska; citation_author=KS Abu; citation_author=A Jerez; citation_author=B Przychodzen; citation_author=M Bupathi; citation_author=K Guinta; citation_author=MG Afable; citation_author=MA Sekeres; citation_author=RA Padgett; citation_author=RV Tiu; citation_author=JP Maciejewski; citation_volume=119; citation_publication_date=2012; citation_pages=3203-3210; citation_id=CR41;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes; citation_author=F Thol; citation_author=S Kade; citation_author=C Schlarmann; citation_author=P Loffeld; citation_author=M Morgan; citation_author=J Krauter; citation_author=MW Wlodarski; citation_author=B Kolking; citation_author=M Wichmann; citation_author=K Gorlich; citation_author=G Gohring; citation_author=G Bug; citation_author=O Ottmann; citation_author=CM Niemeyer; citation_author=WK Hofmann; citation_author=B Schlegelberger; citation_author=A Ganser; citation_author=M Heuser; citation_volume=119; citation_publication_date=2012; citation_pages=3578-3584; citation_id=CR42;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Semin Oncol; citation_title=Mutational determinants of epigenetic instability in myeloid malignancies; citation_author=AM Jankowska; citation_author=H Szpurka; citation_volume=39; citation_publication_date=2012; citation_pages=80-96; citation_id=CR43;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Deletion of the tumor-suppressor gene NF1 occurs in 5&#8201;% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases; citation_author=C Haferlach; citation_author=V Grossmann; citation_author=A Kohlmann; citation_author=S Schindela; citation_author=W Kern; citation_author=S Schnittger; citation_author=T Haferlach; citation_volume=26; citation_publication_date=2011; citation_pages=834-839; citation_id=CR44;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Clin Cancer Res; citation_title=NF1 inactivation in adult acute myelogenous leukemia; citation_author=B Parkin; citation_author=P Ouillette; citation_author=Y Wang; citation_author=Y Liu; citation_author=W Wright; citation_author=D Roulston; citation_author=A Purkayastha; citation_author=A Dressel; citation_author=J Karp; citation_author=P Bockenstedt; citation_author=A Al-Zoubi; citation_author=M Talpaz; citation_author=L Kujawski; citation_author=Y Liu; citation_author=K Shedden; citation_author=S Shakhan; citation_author=C Li; citation_author=H Erba; citation_author=SN Malek; citation_volume=16; citation_publication_date=2010; citation_pages=4135-4147; citation_id=CR45;'/>
    
    <meta name="citation_reference" content='citation_journal_title=BMC Cancer; citation_title=Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes; citation_author=V Gelsi-Boyer; citation_author=V Trouplin; citation_author=J Ad&#233;laide; citation_author=N Aceto; citation_author=V Remy; citation_author=S Pinson; citation_author=C Houdayer; citation_author=C Arnoulet; citation_author=D Sainty; citation_author=M Bentires-Alj; citation_author=S Olschwang; citation_author=N Vey; citation_author=MJ Mozziconacci; citation_author=D Birnbaum; citation_author=M Chaffanet; citation_volume=8; citation_publication_date=2008; citation_pages=299-314; citation_id=CR46;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing; citation_author=PA Greif; citation_author=SH Eck; citation_author=NP Konstandin; citation_author=A Benet-Pages; citation_author=B Ksienzyk; citation_author=A Dufour; citation_author=AT Vetter; citation_author=HD Popp; citation_author=B Lorenz-Depiereux; citation_author=T Meitinger; citation_author=SK Bohlander; citation_author=TM Strom; citation_volume=25; citation_publication_date=2011; citation_pages=821-827; citation_id=CR47;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies; citation_author=J Ad&#233;laide; citation_author=V Gelsi-Boyer; citation_author=J Rocquain; citation_author=N Carbuccia; citation_author=DJ Birnbaum; citation_author=P Finetti; citation_author=F Bertucci; citation_author=MJ Mozziconacci; citation_author=N Vey; citation_author=D Birnbaum; citation_author=M Chaffanet; citation_volume=24; citation_publication_date=2010; citation_pages=1539-1541; citation_id=CR48;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms; citation_author=FH Grand; citation_author=CE Hidalgo-Curtis; citation_author=T Ernst; citation_author=K Zoi; citation_author=C Zoi; citation_author=C McGuire; citation_author=S Kreil; citation_author=A Jones; citation_author=J Score; citation_author=G Metzgeroth; citation_author=D Oscier; citation_author=A Hall; citation_author=C Brandts; citation_author=H Serve; citation_author=A Reiter; citation_author=AJ Chase; citation_author=NC Cross; citation_volume=113; citation_publication_date=2009; citation_pages=6182-6192; citation_id=CR49;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies; citation_author=H Makishima; citation_author=H Cazzolli; citation_author=H Szpurka; citation_author=A Dunbar; citation_author=R Tiu; citation_author=J Huh; citation_author=H Muramatsu; citation_author=C O&#39;Keefe; citation_author=E Hsi; citation_author=RL Paquette; citation_author=S Kojima; citation_author=AF List; citation_author=MA Sekeres; citation_author=MA McDevitt; citation_author=JP Maciejewski; citation_volume=27; citation_publication_date=2009; citation_pages=6109-6116; citation_id=CR50;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms; citation_author=J Score; citation_author=C Hidalgo-Curtis; citation_author=AV Jones; citation_author=N Winkelmann; citation_author=A Skinner; citation_author=D Ward; citation_author=K Zoi; citation_author=T Ernst; citation_author=F Stegelmann; citation_author=K Dohner; citation_author=A Chase; citation_author=NC Cross; citation_volume=119; citation_publication_date=2011; citation_pages=1208-1213; citation_id=CR51;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Genes Chromosomes Cancer; citation_title=ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events; citation_author=C Haferlach; citation_author=U Bacher; citation_author=S Schnittger; citation_author=T Alpermann; citation_author=M Zenger; citation_author=W Kern; citation_author=T Haferlach; citation_volume=51; citation_publication_date=2012; citation_pages=328-337; citation_id=CR52;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Neoplasma; citation_title=Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia; citation_author=H Cechova; citation_author=P Lassuthova; citation_author=L Novakova; citation_author=M Belickova; citation_author=R Stemberkova; citation_author=J Jencik; citation_author=M Stankova; citation_author=P Hrabakova; citation_author=K Pegova; citation_author=H Zizkova; citation_author=J Cermak; citation_volume=59; citation_publication_date=2012; citation_pages=168-174; citation_id=CR53;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Invest; citation_title=Transcription intermediary factor 1gamma is a tumor suppressor in mouse and human chronic myelomonocytic leukemia; citation_author=R Aucagne; citation_author=N Droin; citation_author=J Paggetti; citation_author=B Lagrange; citation_author=A Largeot; citation_author=A Hammann; citation_author=A Bataille; citation_author=L Martin; citation_author=KP Yan; citation_author=P Fenaux; citation_author=R Losson; citation_author=E Solary; citation_author=JN Bastie; citation_author=L Delva; citation_volume=121; citation_publication_date=2011; citation_pages=2361-2370; citation_id=CR54;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Med; citation_title=Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation; citation_author=TX Liu; citation_author=MW Becker; citation_author=J Jelinek; citation_author=WS Wu; citation_author=M Deng; citation_author=N Mikhalkevich; citation_author=K Hsu; citation_author=CD Bloomfield; citation_author=RM Stone; citation_author=DJ DeAngelo; citation_author=IA Galinsky; citation_author=JP Issa; citation_author=MF Clarke; citation_author=AT Look; citation_volume=13; citation_publication_date=2007; citation_pages=78-83; citation_id=CR55;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Br J Haematol; citation_title=Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome; citation_author=K Brakensiek; citation_author=F Langer; citation_author=B Schlegelberger; citation_author=H Kreipe; citation_author=U Lehmann; citation_volume=130; citation_publication_date=2005; citation_pages=209-217; citation_id=CR56;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Semin Oncol; citation_title=Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies; citation_author=MA McDevitt; citation_volume=39; citation_publication_date=2012; citation_pages=109-122; citation_id=CR57;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=Clinical effect of point mutations in myelodysplastic syndromes; citation_author=R Bejar; citation_author=K Stevenson; citation_author=O Abdel-Wahab; citation_author=N Galili; citation_author=B Nilsson; citation_author=G Garcia-Manero; citation_author=H Kantarjian; citation_author=A Raza; citation_author=RL Levine; citation_author=D Neuberg; citation_author=BL Ebert; citation_volume=364; citation_publication_date=2011; citation_pages=2496-2506; citation_id=CR58;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome; citation_author=TJ Ley; citation_author=ER Mardis; citation_author=L Ding; citation_author=B Fulton; citation_author=MD McLellan; citation_author=K Chen; citation_author=D Dooling; citation_author=BH Dunford-Shore; citation_author=S McGrath; citation_author=M Hickenbotham; citation_author=L Cook; citation_author=R Abbott; citation_author=DE Larson; citation_author=DC Koboldt; citation_author=C Pohl; citation_author=S Smith; citation_author=A Hawkins; citation_author=S Abbott; citation_author=D Locke; citation_author=LW Hillier; citation_author=T Miner; citation_author=L Fulton; citation_author=V Magrini; citation_author=T Wylie; citation_author=J Glasscock; citation_author=J Conyers; citation_author=N Sander; citation_author=X Shi; citation_author=JR Osborne; citation_author=P Minx; citation_author=D Gordon; citation_author=A Chinwalla; citation_author=Y Zhao; citation_author=RE Ries; citation_author=JE Payton; citation_author=P Westervelt; citation_author=MH Tomasson; citation_author=M Watson; citation_author=J Baty; citation_author=J Ivanovich; citation_author=S Heath; citation_author=WD Shannon; citation_author=R Nagarajan; citation_author=MJ Walter; citation_author=DC Link; citation_author=TA Graubert; citation_author=JF DiPersio; citation_author=RK Wilson; citation_volume=456; citation_publication_date=2008; citation_pages=66-72; citation_id=CR59;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression; citation_author=T Klampfl; citation_author=A Harutyunyan; citation_author=T Berg; citation_author=B Gisslinger; citation_author=M Schalling; citation_author=K Bagienski; citation_author=D Olcaydu; citation_author=F Passamonti; citation_author=E Rumi; citation_author=D Pietra; citation_author=R Jager; citation_author=L Pieri; citation_author=P Guglielmelli; citation_author=I Iacobucci; citation_author=G Martinelli; citation_author=M Cazzola; citation_author=AM Vannucchi; citation_author=H Gisslinger; citation_author=R Kralovics; citation_volume=118; citation_publication_date=2011; citation_pages=167-176; citation_id=CR60;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=PHF6 mutations in adult acute myeloid leukemia; citation_author=P Van Vlierberghe; citation_author=J Patel; citation_author=O Abdel-Wahab; citation_author=C Lobry; citation_author=CV Hedvat; citation_author=M Balbin; citation_author=C Nicolas; citation_author=AR Payer; citation_author=HF Fernandez; citation_author=MS Tallman; citation_author=E Paietta; citation_author=A Melnick; citation_author=P Vandenberghe; citation_author=F Speleman; citation_author=I Aifantis; citation_author=J Cools; citation_author=R Levine; citation_author=A Ferrando; citation_volume=25; citation_publication_date=2011; citation_pages=130-134; citation_id=CR61;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia; citation_author=F Damm; citation_author=T Bunke; citation_author=F Thol; citation_author=B Markus; citation_author=K Wagner; citation_author=G Gohring; citation_author=B Schlegelberger; citation_author=G Heil; citation_author=CW Reuter; citation_author=K Pullmann; citation_author=RF Schlenk; citation_author=K Dohner; citation_author=M Heuser; citation_author=J Krauter; citation_author=H Dohner; citation_author=A Ganser; citation_author=MA Morgan; citation_volume=26; citation_publication_date=2012; citation_pages=289-295; citation_id=CR62;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Am J Hematol; citation_title=Alteration of cohesin genes in myeloid diseases; citation_author=J Rocquain; citation_author=V Gelsi-Boyer; citation_author=J Ad&#233;laide; citation_author=A Murati; citation_author=N Carbuccia; citation_author=N Vey; citation_author=D Birnbaum; citation_author=MJ Mozziconacci; citation_author=M Chaffanet; citation_volume=85; citation_publication_date=2010; citation_pages=717-719; citation_id=CR63;'/>
    
    <meta name="citation_reference" content='citation_journal_title=FEBS Lett; citation_title=Transcriptional and epigenetic networks in haematological malignancy; citation_author=N Cheung; citation_author=CW So; citation_volume=585; citation_publication_date=2011; citation_pages=2100-2111; citation_id=CR64;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Prog Drug Res; citation_title=Epigenetic mechanisms in acute myeloid leukemia; citation_author=AH Peters; citation_author=J Schwaller; citation_volume=67; citation_publication_date=2011; citation_pages=197-219; citation_id=CR65;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes; citation_author=GL Dalgliesh; citation_author=K Furge; citation_author=C Greenman; citation_author=L Chen; citation_author=G Bignell; citation_author=A Butler; citation_author=H Davies; citation_author=S Edkins; citation_author=C Hardy; citation_author=C Latimer; citation_author=J Teague; citation_author=J Andrews; citation_author=S Barthorpe; citation_author=D Beare; citation_author=G Buck; citation_author=PJ Campbell; citation_author=S Forbes; citation_author=M Jia; citation_author=D Jones; citation_author=H Knott; citation_author=CY Kok; citation_author=KW Lau; citation_author=C Leroy; citation_author=ML Lin; citation_author=DJ McBride; citation_author=M Maddison; citation_author=S Maguire; citation_author=K McLay; citation_author=A Menzies; citation_author=T Mironenko; citation_author=L Mulderrig; citation_author=L Mudie; citation_author=S O&#39;Meara; citation_author=E Pleasance; citation_author=A Rajasingham; citation_author=R Shepherd; citation_author=R Smith; citation_author=L Stebbings; citation_author=P Stephens; citation_author=G Tang; citation_author=PS Tarpey; citation_author=K Turrell; citation_author=KJ Dykema; citation_author=SK Khoo; citation_author=D Petillo; citation_author=B Wondergem; citation_author=J Anema; citation_author=RJ Kahnoski; citation_author=BT Teh; citation_author=MR Stratton; citation_author=PA Futreal; citation_volume=463; citation_publication_date=2010; citation_pages=360-363; citation_id=CR66;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma; citation_author=I Varela; citation_author=P Tarpey; citation_author=K Raine; citation_author=D Huang; citation_author=CK Ong; citation_author=P Stephens; citation_author=H Davies; citation_author=D Jones; citation_author=ML Lin; citation_author=J Teague; citation_author=G Bignell; citation_author=A Butler; citation_author=J Cho; citation_author=GL Dalgliesh; citation_author=D Galappaththige; citation_author=C Greenman; citation_author=C Hardy; citation_author=M Jia; citation_author=C Latimer; citation_author=KW Lau; citation_author=J Marshall; citation_author=S McLaren; citation_author=A Menzies; citation_author=L Mudie; citation_author=L Stebbings; citation_author=DA Largaespada; citation_author=LF Wessels; citation_author=S Richard; citation_author=RJ Kahnoski; citation_author=J Anema; citation_author=DA Tuveson; citation_author=PA Perez-Mancera; citation_author=V Mustonen; citation_author=A Fischer; citation_author=DJ Adams; citation_author=A Rust; citation_author=W Chan-on; citation_author=C Subimerb; citation_author=K Dykema; citation_author=K Furge; citation_author=PJ Campbell; citation_author=BT Teh; citation_author=MR Stratton; citation_author=PA Futreal; citation_volume=469; citation_publication_date=2011; citation_pages=539-542; citation_id=CR67;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation; citation_author=ME Figueroa; citation_author=O Abdel-Wahab; citation_author=C Lu; citation_author=PS Ward; citation_author=J Patel; citation_author=A Shih; citation_author=Y Li; citation_author=N Bhagwat; citation_author=A Vasanthakumar; citation_author=HF Fernandez; citation_author=MS Tallman; citation_author=Z Sun; citation_author=K Wolniak; citation_author=JK Peeters; citation_author=W Liu; citation_author=SE Choe; citation_author=VR Fantin; citation_author=E Paietta; citation_author=B Lowenberg; citation_author=JD Licht; citation_author=LA Godley; citation_author=R Delwel; citation_author=PJ Valk; citation_author=CB Thompson; citation_author=RL Levine; citation_author=A Melnick; citation_volume=18; citation_publication_date=2010; citation_pages=553-567; citation_id=CR68;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=Vander Heiden MG, Su SM: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate; citation_author=L Dang; citation_author=DW White; citation_author=S Gross; citation_author=BD Bennett; citation_author=MA Bittinger; citation_author=EM Driggers; citation_author=VR Fantin; citation_author=HG Jang; citation_author=S Jin; citation_author=MC Keenan; citation_author=KM Marks; citation_author=RM Prins; citation_author=PS Ward; citation_author=KE Yen; citation_author=LM Liau; citation_author=JD Rabinowitz; citation_author=LC Cantley; citation_author=CB Thompson; citation_volume=465; citation_publication_date=2010; citation_pages=966; citation_id=CR69;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate; citation_author=PS Ward; citation_author=J Patel; citation_author=DR Wise; citation_author=O Abdel-Wahab; citation_author=BD Bennett; citation_author=HA Coller; citation_author=JR Cross; citation_author=VR Fantin; citation_author=CV Hedvat; citation_author=AE Perl; citation_author=JD Rabinowitz; citation_author=M Carroll; citation_author=SM Su; citation_author=KA Sharp; citation_author=RL Levine; citation_author=CB Thompson; citation_volume=17; citation_publication_date=2010; citation_pages=225-234; citation_id=CR70;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Science; citation_title=Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1; citation_author=M Tahiliani; citation_author=KP Koh; citation_author=Y Shen; citation_author=WA Pastor; citation_author=H Bandukwala; citation_author=Y Brudno; citation_author=S Agarwal; citation_author=LM Iyer; citation_author=DR Liu; citation_author=L Aravind; citation_author=A Rao; citation_volume=324; citation_publication_date=2009; citation_pages=930-935; citation_id=CR71;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cell Stem Cell; citation_title=TET family proteins and their role in stem cell differentiation and transformation; citation_author=L Cimmino; citation_author=O Abdel-Wahab; citation_author=RL Levine; citation_author=I Aifantis; citation_volume=9; citation_publication_date=2011; citation_pages=193-204; citation_id=CR72;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Science; citation_title=Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine; citation_author=S Ito; citation_author=L Shen; citation_author=Q Dai; citation_author=SC Wu; citation_author=LB Collins; citation_author=JA Swenberg; citation_author=C He; citation_author=Y Zhang; citation_volume=233; citation_publication_date=2011; citation_pages=1300-1303; citation_id=CR73;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity; citation_author=K Williams; citation_author=J Christensen; citation_author=MT Pedersen; citation_author=JV Johansen; citation_author=PA Cloos; citation_author=J Rappsilber; citation_author=K Helin; citation_volume=473; citation_publication_date=2011; citation_pages=343-348; citation_id=CR74;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=Histone demethylation by a family of JmjC domain-containing proteins; citation_author=Y Tsukada; citation_author=J Fang; citation_author=H Erdjument-Bromage; citation_author=ME Warren; citation_author=CH Borchers; citation_author=P Tempst; citation_author=Y Zhang; citation_volume=439; citation_publication_date=2006; citation_pages=811-816; citation_id=CR75;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation; citation_author=K Moran-Crusio; citation_author=L Reavie; citation_author=A Shih; citation_author=O Abdel-Wahab; citation_author=D Ndiaye-Lobry; citation_author=C Lobry; citation_author=ME Figueroa; citation_author=A Vasanthakumar; citation_author=J Patel; citation_author=X Zhao; citation_author=F Perna; citation_author=S Pandey; citation_author=J Madzo; citation_author=C Song; citation_author=Q Dai; citation_author=C He; citation_author=S Ibrahim; citation_author=M Beran; citation_author=J Zavadil; citation_author=SD Nimer; citation_author=A Melnick; citation_author=LA Godley; citation_author=I Aifantis; citation_author=RL Levine; citation_volume=20; citation_publication_date=2011; citation_pages=11-24; citation_id=CR76;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis; citation_author=C Quivoron; citation_author=L Couronne; citation_author=VV Della; citation_author=CK Lopez; citation_author=I Plo; citation_author=O Wagner-Ballon; citation_author=CM Do; citation_author=F Delhommeau; citation_author=B Arnulf; citation_author=MH Stern; citation_author=L Godley; citation_author=P Opolon; citation_author=H Tilly; citation_author=E Solary; citation_author=Y Duffourd; citation_author=P Dessen; citation_author=H Merle-Beral; citation_author=F Nguyen-Khac; citation_author=M Fontenay; citation_author=W Vainchenker; citation_author=C Bastard; citation_author=T Mercher; citation_author=OA Bernard; citation_volume=20; citation_publication_date=2011; citation_pages=25-38; citation_id=CR77;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=de LY, Fuks F: The Polycomb group protein EZH2 directly controls DNA methylation; citation_author=E Vire; citation_author=C Brenner; citation_author=R Deplus; citation_author=L Blanchon; citation_author=M Fraga; citation_author=C Didelot; citation_author=L Morey; citation_author=EA Van; citation_author=D Bernard; citation_author=JM Vanderwinden; citation_author=M Bollen; citation_author=M Esteller; citation_author=CL Di; citation_volume=439; citation_publication_date=2006; citation_pages=871-874; citation_id=CR78;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Genet; citation_title=Dnmt3a is essential for hematopoietic stem cell differentiation; citation_author=GA Challen; citation_author=D Sun; citation_author=M Jeong; citation_author=M Luo; citation_author=J Jelinek; citation_author=JS Berg; citation_author=C Bock; citation_author=A Vasanthakumar; citation_author=H Gu; citation_author=Y Xi; citation_author=S Liang; citation_author=Y Lu; citation_author=GJ Darlington; citation_author=A Meissner; citation_author=JP Issa; citation_author=LA Godley; citation_author=W Li; citation_author=MA Goodell; citation_volume=44; citation_publication_date=2012; citation_pages=23-31; citation_id=CR79;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation; citation_author=G Ficz; citation_author=MR Branco; citation_author=S Seisenberger; citation_author=F Santos; citation_author=F Krueger; citation_author=TA Hore; citation_author=CJ Marques; citation_author=S Andrews; citation_author=W Reik; citation_volume=473; citation_publication_date=2011; citation_pages=398-402; citation_id=CR80;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells; citation_author=H Wu; citation_author=AC D&#39;Alessio; citation_author=S Ito; citation_author=K Xia; citation_author=Z Wang; citation_author=K Cui; citation_author=K Zhao; citation_author=YE Sun; citation_author=Y Zhang; citation_volume=473; citation_publication_date=2011; citation_pages=389-393; citation_id=CR81;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Mol Cell Biol; citation_title=CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop; citation_author=T Li; citation_author=JF Hu; citation_author=X Qiu; citation_author=J Ling; citation_author=H Chen; citation_author=S Wang; citation_author=A Hou; citation_author=TH Vu; citation_author=AR Hoffman; citation_volume=28; citation_publication_date=2008; citation_pages=6473-6482; citation_id=CR82;'/>
    
    <meta name="citation_reference" content='citation_journal_title=ASH Annual Meeting Abstracts; citation_title=ASXL1 Mutations Promote Myeloid Transformation Through Inhibition of PRC2-Mediated Gene Repression; citation_author=O Abdel-Wahab; citation_author=M Adli; citation_author=L Saunders; citation_author=J Gao; citation_author=A Shih; citation_author=S Pandey; citation_author=J Jaffe; citation_author=X Zhao; citation_author=F Perna; citation_author=M Caroll; citation_author=A Melnick; citation_author=SD Nimer; citation_author=I Aifantis; citation_author=B Bernstein; citation_author=R Levine; citation_volume=118; citation_publication_date=2011; citation_pages=405; citation_id=CR83;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Rev Genet; citation_title=Silencing chromatin: comparing modes and mechanisms; citation_author=C Beisel; citation_author=R Paro; citation_volume=12; citation_publication_date=2011; citation_pages=123-135; citation_id=CR84;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Med; citation_title=da RV, Tang Z, Siegle J, Asp P, Hadler M, Rigo I, Keersmaecker KD, Patel J, Huynh T, Utro F, Poglio S, Samon JB, Paietta E, Racevskis J, Rowe JM, Rabadan R, Levine RL, Brown S, Pflumio F, Dominguez M, Ferrando A, Aifantis I: Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia; citation_author=P Ntziachristos; citation_author=A Tsirigos; citation_author=PV Vlierberghe; citation_author=J Nedjic; citation_author=T Trimarchi; citation_author=MS Flaherty; citation_author=D Ferres-Marco; citation_volume=18; citation_publication_date=2012; citation_pages=298-303; citation_id=CR85;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Exp Med; citation_title=Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes; citation_author=H Oguro; citation_author=J Yuan; citation_author=S Tanaka; citation_author=S Miyagi; citation_author=M Mochizuki-Kashio; citation_author=H Ichikawa; citation_author=S Yamazaki; citation_author=H Koseki; citation_author=H Nakauchi; citation_author=A Iwama; citation_volume=209; citation_publication_date=2012; citation_pages=445-454; citation_id=CR86;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cell Cycle; citation_title=Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms; citation_author=M Brecqueville; citation_author=J Ad&#233;laide; citation_author=F Bertucci; citation_author=P Finetti; citation_author=M Chaffanet; citation_author=D Birnbaum; citation_author=A Murati; citation_volume=in press; citation_publication_date=2012; citation_pages=in press; citation_id=CR87;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Rev Mol Cell Biol; citation_title=Mechanisms of polycomb gene silencing: knowns and unknowns; citation_author=JA Simon; citation_author=RE Kingston; citation_volume=10; citation_publication_date=2009; citation_pages=697-708; citation_id=CR88;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Science; citation_title=Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N: DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors; citation_author=Y Jiao; citation_author=C Shi; citation_author=BH Edil; citation_author=RF de Wilde; citation_author=DS Klimstra; citation_author=A Maitra; citation_author=RD Schulick; citation_author=LH Tang; citation_author=CL Wolfgang; citation_author=MA Choti; citation_author=VE Velculescu; citation_author=LA Diaz; citation_volume=331; citation_publication_date=2011; citation_pages=1199-1203; citation_id=CR89;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=von DA, Ichimura K, Collins VP, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister SM, Jabado N: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma; citation_author=J Schwartzentruber; citation_author=A Korshunov; citation_author=XY Liu; citation_author=DT Jones; citation_author=E Pfaff; citation_author=K Jacob; citation_author=D Sturm; citation_author=AM Fontebasso; citation_author=DA Quang; citation_author=M Tonjes; citation_author=V Hovestadt; citation_author=S Albrecht; citation_author=M Kool; citation_author=A Nantel; citation_author=C Konermann; citation_author=A Lindroth; citation_author=N Jager; citation_author=T Rausch; citation_author=M Ryzhova; citation_author=JO Korbel; citation_author=T Hielscher; citation_author=P Hauser; citation_author=M Garami; citation_author=A Klekner; citation_author=L Bognar; citation_author=M Ebinger; citation_author=MU Schuhmann; citation_author=W Scheurlen; citation_author=A Pekrun; citation_author=MC Fruhwald; citation_author=W Roggendorf; citation_author=C Kramm; citation_author=M Durken; citation_author=J Atkinson; citation_author=P Lepage; citation_author=A Montpetit; citation_author=M Zakrzewska; citation_author=K Zakrzewski; citation_author=PP Liberski; citation_author=Z Dong; citation_author=P Siegel; citation_author=AE Kulozik; citation_author=M Zapatka; citation_author=A Guha; citation_author=D Malkin; citation_author=J Felsberg; citation_author=G Reifenberger; citation_volume=482; citation_publication_date=2012; citation_pages=226-231; citation_id=CR90;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Pathol; citation_title=Haplo-insufficiency: a driving force in cancer; citation_author=AH Berger; citation_author=PP Pandolfi; citation_volume=223; citation_publication_date=2011; citation_pages=137-146; citation_id=CR91;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Myelodysplastic syndromes: lost between two states?; citation_author=C Acquaviva; citation_author=V Gelsi-Boyer; citation_author=D Birnbaum; citation_volume=24; citation_publication_date=2010; citation_pages=1-5; citation_id=CR92;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Genes Dev; citation_title=Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1; citation_author=K Isono; citation_author=Y Mizutani-Koseki; citation_author=T Komori; citation_author=MS Schmidt-Zachmann; citation_author=H Koseki; citation_volume=19; citation_publication_date=2005; citation_pages=536-541; citation_id=CR93;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Science; citation_title=Regulation of alternative splicing by histone modifications; citation_author=RF Luco; citation_author=Q Pan; citation_author=K Tominaga; citation_author=BJ Blencowe; citation_author=OM Pereira-Smith; citation_author=T Misteli; citation_volume=327; citation_publication_date=2010; citation_pages=996-1000; citation_id=CR94;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Genetic complexity of myeloproliferative neoplasms. Leukemia; citation_author=R Kralovics; citation_volume=22; citation_publication_date=2008; citation_pages=1841-1848; citation_id=CR95;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations; citation_author=A Pardanani; citation_author=T Lasho; citation_author=C Finke; citation_author=ST Oh; citation_author=J Gotlib; citation_author=A Tefferi; citation_volume=24; citation_publication_date=2010; citation_pages=1713-1718; citation_id=CR96;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients; citation_author=AD Pardanani; citation_author=RL Levine; citation_author=T Lasho; citation_author=Y Pikman; citation_author=RA Mesa; citation_author=M Wadleigh; citation_author=DP Steensma; citation_author=MA Elliott; citation_author=AP Wolanskyj; citation_author=WJ Hogan; citation_author=RF McClure; citation_author=MR Litzow; citation_author=DG Gilliland; citation_author=A Tefferi; citation_volume=108; citation_publication_date=2006; citation_pages=3472-3476; citation_id=CR97;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Haematologica; citation_title=Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias; citation_author=S Abbas; citation_author=G Rotmans; citation_author=B Lowenberg; citation_author=PJ Valk; citation_volume=93; citation_publication_date=2008; citation_pages=1595-1597; citation_id=CR98;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias; citation_author=N Carbuccia; citation_author=V Trouplin; citation_author=V Gelsi-Boyer; citation_author=A Murati; citation_author=J Rocquain; citation_author=J Ad&#233;laide; citation_author=S Olschwang; citation_author=L Xerri; citation_author=N Vey; citation_author=M Chaffanet; citation_author=D Birnbaum; citation_author=MJ Mozziconacci; citation_volume=24; citation_publication_date=2010; citation_pages=469-473; citation_id=CR99;'/>
    
    <meta name="citation_reference" content='citation_journal_title=BMC Cancer; citation_title=Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias; citation_author=J Rocquain; citation_author=N Carbuccia; citation_author=V Trouplin; citation_author=S Raynaud; citation_author=A Murati; citation_author=M Nezri; citation_author=Z Tadrist; citation_author=S Olschwang; citation_author=N Vey; citation_author=D Birnbaum; citation_author=V Gelsi-Boyer; citation_author=MJ Mozziconacci; citation_volume=10; citation_publication_date=2010; citation_pages=401-405; citation_id=CR100;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Gene mutation patterns and their prognostic impact in a cohort of 1,185 patients with acute myeloid leukemia; citation_author=Y Shen; citation_author=YM Zhu; citation_author=X Fan; citation_author=JY Shi; citation_author=QR Wang; citation_author=XJ Yan; citation_author=ZH Gu; citation_author=YY Wang; citation_author=B Chen; citation_author=CL Jiang; citation_author=H Yan; citation_author=FF Chen; citation_author=HM Chen; citation_author=Z Chen; citation_author=J Jin; citation_author=SJ Chen; citation_volume=118; citation_publication_date=2011; citation_pages=5593-5603; citation_id=CR101;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Alterations of NFIA in chronic malignant myeloid diseases; citation_author=F Bernard; citation_author=V Gelsi-Boyer; citation_author=A Murati; citation_author=S Giraudier; citation_author=V Trouplin; citation_author=J Ad&#233;laide; citation_author=J Rey; citation_author=S Olschwang; citation_author=W Vainchenker; citation_author=M Chaffanet; citation_author=N Vey; citation_author=MJ Mozziconacci; citation_author=D Birnbaum; citation_volume=23; citation_publication_date=2009; citation_pages=583-585; citation_id=CR102;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=Point mutations in myelodysplastic syndromes; citation_author=F Damm; citation_author=M Fontenay; citation_author=OA Bernard; citation_volume=365; citation_publication_date=2011; citation_pages=1154-1155; citation_id=CR103;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Treat Res; citation_title=Murine models of human acute myeloid leukemia; citation_author=JM Fortier; citation_author=TA Graubert; citation_volume=145; citation_publication_date=2010; citation_pages=183-196; citation_id=CR104;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Animal models of acute myelogenous leukaemia - development, application and future perspectives; citation_author=E McCormack; citation_author=O Bruserud; citation_author=BT Gjertsen; citation_volume=19; citation_publication_date=2005; citation_pages=687-706; citation_id=CR105;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Haematologica; citation_title=JAK2V(1)F/TET2 mutations: does the order matter?; citation_author=E Pronier; citation_author=C Quivoron; citation_author=OA Bernard; citation_author=JL Villeval; citation_volume=96; citation_publication_date=2011; citation_pages=638-640; citation_id=CR106;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=Clonal architecture of secondary acute myeloid leukemia; citation_author=MJ Walter; citation_author=D Shen; citation_author=L Ding; citation_author=J Shao; citation_author=DC Koboldt; citation_author=K Chen; citation_author=DE Larson; citation_author=MD McLellan; citation_author=D Dooling; citation_author=R Abbott; citation_author=R Fulton; citation_author=V Magrini; citation_author=H Schmidt; citation_author=J Kalicki-Veizer; citation_author=M O&#39;Laughlin; citation_author=X Fan; citation_author=M Grillot; citation_author=S Witowski; citation_author=S Heath; citation_author=JL Frater; citation_author=W Eades; citation_author=M Tomasson; citation_author=P Westervelt; citation_author=JF DiPersio; citation_author=DC Link; citation_author=ER Mardis; citation_author=TJ Ley; citation_author=RK Wilson; citation_author=TA Graubert; citation_volume=366; citation_publication_date=2012; citation_pages=1090-1098; citation_id=CR107;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Proc Natl Acad Sci U S A; citation_title=Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?; citation_author=E Passegue; citation_author=CH Jamieson; citation_author=LE Ailles; citation_author=IL Weissman; citation_volume=100; citation_issue=Suppl 1; citation_publication_date=2003; citation_pages=11842-11849; citation_id=CR108;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm; citation_author=JR Lambert; citation_author=T Everington; citation_author=DC Linch; citation_author=RE Gale; citation_volume=114; citation_publication_date=2009; citation_pages=3018-3023; citation_id=CR109;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Semin Hematol; citation_title=Molecular genetics of human leukemias: new insights into therapy; citation_author=DG Gilliland; citation_volume=39; citation_publication_date=2002; citation_pages=6-11; citation_id=CR110;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin; citation_author=MA Dawson; citation_author=AJ Bannister; citation_author=B Gottgens; citation_author=SD Foster; citation_author=T Bartke; citation_author=AR Green; citation_author=T Kouzarides; citation_volume=461; citation_publication_date=2009; citation_pages=819-822; citation_id=CR111;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=Unraveling the molecular pathophysiology of myelodysplastic syndromes; citation_author=R Bejar; citation_author=R Levine; citation_author=BL Ebert; citation_volume=29; citation_publication_date=2011; citation_pages=504-515; citation_id=CR112;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia; citation_author=H Makishima; citation_author=AM Jankowska; citation_author=MA McDevitt; citation_author=C O&#39;Keefe; citation_author=S Dujardin; citation_author=H Cazzolli; citation_author=B Przychodzen; citation_author=C Prince; citation_author=J Nicoll; citation_author=H Siddaiah; citation_author=M Shaik; citation_author=H Szpurka; citation_author=E Hsi; citation_author=A Advani; citation_author=R Paquette; citation_author=JP Maciejewski; citation_volume=117; citation_publication_date=2011; citation_pages=e198-e206; citation_id=CR113;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia; citation_author=C Roche-Lestienne; citation_author=A Marceau; citation_author=E Labis; citation_author=O Nibourel; citation_author=V Coiteux; citation_author=J Guilhot; citation_author=L Legros; citation_author=F Nicolini; citation_author=P Rousselot; citation_author=M Gardembas; citation_author=N Helevaut; citation_author=C Frimat; citation_author=FX Mahon; citation_author=F Guilhot; citation_author=C Preudhomme; citation_volume=25; citation_publication_date=2011; citation_pages=1661-1664; citation_id=CR114;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group; citation_author=T Haferlach; citation_author=A Kohlmann; citation_author=L Wieczorek; citation_author=G Basso; citation_author=GT Kronnie; citation_author=MC Bene; citation_author=VJ De; citation_author=JM Hernandez; citation_author=WK Hofmann; citation_author=KI Mills; citation_author=A Gilkes; citation_author=S Chiaretti; citation_author=SA Shurtleff; citation_author=TJ Kipps; citation_author=LZ Rassenti; citation_author=AE Yeoh; citation_author=PR Papenhausen; citation_author=WM Liu; citation_author=PM Williams; citation_author=R Foa; citation_volume=28; citation_publication_date=2010; citation_pages=2529-2537; citation_id=CR115;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Oncogene; citation_title=Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling; citation_author=N Vey; citation_author=MJ Mozziconacci; citation_author=A Groulet-Martinec; citation_author=S Debono; citation_author=P Finetti; citation_author=N Carbuccia; citation_author=E Beillard; citation_author=E Devilard; citation_author=C Arnoulet; citation_author=D Coso; citation_author=D Sainty; citation_author=L Xerri; citation_author=AM Stoppa; citation_author=M Lafage-Pochitaloff; citation_author=C Nguyen; citation_author=R Houlgatte; citation_author=D Blaise; citation_author=D Maraninchi; citation_author=F Birg; citation_author=D Birnbaum; citation_author=F Bertucci; citation_volume=23; citation_publication_date=2004; citation_pages=9381-9391; citation_id=CR116;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=van PW, Skrabanek L, Campagne F, Mazumdar M, Greally JM, Valk PJ, Lowenberg B, Delwel R, Melnick A: DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia; citation_author=ME Figueroa; citation_author=S Lugthart; citation_author=Y Li; citation_author=C Erpelinck-Verschueren; citation_author=X Deng; citation_author=PJ Christos; citation_author=E Schifano; citation_author=J Booth; citation_volume=17; citation_publication_date=2010; citation_pages=13-27; citation_id=CR117;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression; citation_author=J Boultwood; citation_author=J Perry; citation_author=R Zaman; citation_author=C Fernandez-Santamaria; citation_author=T Littlewood; citation_author=R Kusec; citation_author=A Pellagatti; citation_author=L Wang; citation_author=RE Clark; citation_author=JS Wainscoat; citation_volume=24; citation_publication_date=2010; citation_pages=1139-1145; citation_id=CR118;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations; citation_author=WC Chou; citation_author=HH Huang; citation_author=HA Hou; citation_author=CY Chen; citation_author=JL Tang; citation_author=M Yao; citation_author=W Tsay; citation_author=BS Ko; citation_author=SJ Wu; citation_author=SY Huang; citation_author=SC Hsu; citation_author=YC Chen; citation_author=YN Huang; citation_author=YC Chang; citation_author=FY Lee; citation_author=MC Liu; citation_author=CW Liu; citation_author=MH Tseng; citation_author=CF Huang; citation_author=HF Tien; citation_volume=116; citation_publication_date=2010; citation_pages=4086-4094; citation_id=CR119;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes; citation_author=F Thol; citation_author=I Friesen; citation_author=F Damm; citation_author=H Yun; citation_author=EM Weissinger; citation_author=J Krauter; citation_author=K Wagner; citation_author=A Chaturvedi; citation_author=A Sharma; citation_author=M Wichmann; citation_author=G Gohring; citation_author=C Schumann; citation_author=G Bug; citation_author=O Ottmann; citation_author=WK Hofmann; citation_author=B Schlegelberger; citation_author=M Heuser; citation_author=A Ganser; citation_volume=29; citation_publication_date=2011; citation_pages=2499-2506; citation_id=CR120;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Haematologica; citation_title=Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes; citation_author=BL Stein; citation_author=DM Williams; citation_author=C O&#39;Keefe; citation_author=O Rogers; citation_author=RG Ingersoll; citation_author=JL Spivak; citation_author=A Verma; citation_author=JP Maciejewski; citation_author=MA McDevitt; citation_author=AR Moliterno; citation_volume=96; citation_publication_date=2011; citation_pages=1462-1469; citation_id=CR121;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs); citation_author=O Kosmider; citation_author=V Gelsi-Boyer; citation_author=M Cheok; citation_author=S Grabar; citation_author=V Della-Valle; citation_author=F Picard; citation_author=F Viguie; citation_author=B Quesnel; citation_author=O Beyne-Rauzy; citation_author=E Solary; citation_author=N Vey; citation_author=M Hunault-Berger; citation_author=P Fenaux; citation_author=MV Mansat-De; citation_author=E Delabesse; citation_author=P Guardiola; citation_author=C Lacombe; citation_author=W Vainchenker; citation_author=C Preudhomme; citation_author=F Dreyfus; citation_author=OA Bernard; citation_author=D Birnbaum; citation_author=M Fontenay; citation_volume=114; citation_publication_date=2009; citation_pages=3285-3291; citation_id=CR122;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study; citation_author=KH Metzeler; citation_author=K Maharry; citation_author=MD Radmacher; citation_author=K Mrozek; citation_author=D Margeson; citation_author=H Becker; citation_author=J Curfman; citation_author=KB Holland; citation_author=S Schwind; citation_author=SP Whitman; citation_author=YZ Wu; citation_author=W Blum; citation_author=BL Powell; citation_author=TH Carter; citation_author=M Wetzler; citation_author=JO Moore; citation_author=JE Kolitz; citation_author=MR Baer; citation_author=AJ Carroll; citation_author=RA Larson; citation_author=MA Caligiuri; citation_author=G Marcucci; citation_author=CD Bloomfield; citation_volume=29; citation_publication_date=2011; citation_pages=1373-1381; citation_id=CR123;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission; citation_author=O Nibourel; citation_author=O Kosmider; citation_author=M Cheok; citation_author=N Boissel; citation_author=A Renneville; citation_author=N Philippe; citation_author=H Dombret; citation_author=F Dreyfus; citation_author=B Quesnel; citation_author=S Geffroy; citation_author=S Quentin; citation_author=C Roche-Lestienne; citation_author=JM Cayuela; citation_author=C Roumier; citation_author=P Fenaux; citation_author=W Vainchenker; citation_author=OA Bernard; citation_author=J Soulier; citation_author=M Fontenay; citation_author=C Preudhomme; citation_volume=116; citation_publication_date=2010; citation_pages=1132-1135; citation_id=CR124;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=Prognostic relevance of integrated genetic profiling in acute myeloid leukemia; citation_author=JP Patel; citation_author=M Gonen; citation_author=ME Figueroa; citation_author=H Fernandez; citation_author=Z Sun; citation_author=J Racevskis; citation_author=VP Van; citation_author=I Dolgalev; citation_author=S Thomas; citation_author=O Aminova; citation_author=K Huberman; citation_author=J Cheng; citation_author=A Viale; citation_author=ND Socci; citation_author=A Heguy; citation_author=A Cherry; citation_author=G Vance; citation_author=RR Higgins; citation_author=RP Ketterling; citation_author=RE Gallagher; citation_author=M Litzow; citation_author=MR van den Brink; citation_author=HM Lazarus; citation_author=JM Rowe; citation_author=S Luger; citation_author=A Ferrando; citation_author=E Paietta; citation_author=MS Tallman; citation_author=A Melnick; citation_author=O Abdel-Wahab; citation_author=RL Levine; citation_volume=366; citation_publication_date=2012; citation_pages=1079-1089; citation_id=CR125;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis; citation_author=C Harrison; citation_author=JJ Kiladjian; citation_author=HK Al-Ali; citation_author=H Gisslinger; citation_author=R Waltzman; citation_author=V Stalbovskaya; citation_author=M McQuitty; citation_author=DS Hunter; citation_author=R Levy; citation_author=L Knoops; citation_author=F Cervantes; citation_author=AM Vannucchi; citation_author=T Barbui; citation_author=G Barosi; citation_volume=366; citation_publication_date=2012; citation_pages=787-798; citation_id=CR126;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Curr Opin Hematol; citation_title=Targeting myeloproliferative neoplasms with JAK inhibitors; citation_author=A Pardanani; citation_author=A Tefferi; citation_volume=18; citation_publication_date=2011; citation_pages=105-110; citation_id=CR127;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis; citation_author=S Verstovsek; citation_author=RA Mesa; citation_author=J Gotlib; citation_author=RS Levy; citation_author=V Gupta; citation_author=JF DiPersio; citation_author=JV Catalano; citation_author=M Deininger; citation_author=C Miller; citation_author=RT Silver; citation_author=M Talpaz; citation_author=EF Winton; citation_author=JH Harvey; citation_volume=366; citation_publication_date=2012; citation_pages=799-807; citation_id=CR128;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Science; citation_title=The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation; citation_author=L Wang; citation_author=A Gural; citation_author=XJ Sun; citation_author=X Zhao; citation_author=F Perna; citation_author=G Huang; citation_author=MA Hatlen; citation_author=L Vu; citation_author=F Liu; citation_author=H Xu; citation_author=T Asai; citation_author=H Xu; citation_author=T Deblasio; citation_author=S Menendez; citation_author=F Voza; citation_author=Y Jiang; citation_author=PA Cole; citation_author=J Zhang; citation_author=A Melnick; citation_author=RG Roeder; citation_author=SD Nimer; citation_volume=333; citation_publication_date=2011; citation_pages=765-769; citation_id=CR129;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias; citation_author=R Itzykson; citation_author=O Kosmider; citation_author=T Cluzeau; citation_author=MV Mansat-De; citation_author=F Dreyfus; citation_author=O Beyne-Rauzy; citation_author=B Quesnel; citation_author=N Vey; citation_author=V Gelsi-Boyer; citation_author=S Raynaud; citation_author=C Preudhomme; citation_author=L Ades; citation_author=P Fenaux; citation_author=M Fontenay; citation_volume=25; citation_publication_date=2011; citation_pages=1147-1152; citation_id=CR130;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Hematol Oncol; citation_title=Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors; citation_author=DA Pollyea; citation_author=A Raval; citation_author=B Kusler; citation_author=JR Gotlib; citation_author=AA Alizadeh; citation_author=BS Mitchell; citation_volume=29; citation_publication_date=2010; citation_pages=157-160; citation_id=CR131;'/>
    
    <meta name="citation_reference" content='citation_journal_title=FEBS J; citation_title=Biological validation that SF3b is a target of the antitumor macrolide pladienolide; citation_author=A Yokoi; citation_author=Y Kotake; citation_author=K Takahashi; citation_author=T Kadowaki; citation_author=Y Matsumoto; citation_author=Y Minoshima; citation_author=NH Sugi; citation_author=K Sagane; citation_author=M Hamaguchi; citation_author=M Iwata; citation_author=Y Mizui; citation_volume=278; citation_publication_date=2011; citation_pages=4870-4880; citation_id=CR132;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Med; citation_title=Reciprocal repression between P53 and TCTP; citation_author=R Amson; citation_author=S Pece; citation_author=A Lespagnol; citation_author=R Vyas; citation_author=G Mazzarol; citation_author=D Tosoni; citation_author=I Colaluca; citation_author=G Viale; citation_author=S Rodrigues-Ferreira; citation_author=J Wynendaele; citation_author=O Chaloin; citation_author=J Hoebeke; citation_author=JC Marine; citation_author=PP Di Fiore; citation_author=A Telerman; citation_volume=18; citation_publication_date=2012; citation_pages=91-99; citation_id=CR133;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Med; citation_title=Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound; citation_author=VJ Bykov; citation_author=N Issaeva; citation_author=A Shilov; citation_author=M Hultcrantz; citation_author=E Pugacheva; citation_author=P Chumakov; citation_author=J Bergman; citation_author=KG Wiman; citation_author=G Selivanova; citation_volume=8; citation_publication_date=2002; citation_pages=282-288; citation_id=CR134;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood Rev; citation_title=Managing resistance in chronic myeloid leukemia; citation_author=S Roychowdhury; citation_author=M Talpaz; citation_volume=25; citation_publication_date=2011; citation_pages=279-290; citation_id=CR135;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nat Rev Drug Discov; citation_title=Harnessing synthetic lethal interactions in anticancer drug discovery; citation_author=DA Chan; citation_author=AJ Giaccia; citation_volume=10; citation_publication_date=2011; citation_pages=351-364; citation_id=CR136;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Oncol Rep; citation_title=Hypothesis: more mutations to cure cancer?; citation_author=F Eisinger; citation_author=H Sobol; citation_author=D Birnbaum; citation_volume=6; citation_publication_date=1999; citation_pages=1189-1190; citation_id=CR137;'/>
    
    <meta name="prism.doi" content='10.1186/1471-2407-12-304'/>
    
    <meta name="dc.identifier" content='10.1186/1471-2407-12-304'/>
    
    <meta name="citation_doi" content='10.1186/1471-2407-12-304'/>
    
    <meta name="citation_abstract" content='&lt;h2&gt;Abstract&lt;/h2&gt;Myeloid malignant diseases comprise chronic (including myelodysplastic syndromes, myeloproliferative neoplasms and chronic myelomonocytic leukemia) and acute (acute myeloid leukemia) stages. They are clonal diseases arising in hematopoietic stem or progenitor cells. Mutations responsible for these diseases occur in several genes whose encoded proteins belong principally to five classes: signaling pathways proteins (e.g. CBL, FLT3, JAK2, RAS), transcription factors (e.g. CEBPA, ETV6, RUNX1), epigenetic regulators (e.g. ASXL1, DNMT3A, EZH2, IDH1, IDH2, SUZ12, TET2, UTX), tumor suppressors (e.g. TP53), and components of the spliceosome (e.g. SF3B1, SRSF2). Large-scale sequencing efforts will soon lead to the establishment of a comprehensive repertoire of these mutations, allowing for a better definition and classification of myeloid malignancies, the identification of new prognostic markers and therapeutic targets, and the development of novel therapies. Given the importance of epigenetic deregulation in myeloid diseases, the use of drugs targeting epigenetic regulators appears as a most promising therapeutic approach.'/>
    
    <meta name="DOI" content='10.1186/1471-2407-12-304'/>
    

        
    <script type="text/javascript">
        dataLayer = [{"content":{"article":{"doi":"10.1186/1471-2407-12-304","articleType":"Review","peerReviewType":"Open"},"contentInfo":{"imprint":"BioMed Central","title":"Myeloid malignancies: mutations, models and management","publishedAt":1343001600000,"publishedAtDate":"2012-07-23","authors":["Anne Murati","Mandy Brecqueville","Raynier Devillier","Marie-Joelle Mozziconacci","Vronique Gelsi-Boyer","Daniel Birnbaum"],"collections":[]},"attributes":{"deliveryPlatform":"oscar","template":null,"cms":null,"copyright":{"creativeCommonsType":null}},"journal":{"volume":"12","issue":"1","title":"BMC Cancer","category":"SERIES","id":12885},"category":{"pmc":{"primarySubject":"Biomedicine"}}}}]

    </script>

        

        <meta charset="UTF-8"/>
        <meta http-equiv="X-UA-Compatible" content="IE=edge"/>
        <meta name="viewport" content="width=device-width, initial-scale=1"/>
        <!-- For IE 9 and below -->
<!--[if IE]><link rel="shortcut icon" href=/static/images/favicons/biomedcentral/favicon-dc10a51d5f.ico><![endif]-->
<!-- Touch Icons - iOS and Android 2.1+ -->
<link rel="apple-touch-icon" href=/static/images/favicons/biomedcentral/favicon-0969f3a317.png>
<!-- Firefox, Chrome, Safari, IE 11+ and Opera -->
<link rel="icon" href=/static/images/favicons/biomedcentral/favicon-0969f3a317.png>
        <script>(function(H){H.className=H.className.replace(/\bno-js\b/,'js')})(document.documentElement)</script>
        <script>(function(d) {if (sessionStorage.getItem('webfonts') == 'true'){d.className += ' webfonts-loaded';}})(document.documentElement);</script>
        <link rel="stylesheet" media="screen" href=/static/styles/basic/basic-8a9ed7dce9.css>
<link rel="stylesheet" media="print" href=/static/styles/biomedcentral/biomedcentral-print-9d9c0bc8d5.css>

<link rel="stylesheet" class="js-ctm" href=/static/styles/biomedcentral/biomedcentral-1a58e9106c.css
      media="only screen and (-webkit-min-device-pixel-ratio:0) and (min-color-index:0), (-ms-high-contrast: none), only all and (min--moz-device-pixel-ratio:0) and (min-resolution: 3e1dpcm)">
        
    <script type="text/javascript">
        config = {
            env: 'live',
            site: 'bmccancer.biomedcentral.com',
            siteWithPath: 'bmccancer.biomedcentral.com' + window.location.pathname,
            twitterHashtag: '',
            cmsPrefix: 'http://studio-cms.springer.com/studio/',
            
            doi: '10.1186/1471-2407-12-304',
            figshareScriptUrl: 'https://widgets.figshare.com/static/figshare.js',
            publisherBrand: 'BioMed Central'
        };
    </script>

        
    
    <script>
        window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;

        (function() {
            var sampleRate = 20;

            ga('create', "UA-62067970-3", {
                cookieDomain: 'none',
                allowLinker: true,
                siteSpeedSampleRate: sampleRate
            });

            ga("set", "anonymizeIp", true);
            ga('send', 'pageview');

        
            ga('create', "UA-54492316-9", {
                cookieDomain: 'none',
                allowLinker: true,
                siteSpeedSampleRate: sampleRate,
                name: 'global'
            });
            ga("global.set", "anonymizeIp", true);
            ga('global.send', 'pageview');
            ga('set', 'transport', 'beacon');
        
        }())
    </script>
    <script async src='https://www.google-analytics.com/analytics.js'></script>
    

        
    
    <link rel="canonical" href="//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-304"/>
    


        

        
        
    <meta property="og:url" content="https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-304"/>
    <meta property="og:type" content="article"/>
    <meta property="og:site_name" content="BMC Cancer"/>
    <meta property="og:title" content="Myeloid malignancies: mutations, models and management"/>
    <meta property="og:description" content="Myeloid malignant diseases comprise chronic (including myelodysplastic syndromes, myeloproliferative neoplasms and chronic myelomonocytic leukemia) and acute (acute myeloid leukemia) stages. They are clonal diseases arising in hematopoietic stem or progenitor cells. Mutations responsible for these diseases occur in several genes whose encoded proteins belong principally to five classes: signaling pathways proteins (e.g. CBL, FLT3, JAK2, RAS), transcription factors (e.g. CEBPA, ETV6, RUNX1), epigenetic regulators (e.g. ASXL1, DNMT3A, EZH2, IDH1, IDH2, SUZ12, TET2, UTX), tumor suppressors (e.g. TP53), and components of the spliceosome (e.g. SF3B1, SRSF2). Large-scale sequencing efforts will soon lead to the establishment of a comprehensive repertoire of these mutations, allowing for a better definition and classification of myeloid malignancies, the identification of new prognostic markers and therapeutic targets, and the development of novel therapies. Given the importance of epigenetic deregulation in myeloid diseases, the use of drugs targeting epigenetic regulators appears as a most promising therapeutic approach."/>
    <meta property="og:image" content="https://images.springer.com/sgw/journals/medium/12885.jpg"/>

        
    </head>

    <body class="fulltext" >
    
    
        
    

    
    <div class="container" style="height: 0"><div id="wt_refpoint"></div></div>
    <p class="skip-to-main">
    <a class="skip-to-main__link" href="#main">Skip to main content</a>
</p>

    <div id="top">
        
<div id="RealMediaLeaderboard" class="adsbox RealMediaAd Ad Ad--leaderboard" data-position="Top">
    <div class="Ad_content">
        <p class="Ad_label">Advertisement</p>
        
    </div>
</div>


        



         
    <div id="membership-message-loader-desktop" class="placeholder" data-placeholder="/placeholder/v1/membership/message"></div>
    <header class="header" role="banner">
        <div class="header__inner">
            <a id="header-logo" href="//www.biomedcentral.com/" class="logo header__logo" title="BioMed Central">
                <img srcset="/static/images/biomed-central-logo-976eb64772.svg" src="/static/images/biomed-central-logo-5300b47908.png" class="logo__img" alt="Biomed Central" />
            </a>
            <div class="header__right">
                <div class="toggles js-fade-toggle">
                    <p id="loginLink" class="sign-in toggles__item" data-replace="true" data-placeholder="/placeholder/v1/username">
    <a class="sign-in__link" href="//www.biomedcentral.com/login" data-track-event="click" data-event-category="Account" data-event-action="Click Login Link">
        <span class="sign-in__no-js-account-hide">Login
            <span class="sign-in__js-account-hide"> to </span>
        </span>
        <span class="sign-in__js-account-hide sign-in__no-js-capitalise">your account</span>
    </a>
</p>
                    
                    <a href="#globalSearch" class="toggles__item toggles__item--search" data-toggle="search"><span class="sr-only">Search</span></a>
                </div>
                <form role="search" id="globalSearch" class="search search--expandable header__search" method="GET" action="//www.biomedcentral.com/search" data-track-event="submit"
      data-event-category="Search and Results" data-event-action="Submit search" data-event-label="">
    <div class="search__content">
        <label for="publisherSearch" class="sr-only">Search BioMed Central articles</label>
        <input id="publisherSearch" class="search__input" autocomplete="off" role="textbox" name="query" type="text" value="" title="Search BioMed Central" placeholder="Search BioMed Central articles"/>
        <button id="search" class="search__button" type="submit">
            <span class="sr-only">Search</span>
        </button>
        <input type="hidden" name="searchType" value="publisherSearch"/>
    </div>
</form>

            </div>
            
        </div>
    </header>

        <main role="main">
            
            <header class="journal-header" role="banner">
                <div class="journal-header__inner">
                    <h2 class="journal-header__title journal-header__title--medium" id="journalTitle">
                        
                        <a class="journal-header__title-text" href="/">
                            BMC Cancer
                        </a>
                    </h2>
                    
                </div>
                <div class="navbar">
                    <div class="navbar__inner">
                        

                        
                        <nav class="navbar__nav">
                            <h3 class="navbar__menu-toggle" data-toggle="collapse" data-target="journal-menu">
                                <span class="sr-only">Main </span>menu
                            </h3>
                            <ul id="journal-menu" class="navbar__menu" id="siteNavigation" role="menu">
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link" href='/'>Home</a>
                                    </li>
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link" href='/about'>About</a>
                                    </li>
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link is-active" href='/articles'>Articles</a>
                                    </li>
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link" href='/submission-guidelines'>Submission Guidelines</a>
                                    </li>
                                
                            </ul>
                        </nav>
                        
                    </div>
                </div>
                <div class="journal-identity journal-identity--networks-aqua">
                    
                </div>
            </header>
            
        
            <div class="container">
                
                <div id="main" class="layout">
                
                    <div class="layout__main--wide" id="main-content">
                        <div class="block" id="Test-ImgSrc">
                            
                            
    <div class="FulltextWrapper">
        <div class="Categories">
            <div class="ArticleCategory">Review</div>
            <div class="OpenAccessLabel">Open Access</div>
            
            <div class="OpenPeerReview" data-tooltip-content="open-peer-review-description">Open Peer Review</div>
            
        </div>
        
        <div class="open-peer-review-message" id="open-peer-review-description">
            <p>This article has Open Peer Review reports available.</p>
            <p><a href="/about#peer-review+policy"
                  data-track-event="click"
                  data-event-category="Article Page"
                  data-event-action="Click how does Open Peer Review work?"
                  data-event-label="10.1186/1471-2407-12-304">How does Open Peer Review work?</a></p>
        </div>
        
    </div>

                            <div class="FulltextWrapper"><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="MainTitleSection"><h1 xmlns="http://www.w3.org/1999/xhtml" class="ArticleTitle" lang="en">Myeloid malignancies: mutations, models and management</h1></div><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="AuthorNames" data-author-affiliations="true"><ul class="u-listReset"><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Anne&nbsp;Murati</span><sup><a href="#Aff1" class="AffiliationID">1</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Mandy&nbsp;Brecqueville</span><sup><a href="#Aff1" class="AffiliationID">1</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Raynier&nbsp;Devillier</span><sup><a href="#Aff1" class="AffiliationID">1</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Marie-Joelle&nbsp;Mozziconacci</span><sup><a href="#Aff1" class="AffiliationID">1</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Vronique&nbsp;Gelsi-Boyer</span><sup><a href="#Aff1" class="AffiliationID">1</a></sup> and </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Daniel&nbsp;Birnbaum</span><sup><a href="#Aff1" class="AffiliationID">1</a></sup><a href="mailto:daniel.birnbaum@inserm.fr" class="EmailAuthor" title="Email author"><span class="ContactIcon" aria-hidden="true"></span><span class="u-srOnly">Email author</span></a></li></ul></div><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="ArticleContextInformation"><div class="ContextInformation"><div class="ContextInformationJournalTitles"><span class="ArticleCitation"><span xmlns="http://www.w3.org/1999/xhtml" class="JournalTitle">BMC Cancer</span><span class="ArticleCitation_Year">2012</span><span class="ArticleCitation_Volume"><strong>12</strong>:304</span></span></div><p class="ArticleDOI"><a target="_blank" href="https://doi.org/10.1186/1471-2407-12-304">https://doi.org/10.1186/1471-2407-12-304</a></p><p class="Copyright"> &nbsp;Murati et al.; licensee BioMed Central Ltd.&nbsp;2012</p></div></div><div class="ArticleHistory"><p class="History HistoryReceived"><strong>Received: </strong>5&nbsp;October&nbsp;2011</p><p class="History HistoryAccepted"><strong>Accepted: </strong>30&nbsp;June&nbsp;2012</p><p class="History HistoryOnlineDate"><strong>Published: </strong>23&nbsp;July&nbsp;2012</p></div></div>
                            
                            
                            
    
    <div class="Message Message--opr u-marginTopL u-marginBtmL">
        <div class="Message_content">
            <p><a href="/articles/10.1186/1471-2407-12-304/open-peer-review"
                  data-track-event="click"
                  data-event-category="Article Page"
                  data-event-action="Click Open Peer Review reports"
                  data-event-label="10.1186/1471-2407-12-304">Open Peer Review reports</a></p>
        </div>
    </div>
    

                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Abstract" id="Abs1" lang="en"><h2 class="Heading js-ToggleCollapseSection">Abstract</h2><div class="js-CollapseSection"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Myeloid malignant diseases comprise chronic (including myelodysplastic syndromes, myeloproliferative neoplasms and chronic myelomonocytic leukemia) and acute (acute myeloid leukemia) stages. They are clonal diseases arising in hematopoietic stem or progenitor cells. Mutations responsible for these diseases occur in several genes whose encoded proteins belong principally to five classes: signaling pathways proteins (e.g. CBL, FLT3, JAK2, RAS), transcription factors (e.g. CEBPA, ETV6, RUNX1), epigenetic regulators (e.g. ASXL1, DNMT3A, EZH2, IDH1, IDH2, SUZ12, TET2, UTX), tumor suppressors (e.g. TP53), and components of the spliceosome (e.g. SF3B1, SRSF2). Large-scale sequencing efforts will soon lead to the establishment of a comprehensive repertoire of these mutations, allowing for a better definition and classification of myeloid malignancies, the identification of new prognostic markers and therapeutic targets, and the development of novel therapies. Given the importance of epigenetic deregulation in myeloid diseases, the use of drugs targeting epigenetic regulators appears as a most promising therapeutic approach.</p></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec1" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Introduction</h2><div class="js-CollapseSection"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Myeloid malignancies are clonal diseases of hematopoietic stem or progenitor cells. They result from genetic and epigenetic alterations that perturb key processes such as self-renewal, proliferation and differentiation. They comprise chronic stages such as myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) and acute stages, i.e acute myeloid leukemia (AML). AML can occur <em xmlns="" class="EmphasisTypeItalic">de novo</em> (~80% of the cases) or follow a chronic stage (secondary AML). According to the karyotype, AMLs can be subdivided into AML with favorable, intermediate or unfavorable cytogenetic risk [<span class="CitationRef"><a href="#CR1" data-toggle="citation" data-target="CR1">1</a></span>]. MPNs comprise a variety of disorders such as chronic myeloid leukemia (CML) and non-CML MPNs such as polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF).</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Molecular biology has always been important in hematology, especially myeloid malignant diseases. Currently however, except in some specific examples such as the <em xmlns="" class="EmphasisTypeItalic">BCR-ABL1</em> fusion in CML, and <em xmlns="" class="EmphasisTypeItalic">NPM1</em> or <em xmlns="" class="EmphasisTypeItalic">FLT3</em> mutations in <em xmlns="" class="EmphasisTypeItalic">de novo</em> AML, molecular data are not associated with optimal clinical and therapeutic exploitation in the clinic. This may change with the flurry of new data that are being generated. It all started with the discovery of the JAK2V617F mutation in MPNs [<span class="CitationRef"><a href="#CR2" data-toggle="citation" data-target="CR2">2</a></span><span class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>]. Like the characterization of the BCR-ABL1 fusion kinase, which has led to the development of an efficient targeted therapy [<span class="CitationRef"><a href="#CR6" data-toggle="citation" data-target="CR6">6</a></span>], this breakthrough showed how much progress can be made by the identification of a single molecular event regarding disease definition, understanding and classification, prognosis assessment, clinical monitoring and treatment. Since then, many new mutated genes have been identified. They affect various cell processes such as signaling, regulation of gene transcription and epigenetics, mRNA splicing and others. The aim of this review is not to describe these results in detail; this has been done in several excellent recently-published reviews [<span class="CitationRef"><a href="#CR7" data-toggle="citation" data-target="CR7">7</a></span><span class="CitationRef"><a href="#CR16" data-toggle="citation" data-target="CR16">16</a></span>]. Without putting emphasis on a particular gene, disease or cell process, it is more to discuss how the new data may improve our global vision of leukemogenesis and may be used for progress in at least three directions.</p></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec2" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Review</h2><div class="js-CollapseSection"><section id="Sec3" class="Section2 RenderAsSection2">
                <h3 class="Heading">Understanding molecular leukemogenesis</h3>
                <section id="Sec4" class="Section3 RenderAsSection3">
                  <h4 class="Heading">Identification of new mutations</h4>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The genetic events involved in leukemogenesis have been deciphered by using two approaches. First, genomic alterations have been identified by using karyotype analysis and DNA hybridization onto oligonucleotide arrays (SNP-arrays, array-CGH); several types of genomic profiles have been found: lack of detectable changes, uniparental disomies (UPD), losses of chromosomes or large chromosomal regions, trisomies, losses or gains of small regions or genes. Second, small gene mutations have been detected by classical Sanger sequencing [<span class="CitationRef"><a href="#CR17" data-toggle="citation" data-target="CR17">17</a></span><span class="CitationRef"><a href="#CR22" data-toggle="citation" data-target="CR22">22</a></span>] or, more recently, by the use of new technologies such as next generation sequencing (NGS) [<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span><span class="CitationRef"><a href="#CR31" data-toggle="citation" data-target="CR31">31</a></span>].</p>
                  <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">These studies, together with previous ones that had identified <em xmlns="" class="EmphasisTypeItalic">JAK2, NPM1, MPL, RAS</em> and <em xmlns="" class="EmphasisTypeItalic">RUNX1</em> mutations, among others, led to the discovery of several major players in leukemogenesis: <em xmlns="" class="EmphasisTypeItalic">ASXL1</em>[<span class="CitationRef"><a href="#CR21" data-toggle="citation" data-target="CR21">21</a></span>], <em xmlns="" class="EmphasisTypeItalic">BCORL1</em>[<span class="CitationRef"><a href="#CR25" data-toggle="citation" data-target="CR25">25</a></span>], <em xmlns="" class="EmphasisTypeItalic">CBL</em>[<span class="CitationRef"><a href="#CR19" data-toggle="citation" data-target="CR19">19</a></span>], <em xmlns="" class="EmphasisTypeItalic">DNMT3A</em>[<span class="CitationRef"><a href="#CR24" data-toggle="citation" data-target="CR24">24</a></span>, <span class="CitationRef"><a href="#CR32" data-toggle="citation" data-target="CR32">32</a></span>], <em xmlns="" class="EmphasisTypeItalic">EZH2</em>[<span class="CitationRef"><a href="#CR20" data-toggle="citation" data-target="CR20">20</a></span>, <span class="CitationRef"><a href="#CR22" data-toggle="citation" data-target="CR22">22</a></span>], <em xmlns="" class="EmphasisTypeItalic">IDH1/IDH2</em>[<span class="CitationRef"><a href="#CR26" data-toggle="citation" data-target="CR26">26</a></span>], <em xmlns="" class="EmphasisTypeItalic">TET2</em>[<span class="CitationRef"><a href="#CR18" data-toggle="citation" data-target="CR18">18</a></span>] and <em xmlns="" class="EmphasisTypeItalic">UTX</em>[<span class="CitationRef"><a href="#CR33" data-toggle="citation" data-target="CR33">33</a></span>]. The mutational frequencies of these genes range from a few percent to more than 50%, or even virtually 100%, depending on the gene, the disease and the series studied. Thus, almost all cases of PV have a mutation of <em xmlns="" class="EmphasisTypeItalic">JAK2</em>[<span class="CitationRef"><a href="#CR34" data-toggle="citation" data-target="CR34">34</a></span>, <span class="CitationRef"><a href="#CR35" data-toggle="citation" data-target="CR35">35</a></span>]. Not counting the latter, mutations in <em xmlns="" class="EmphasisTypeItalic">ASXL1</em> and <em xmlns="" class="EmphasisTypeItalic">TET2</em> are frequently observed throughout the whole myeloid spectrum (Figure <span class="InternalRef"><a href="#Fig1">1</a></span>), reaching 40-50% in CMML [<span class="CitationRef"><a href="#CR33" data-toggle="citation" data-target="CR33">33</a></span>, <span class="CitationRef"><a href="#CR36" data-toggle="citation" data-target="CR36">36</a></span>]. Mutations in <em xmlns="" class="EmphasisTypeItalic">DNMT3A</em> and <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> are rare in the chronic stages but reach 15-20% in AML and exhibit a strong association with monocytic features [<span class="CitationRef"><a href="#CR30" data-toggle="citation" data-target="CR30">30</a></span>]. Genes encoding components of the splicing machinery that is involved in the splicing of introns during pre-mRNA maturation (mainly <em xmlns="" class="EmphasisTypeItalic">SF3B1, SRSF2, U2AF35/U2AF1</em>, and <em xmlns="" class="EmphasisTypeItalic">ZRSR2</em>) have been found frequently mutated in MDSs and CMML, and more rarely in MPNs and AML (Figure <span class="InternalRef"><a href="#Fig1">1</a></span>) [<span class="CitationRef"><a href="#CR31" data-toggle="citation" data-target="CR31">31</a></span>, <span class="CitationRef"><a href="#CR37" data-toggle="citation" data-target="CR37">37</a></span><span class="CitationRef"><a href="#CR42" data-toggle="citation" data-target="CR42">42</a></span>]. Mutations in splicing factors are found in more than 60% of MDS with ring sideroblasts and in more than 50% of CMML [<span class="CitationRef"><a href="#CR31" data-toggle="citation" data-target="CR31">31</a></span>].<figure xmlns="" class="Figure" id="Fig1"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                        <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_Article_3221_Fig1_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_Article_3221_Fig1_HTML.jpg"></img></a>
                      </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 1</span>
                          <p xmlns="" class="SimplePara">
<strong class="EmphasisTypeBold">Circos diagrams depict the relative frequency and associations of the major mutations in MPNs (a) and MDSs (b), respectively based on data from our work</strong>[<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR37" data-toggle="citation" data-target="CR37">37</a></span>]<strong class="EmphasisTypeBold">on</strong> <strong class="EmphasisTypeBold">127 classic MPNs and from Damms study</strong>[<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR38" data-toggle="citation" data-target="CR38">38</a></span>]<strong class="EmphasisTypeBold">on 221 MDSs.</strong> Wild-type means that no disease allele has been detected in the genes listed.</p>
                        </div></figcaption></figure>
</div>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Mutations in leukemogenic genes have been described in detail in recent reviews [<span class="CitationRef"><a href="#CR7" data-toggle="citation" data-target="CR7">7</a></span>, <span class="CitationRef"><a href="#CR9" data-toggle="citation" data-target="CR9">9</a></span>, <span class="CitationRef"><a href="#CR10" data-toggle="citation" data-target="CR10">10</a></span>, <span class="CitationRef"><a href="#CR12" data-toggle="citation" data-target="CR12">12</a></span><span class="CitationRef"><a href="#CR16" data-toggle="citation" data-target="CR16">16</a></span>, <span class="CitationRef"><a href="#CR43" data-toggle="citation" data-target="CR43">43</a></span>]; and will not be reviewed here. We will rather delve on the questions aroused by these recent data.</p>
                </section>
                <section id="Sec5" class="Section3 RenderAsSection3">
                  <h4 class="Heading">Have we already identified the entire repertoire of mutated genes?</h4>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">We may have identified (most of) the major culprits [<span class="CitationRef"><a href="#CR14" data-toggle="citation" data-target="CR14">14</a></span>]. First, there are hundreds of background mutations (i.e. that do not provide selective advantage) but only a limited number of driver mutations (i.e. that cause the disease) in each malignant disease. Second, many of the newly discovered mutated genes may affect the same pathways or networks as the major mutated genes. For example, deletions and mutations of <em xmlns="" class="EmphasisTypeItalic">NF1</em>, which have been recently identified [<span class="CitationRef"><a href="#CR17" data-toggle="citation" data-target="CR17">17</a></span>, <span class="CitationRef"><a href="#CR44" data-toggle="citation" data-target="CR44">44</a></span>, <span class="CitationRef"><a href="#CR45" data-toggle="citation" data-target="CR45">45</a></span>], or <em xmlns="" class="EmphasisTypeItalic">PTPN11</em>[<span class="CitationRef"><a href="#CR46" data-toggle="citation" data-target="CR46">46</a></span>] are thought to have the same effect as a <em xmlns="" class="EmphasisTypeItalic">RAS</em> mutation; a mutation of the <em xmlns="" class="EmphasisTypeItalic">SHKBP1</em> gene [<span class="CitationRef"><a href="#CR47" data-toggle="citation" data-target="CR47">47</a></span>] or a duplication of the <em xmlns="" class="EmphasisTypeItalic">SH3KBP1</em> gene [<span class="CitationRef"><a href="#CR48" data-toggle="citation" data-target="CR48">48</a></span>], which both encode cytoplasmic regulators of the CBL pathway, may have the same effect as a <em xmlns="" class="EmphasisTypeItalic">CBL</em> mutation [<span class="CitationRef"><a href="#CR49" data-toggle="citation" data-target="CR49">49</a></span>, <span class="CitationRef"><a href="#CR50" data-toggle="citation" data-target="CR50">50</a></span>]. Because EZH2, EED and SUZ12 proteins all belong to the same polycomb complex 2 (PRC2) the rare deletions or mutations of the <em xmlns="" class="EmphasisTypeItalic">EED</em>[<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>, <span class="CitationRef"><a href="#CR51" data-toggle="citation" data-target="CR51">51</a></span>] and <em xmlns="" class="EmphasisTypeItalic">SUZ12</em> genes [<span class="CitationRef"><a href="#CR17" data-toggle="citation" data-target="CR17">17</a></span>, <span class="CitationRef"><a href="#CR51" data-toggle="citation" data-target="CR51">51</a></span>] could have the same effect as <em xmlns="" class="EmphasisTypeItalic">EZH2</em> mutations. Third, several genes (e.g. <em xmlns="" class="EmphasisTypeItalic">ETV6</em>[<span class="CitationRef"><a href="#CR52" data-toggle="citation" data-target="CR52">52</a></span>] or <em xmlns="" class="EmphasisTypeItalic">RUNX1</em>) can be structurally altered by mechanisms other than mutation, such as deletions and breakages. Fourth, some important regulatory genes could be affected not by structural alteration but through other mechanisms such as abnormal DNA methylation (e.g. <em xmlns="" class="EmphasisTypeItalic">CDKN2A/B</em>[<span class="CitationRef"><a href="#CR53" data-toggle="citation" data-target="CR53">53</a></span>], <em xmlns="" class="EmphasisTypeItalic">TRIM33</em>[<span class="CitationRef"><a href="#CR54" data-toggle="citation" data-target="CR54">54</a></span>], <em xmlns="" class="EmphasisTypeItalic">CTNNA1</em>[<span class="CitationRef"><a href="#CR55" data-toggle="citation" data-target="CR55">55</a></span>], <em xmlns="" class="EmphasisTypeItalic">SOCS1</em>[<span class="CitationRef"><a href="#CR56" data-toggle="citation" data-target="CR56">56</a></span>, <span class="CitationRef"><a href="#CR57" data-toggle="citation" data-target="CR57">57</a></span>]), histone modifications, mRNA splicing, microRNA or long non-coding RNA (lncRNA) modulation, or product degradation. Fifth, when all known mutated genes are analyzed in a series of cases, the percentage of samples with at least one mutated candidate driver gene varies from 50% [<span class="CitationRef"><a href="#CR58" data-toggle="citation" data-target="CR58">58</a></span>] to over 90% (in CMML; [<span class="CitationRef"><a href="#CR33" data-toggle="citation" data-target="CR33">33</a></span>]; Gelsi-Boyer et al., submitted). Moreover, most samples studied by NGS were shown to harbor gene mutations [<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>, <span class="CitationRef"><a href="#CR26" data-toggle="citation" data-target="CR26">26</a></span>]. Thus, we are soon approaching the days where all cases can be defined by combination of several alterations. The practical definition of leukemogenesis will then be based on a specific and limited repertoire of alterations, including translocations, mutations and copy number changes, affecting a defined set of driver genes.</p>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">However, some issues still need be addressed. First, many genes may be mutated or deleted with a very low frequency (i.e. under 1%); their involvement and recurrence may be hard to demonstrate. Second, because NGS studies of several malignancies have shown that hundreds of genes can be mutated in a single tumor, background mutations should be discarded and driver genes validated. Third, we still miss information in some diseases such as essential thrombocythemia (ET), in which <em xmlns="" class="EmphasisTypeItalic">JAK2</em> mutations are found in only half the cases, and <em xmlns="" class="EmphasisTypeItalic">TET2</em> mutations in less than 10%. We also lack knowledge about the targeted genes of some frequent genomic alterations such as the 20q11-q13 deletion (<em xmlns="" class="EmphasisTypeItalic">ASXL1</em> and <em xmlns="" class="EmphasisTypeItalic">DNMT3B</em>, more centromeric, are not involved). Fortunately, this lack of information is bound to disappear. The example of refractory anemia with ring sideroblasts (RARS) is instructive; in three-quarters of RARS, mutations have been recently found in <em xmlns="" class="EmphasisTypeItalic">SF3B1</em>, a gene encoding a subunit of a splicing factor (U2 snRNP) and histone acetyltransferase (STAGA) complexes [<span class="CitationRef"><a href="#CR27" data-toggle="citation" data-target="CR27">27</a></span>, <span class="CitationRef"><a href="#CR29" data-toggle="citation" data-target="CR29">29</a></span>, <span class="CitationRef"><a href="#CR31" data-toggle="citation" data-target="CR31">31</a></span>].</p>
                </section>
                <section id="Sec6" class="Section3 RenderAsSection3">
                  <h4 class="Heading">Is there some specificity in gene alterations?</h4>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Gene fusions (e.g. <em xmlns="" class="EmphasisTypeItalic">BCR-ABL1, PML-RARA, FGFR1</em>-associated fusions), 5q deletion and <em xmlns="" class="EmphasisTypeItalic">JAK2</em> mutations are specific of some forms of myeloid diseases, although <em xmlns="" class="EmphasisTypeItalic">JAK2</em> mutations occur in three distinct subtypes of MPN. <em xmlns="" class="EmphasisTypeItalic">RUNX1</em> mutations are frequent in MDSs, CMML and AML but rare in MPNs. Among splicing factor genes, mutations in <em xmlns="" class="EmphasisTypeItalic">SF3B1</em> are highly specific of MDS with ring sideroblasts and <em xmlns="" class="EmphasisTypeItalic">SRSF2</em> mutations are most frequent in CMML [<span class="CitationRef"><a href="#CR31" data-toggle="citation" data-target="CR31">31</a></span>]. In contrast, some mutated genes (e.g. <em xmlns="" class="EmphasisTypeItalic">ASXL1, DNMT3A, EZH2, TET2</em>) occur in a wide range of myeloid diseases and with various frequencies. Future studies may identify mutations or combinations of mutations that drive a specific phenotype.</p>
                </section>
                <section id="Sec7" class="Section3 RenderAsSection3">
                  <h4 class="Heading">What are the functions of the mutated proteins ?</h4>
                  <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Leukemogenic alterations mainly affect five classes of proteins (Figure <span class="InternalRef"><a href="#Fig2">2</a></span>): signaling pathway components, such as ABL, CBL, CBLB, FGFR1, FLT3, JAK2, KIT, LNK, MPL, PDGFRs, PTPN11, PTPRT [<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>, <span class="CitationRef"><a href="#CR59" data-toggle="citation" data-target="CR59">59</a></span>] and RAS, transcription factors (TFs) such as CEBPA, ETV6 [<span class="CitationRef"><a href="#CR58" data-toggle="citation" data-target="CR58">58</a></span>], GATA2 [<span class="CitationRef"><a href="#CR30" data-toggle="citation" data-target="CR30">30</a></span>], IKZF1 [<span class="CitationRef"><a href="#CR60" data-toggle="citation" data-target="CR60">60</a></span>], RARA and RUNX1, epigenetic regulators (ERs), such as ASXL1, BCORL1 [<span class="CitationRef"><a href="#CR25" data-toggle="citation" data-target="CR25">25</a></span>], DAXX [<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>], DNMT3A, EZH2 [<span class="CitationRef"><a href="#CR20" data-toggle="citation" data-target="CR20">20</a></span>, <span class="CitationRef"><a href="#CR22" data-toggle="citation" data-target="CR22">22</a></span>], MLL, MYST3, NSD1 [<span class="CitationRef"><a href="#CR30" data-toggle="citation" data-target="CR30">30</a></span>], PHF6 [<span class="CitationRef"><a href="#CR61" data-toggle="citation" data-target="CR61">61</a></span>], SUZ12 [<span class="CitationRef"><a href="#CR17" data-toggle="citation" data-target="CR17">17</a></span>, <span class="CitationRef"><a href="#CR51" data-toggle="citation" data-target="CR51">51</a></span>], TET2 and UTX [<span class="CitationRef"><a href="#CR28" data-toggle="citation" data-target="CR28">28</a></span>], tumor suppressors (TSG), such as CDKN2A, TP53, and WT1 and components of the spliceosome [<span class="CitationRef"><a href="#CR27" data-toggle="citation" data-target="CR27">27</a></span>, <span class="CitationRef"><a href="#CR29" data-toggle="citation" data-target="CR29">29</a></span>, <span class="CitationRef"><a href="#CR31" data-toggle="citation" data-target="CR31">31</a></span>, <span class="CitationRef"><a href="#CR38" data-toggle="citation" data-target="CR38">38</a></span>, <span class="CitationRef"><a href="#CR39" data-toggle="citation" data-target="CR39">39</a></span>, <span class="CitationRef"><a href="#CR41" data-toggle="citation" data-target="CR41">41</a></span>, <span class="CitationRef"><a href="#CR42" data-toggle="citation" data-target="CR42">42</a></span>]. However, additional alterations occur in genes encoding proteins that it is too early to classified into these defined categories, such as DIS3, DDX41 [<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>], mitochondrial NAPDH dehydrogenase ND4 [<span class="CitationRef"><a href="#CR62" data-toggle="citation" data-target="CR62">62</a></span>], or cohesin complex proteins [<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>, <span class="CitationRef"><a href="#CR63" data-toggle="citation" data-target="CR63">63</a></span>].<figure xmlns="" class="Figure" id="Fig2"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                        <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_Article_3221_Fig2_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_Article_3221_Fig2_HTML.jpg"></img></a>
                      </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 2</span>
                          <p xmlns="" class="SimplePara">
<strong class="EmphasisTypeBold">Schematic representation of five classes of leukemogenic genes.</strong> ERs (class III) can be subdivided into two subclasses (DNA methylation-associated and histone-associated).</p>
                        </div></figcaption></figure>
</div>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">In chronic stages, alterations in signaling molecules can be grouped in two major categories, a first one that is found in MPNs and affects oncogenic tyrosine kinases (ABL1, JAK2, FGFR1, PDGFRs) and the downstream JAK-STAT and/or PI3-kinase pathways, and a second one that is mutated in CMML and affect the RAS-MAP kinase pathway (RAS, PTPN11, NF1). CBL alterations occur in a wide variety of myeloid diseases [<span class="CitationRef"><a href="#CR50" data-toggle="citation" data-target="CR50">50</a></span>].</p>
                  <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">TFs and ERs constitute the largest classes, which involve several categories of proteins (Figure <span class="InternalRef"><a href="#Fig3">3</a></span>); because there are many ways to affect gene expression it is probable that not all of these categories are known yet. The existence of epigenetic alterations in myeloid malignancies has been known for long time [<span class="CitationRef"><a href="#CR64" data-toggle="citation" data-target="CR64">64</a></span>, <span class="CitationRef"><a href="#CR65" data-toggle="citation" data-target="CR65">65</a></span>]. For example, alterations of MLL, a histone methyltransferase (HMT), and MYST3, a histone acetyltransferase (HAT), have shown the importance of epigenetic deregulation in AMLs with translocation [<span class="CitationRef"><a href="#CR45" data-toggle="citation" data-target="CR45">45</a></span>, <span class="CitationRef"><a href="#CR64" data-toggle="citation" data-target="CR64">64</a></span>, <span class="CitationRef"><a href="#CR65" data-toggle="citation" data-target="CR65">65</a></span>]. However, in chronic diseases and in AMLs with normal karyotype, the extent, causes, identities, exact roles and consequences of epigenetic alterations have long remained elusive. Molecular studies have recently shown that both DNA methylation and histone regulation are affected, and that epigenetic alterations may be due to genetic alterations, (i.e. mutations in genes encoding epigenetic regulators). The latter phenomenon has been observed in genome-wide analyses of many neoplasias [<span class="CitationRef"><a href="#CR28" data-toggle="citation" data-target="CR28">28</a></span>, <span class="CitationRef"><a href="#CR66" data-toggle="citation" data-target="CR66">66</a></span>, <span class="CitationRef"><a href="#CR67" data-toggle="citation" data-target="CR67">67</a></span>]. However, not all epigenetic alterations may be due to an abnormal genetic background [<span class="CitationRef"><a href="#CR1" data-toggle="citation" data-target="CR1">1</a></span>, <span class="CitationRef"><a href="#CR53" data-toggle="citation" data-target="CR53">53</a></span>, <span class="CitationRef"><a href="#CR54" data-toggle="citation" data-target="CR54">54</a></span>].<figure xmlns="" class="Figure" id="Fig3"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                        <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_Article_3221_Fig3_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_Article_3221_Fig3_HTML.jpg"></img></a>
                      </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 3</span>
                          <p xmlns="" class="SimplePara">
<strong class="EmphasisTypeBold">Schematic representation of epigenetic regulation of a leukemogenic locus (LL) framed by histone H3.</strong> (<strong class="EmphasisTypeBold">a</strong>) Histone acetyltransferases (HAT; e.g. MYST3) and histone methyltransferases (HMT; e.g. MLL) can activate the locus. (<strong class="EmphasisTypeBold">b</strong>) Reciprocally, the locus is repressed by polycomb complex PRC2 (which comprised EED, EZH2 and SUZ12 proteins). ASXL1 would direct PRC2 to the locus. Loss-of-function mutations in PRC2 components or in ASXL1 remove PRC2 repression. DNMT3A is involved in the formation of 5-methylcytosines (5mC) from cytosines and interacts with HMTs as well as with PRC2 components. TET2 mediates hydroxylation of 5mC to 5hmC. To function, TET2 requires -ketoglutarate (KG), which is provided by IDH1/2 proteins. Aberrant methylation patterns are caused by mutation in TET2 or in IDH1/2, which produces 2-hydroxyglutarate instead of KG.</p>
                        </div></figcaption></figure>
</div>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The recent reports of the interrelated functions of IDH1/2 and TET2 in DNA methylation represent a major breakthrough in our understanding of leukemogenesis [<span class="CitationRef"><a href="#CR68" data-toggle="citation" data-target="CR68">68</a></span>]. It was initially hard to associate mutations of IDH1 and IDH2, two metabolic enzymes, with mutations in TET2, an unknown gene product, and as hard to suspect their role on DNA methylation. A very rapid series of elegant studies have shown i) that <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> and <em xmlns="" class="EmphasisTypeItalic">TET2</em> mutations are mutually exclusive in myeloid malignancies [<span class="CitationRef"><a href="#CR68" data-toggle="citation" data-target="CR68">68</a></span>], ii) that mutated IDH1 and IDH2 produce 2-hydroxyglutarate instead of alpha-ketoglutarate (KG) [<span class="CitationRef"><a href="#CR69" data-toggle="citation" data-target="CR69">69</a></span>, <span class="CitationRef"><a href="#CR70" data-toggle="citation" data-target="CR70">70</a></span>], iii) that <em xmlns="" class="EmphasisTypeItalic">TET2</em> encodes an KGdependent methyl cytosine dioxygenase whose mutation alters the conversion of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) [<span class="CitationRef"><a href="#CR68" data-toggle="citation" data-target="CR68">68</a></span>, <span class="CitationRef"><a href="#CR71" data-toggle="citation" data-target="CR71">71</a></span>] and iv) that both <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> and <em xmlns="" class="EmphasisTypeItalic">TET2</em> mutations impact on DNA methylation and are involved in the same biochemical pathway [<span class="CitationRef"><a href="#CR72" data-toggle="citation" data-target="CR72">72</a></span>]. In addition, TET proteins can generate from 5-hmC 5-formylcytosine and 5-carboxylcytosine, but their roles are currently unknown [<span class="CitationRef"><a href="#CR73" data-toggle="citation" data-target="CR73">73</a></span>]. The recent studies on TET proteins suggest a role in removing aberrant DNA methylation to ensure DNA methylation fidelity [<span class="CitationRef"><a href="#CR74" data-toggle="citation" data-target="CR74">74</a></span>]. This has opened a new area of research since first, other factors involved in DNA demethylation may exist and second, several KGdependent enzymes, such as jumonji histone demethylases [<span class="CitationRef"><a href="#CR75" data-toggle="citation" data-target="CR75">75</a></span>] are epigenetic regulators; therefore, some of these proteins could also be involved in malignancies. However, <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> and <em xmlns="" class="EmphasisTypeItalic">TET2</em> mutations, while mutually exclusive, are not equivalent because <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> mutations are more frequent in acute than in chronic myeloid diseases, whereas it is not the case for <em xmlns="" class="EmphasisTypeItalic">TET2</em> alterations, which are more evenly distributed between chronic and acute stages. Inactivation of TET2 increases self-renewal in hematopoietic stem cells and induces a disease resembling CMML in mouse models [<span class="CitationRef"><a href="#CR76" data-toggle="citation" data-target="CR76">76</a></span>, <span class="CitationRef"><a href="#CR77" data-toggle="citation" data-target="CR77">77</a></span>]. Mutated IDH1/2 enzymes may impact on self-renewal but with a different strength. The likely explanation is that IDH1/2 and TET2 have other, non-overlapping functions on the regulation of DNA methylation and histone marks. Also, an IDH-mutated product may depend on another, rate-limiting factor to exert a leukemogenic effect. DNMT3A is a <em xmlns="" class="EmphasisTypeItalic">de novo</em> DNA methyltransferase involved in the formation of 5-mC and has complex interactions with polycomb and HMT proteins [<span class="CitationRef"><a href="#CR78" data-toggle="citation" data-target="CR78">78</a></span>]. How DNMT3A mutations affect DNA methylation remains to be defined [<span class="CitationRef"><a href="#CR24" data-toggle="citation" data-target="CR24">24</a></span>, <span class="CitationRef"><a href="#CR30" data-toggle="citation" data-target="CR30">30</a></span>, <span class="CitationRef"><a href="#CR79" data-toggle="citation" data-target="CR79">79</a></span>]; they probably do so in a different way from <em xmlns="" class="EmphasisTypeItalic">TET2</em> or <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> mutations since they may co-occur with either of them. A recent study showed that DNMT3A loss leads to upregulation of hematopoietic stem cell genes and downregulation of differentiation genes but is alone insufficient to induce a malignant disease in a mouse model [<span class="CitationRef"><a href="#CR79" data-toggle="citation" data-target="CR79">79</a></span>].</p>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Mutations in regulators of histone marks have become a major subject of research and the relationships between them are quickly unveiled. Central regulators of myelopoiesis and key players in leukemogenesis seem to be the polycomb regulatory complexes, especially PRC2, which, in addition to direct defects of its components (EED, EZH2, SUZ12), could be affected in its concerted action with several ERs, such as ASXL1, cohesins, DNMT3A, IDH1/2, MLL, TET2 and UTX. TET proteins could regulate pluripotency and self-renewal through interaction with PRC2 [<span class="CitationRef"><a href="#CR74" data-toggle="citation" data-target="CR74">74</a></span>, <span class="CitationRef"><a href="#CR80" data-toggle="citation" data-target="CR80">80</a></span>, <span class="CitationRef"><a href="#CR81" data-toggle="citation" data-target="CR81">81</a></span>]. The cohesin complex is encoded by four genes (<em xmlns="" class="EmphasisTypeItalic">SMC1, SMC3, RAD21</em> and <em xmlns="" class="EmphasisTypeItalic">STAG2</em>), which have been found mutated [<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>] and deleted [<span class="CitationRef"><a href="#CR63" data-toggle="citation" data-target="CR63">63</a></span>]. A major interactor of cohesin complex is CTCF. PRC2 is recruited to specific loci through interaction of SUZ12 with CTCF [<span class="CitationRef"><a href="#CR82" data-toggle="citation" data-target="CR82">82</a></span>]. Another main leukemogenic interactor of PRC2 components is ASXL1. A recent study showed that ASXL1 loss affects PRC2 complexes and H3K27me3 histone marks, and induces a strong hematopoietic phenotype consistent with an MDS in a conditional knock-out mouse model [<span class="CitationRef"><a href="#CR83" data-toggle="citation" data-target="CR83">83</a></span>]. ASXL1 would direct PRC2 to leukemogenic loci such as <em xmlns="" class="EmphasisTypeItalic">HOXA</em> genes. Thus, through direct alterations of its components or of proteins or lncRNAs [<span class="CitationRef"><a href="#CR84" data-toggle="citation" data-target="CR84">84</a></span>] that recruit the complex, PRC2 has emerged as a key node in a network regulating hematopoietic stem cell self-renewal and proliferation and as a major factor in myeloid leukemogenesis. This is also true for T-cell leukemogenesis [<span class="CitationRef"><a href="#CR85" data-toggle="citation" data-target="CR85">85</a></span>]. Correct functioning of polycomb repressive complex 1 (PRC1) seems also to be important for myeloid cells since the loss of BMI1 (a component of PRC1) in the mouse leads to a disease similar to PMF [<span class="CitationRef"><a href="#CR86" data-toggle="citation" data-target="CR86">86</a></span>]. Structural alterations of the <em xmlns="" class="EmphasisTypeItalic">BMI1</em> gene occur but are rare in human myeloid diseases [<span class="CitationRef"><a href="#CR87" data-toggle="citation" data-target="CR87">87</a></span>].</p>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Whether other chromatin-associated complexes play a role in leukemogenesis should soon be revealed. ASXL1 could play a role in a cross-talk between major chromatin silencing systems, PRC1/PRC2, HP1/CBX5 heterochromatin repressive complex and polycomb repressive deubiquitinase (PR-DUB) complex. Mutations in <em xmlns="" class="EmphasisTypeItalic">BCOR</em> and <em xmlns="" class="EmphasisTypeItalic">BCORL1</em> suggest that the RAF/BCOR complex [<span class="CitationRef"><a href="#CR84" data-toggle="citation" data-target="CR84">84</a></span>, <span class="CitationRef"><a href="#CR88" data-toggle="citation" data-target="CR88">88</a></span>] might be involved in AML. The recent identification of a mutation in the <em xmlns="" class="EmphasisTypeItalic">DAXX</em> gene in an AML case [<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>] further supports a wide participation of chromatin-regulatory complexes in leukemogenesis and cancer in general. DAXX and ATRX (which is mutated in X-linked -thalassemia) are subunits of a chromatin remodeling complex and are both mutated in solid tumors [<span class="CitationRef"><a href="#CR89" data-toggle="citation" data-target="CR89">89</a></span>, <span class="CitationRef"><a href="#CR90" data-toggle="citation" data-target="CR90">90</a></span>].</p>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The importance of the fifth class of mutated genes was more unexpected. Mutations in components of the spliceosome, which are mutually exclusive, lead to splicing defects including exon skipping, intron retention and use of incorrect splice site [<span class="CitationRef"><a href="#CR31" data-toggle="citation" data-target="CR31">31</a></span>]. A recent study showed that a consequence of splicing gene mutations is accumulation of unspliced transcripts affecting a specific subset of mRNAs [<span class="CitationRef"><a href="#CR41" data-toggle="citation" data-target="CR41">41</a></span>].</p>
                </section>
                <section id="Sec8" class="Section3 RenderAsSection3">
                  <h4 class="Heading">What are the effects of the gene mutations?</h4>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The dominant-positive effects of oncogenes such as <em xmlns="" class="EmphasisTypeItalic">BCR-ABL1</em>, mutated <em xmlns="" class="EmphasisTypeItalic">FLT3, JAK2</em> or <em xmlns="" class="EmphasisTypeItalic">RAS,</em> have been easy to apprehend. <em xmlns="" class="EmphasisTypeItalic">CBL</em> and <em xmlns="" class="EmphasisTypeItalic">LNK</em> mutations inactivate brakes on signaling pathways and may have a dominant-negative effect. <em xmlns="" class="EmphasisTypeItalic">TET2</em> is inactivated in the manner of a tumor suppressor. <em xmlns="" class="EmphasisTypeItalic">EZH2</em> is frequently associated with UPD and acts as a TSG. A frequent form of defect seems to be haplo-insufficiency [<span class="CitationRef"><a href="#CR91" data-toggle="citation" data-target="CR91">91</a></span>], which could be associated with the (generally) heterozygous loss or mutation of <em xmlns="" class="EmphasisTypeItalic">ASXL1, NF1, NPM1, TP53, RUNX1</em> or <em xmlns="" class="EmphasisTypeItalic">TET2</em>. Neo-functionalization results from <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> mutations, which are always mono-allelic. For genes altered through different mechanisms (mutations, deletions or translocations) such as <em xmlns="" class="EmphasisTypeItalic">RUNX1</em> or with different types of mutations (hotspot or dispersed) such as <em xmlns="" class="EmphasisTypeItalic">DNMT3A</em>, the function might be variably affected and some mutants may have a dominant-negative effect. Mutations in spliceosome genes are mostly missense and could result in proteins with a modified but not inactivated function.</p>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Mutations in signaling pathways, transcription networks and splicing machinery have many downstream consequences. Modifications in epigenetic regulation of DNA and histones may have a strong amplifying effect since they impact on the transcription of thousands of genes. This in turn impacts on the properties of hematopoietic stem cells, favoring self-renewal and proliferation over differentiation, thus promoting leukemogenesis [<span class="CitationRef"><a href="#CR92" data-toggle="citation" data-target="CR92">92</a></span>]. However, chimeric proteins involving TFs and ERs (e.g. MLL, MYST3, NSD1 ) may induce a stronger effect than mutations in other TFs and ERs (such as ASXL1, EZH2 or TET2), which may need to co-occur with several other alterations to trigger AML, often after a chronic phase. Perhaps like the difference between a water jet and a sprinkling rain, this difference may have to do with the specific functions of TFs and ERs [<span class="CitationRef"><a href="#CR64" data-toggle="citation" data-target="CR64">64</a></span>]. TF and ER fusion proteins assemble in complexes that are directly recruited to their target genes where they modify the local histone marks, drastically altering transcription. In contrast, mutated ERs may moderately perturb the epigenetic network, resulting in global gene deregulation.</p>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Mutations in spliceosome components may lead to several types of deregulation, including alterations of the epigenetic control of differentiation and self-renewal; they may thus result in the same defects as TF and ER mutations. This may derive from splicing aberrations of leukemogenic genes (e.g. <em xmlns="" class="EmphasisTypeItalic">RUNX1</em>) [<span class="CitationRef"><a href="#CR41" data-toggle="citation" data-target="CR41">41</a></span>] or from other specific but indirect defects. SF3B1 for example interacts with components of the polycomb repressor complex 1 (PRC1) and <em xmlns="" class="EmphasisTypeItalic">SF3B1</em> mutations may compromise PRC1 regulation of leukemogenic loci [<span class="CitationRef"><a href="#CR93" data-toggle="citation" data-target="CR93">93</a></span>]. Reciprocally, the function of the pre-mRNA splicing machinery involves the reading of histone marks, and defective chromatin regulators may affect splicing [<span class="CitationRef"><a href="#CR94" data-toggle="citation" data-target="CR94">94</a></span>]. Directly or indirectly, <em xmlns="" class="EmphasisTypeItalic">SF3B1</em> mutations, which are associated with the presence of ring sideroblasts, are likely to affect genes involved in red cell biology and mitochondria function. Because mutations in splicing genes, in TFs and in ERs are not mutually exclusive it is probable that the three types of alterations have additive rather than interchangeable effects.</p>
                </section>
              </section><section id="Sec9" class="Section2 RenderAsSection2">
                <h3 class="Heading">Modeling molecular leukemogenesis</h3>
                <section id="Sec10" class="Section3 RenderAsSection3">
                  <h4 class="Heading">Are there preferential combinations and mutual exclusions?</h4>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Two driver mutations may never occur together (mutual exclusion) in the same cell because of epistasis (two hits in the same pathway are not selected because they do not provide a growth advantage) or synthetic lethality (two hits are counter-selected because they compromise the life of the leukemic cell). Associations and cooperation can occur in all other cases.</p>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Some chronic myeloid malignancies, such as CMML (myeloproliferative form, MP-CMML) and MPNs, have a proliferative component. This component is driven by alterations in signaling molecules, such as <em xmlns="" class="EmphasisTypeItalic">CBL, CBLB, FLT3, JAK2, LNK, MPL, NF1, PTPN11</em> or <em xmlns="" class="EmphasisTypeItalic">RAS</em>. These mutations are generally mutually exclusive. However, <em xmlns="" class="EmphasisTypeItalic">JAK2</em> mutations can be found in patients with mutations of <em xmlns="" class="EmphasisTypeItalic">CBL</em> <em xmlns="" class="EmphasisTypeItalic">LNK</em> or <em xmlns="" class="EmphasisTypeItalic">MPL</em>[<span class="CitationRef"><a href="#CR95" data-toggle="citation" data-target="CR95">95</a></span><span class="CitationRef"><a href="#CR97" data-toggle="citation" data-target="CR97">97</a></span>]. In most cases when two signaling mutations are found in the same patient they are not in the same cellular clone. Signaling mutations associate with mutations in genes from the other classes (TSGs, TFs, ERs). <em xmlns="" class="EmphasisTypeItalic">CBL</em> and <em xmlns="" class="EmphasisTypeItalic">KIT</em> mutations are more frequent in AML with t(8;21) and inv(16), i.e. with alterations of the core binding factor (CBF), a dimeric transcriptional factor containing the RUNX1 protein [<span class="CitationRef"><a href="#CR98" data-toggle="citation" data-target="CR98">98</a></span>].</p>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">With rare exceptions, mutations in genes encoding splicing factors do not synergize and are mutually exclusive [<span class="CitationRef"><a href="#CR31" data-toggle="citation" data-target="CR31">31</a></span>, <span class="CitationRef"><a href="#CR38" data-toggle="citation" data-target="CR38">38</a></span>, <span class="CitationRef"><a href="#CR41" data-toggle="citation" data-target="CR41">41</a></span>, <span class="CitationRef"><a href="#CR42" data-toggle="citation" data-target="CR42">42</a></span>].</p>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">As already mentioned, <em xmlns="" class="EmphasisTypeItalic">IDH1</em> or <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations are mutually exclusive with <em xmlns="" class="EmphasisTypeItalic">TET2</em> mutations. Except for this, <em xmlns="" class="EmphasisTypeItalic">TET2</em> mutations seem to be able to cooperate with either of the other recurrent alterations. <em xmlns="" class="EmphasisTypeItalic">ASXL1</em> mutations, which occur preferentially in secondary AML, are mutually exclusive with <em xmlns="" class="EmphasisTypeItalic">NPM1</em> mutations, which occur in <em xmlns="" class="EmphasisTypeItalic">de novo</em> AML [<span class="CitationRef"><a href="#CR99" data-toggle="citation" data-target="CR99">99</a></span>]. Although ASXL1 interacts with PRC2 proteins [<span class="CitationRef"><a href="#CR83" data-toggle="citation" data-target="CR83">83</a></span>]<em xmlns="" class="EmphasisTypeItalic">ASXL1</em> and <em xmlns="" class="EmphasisTypeItalic">EZH2</em> mutations are not mutually exclusive [<span class="CitationRef"><a href="#CR58" data-toggle="citation" data-target="CR58">58</a></span>]. Mutations in <em xmlns="" class="EmphasisTypeItalic">EED</em> and <em xmlns="" class="EmphasisTypeItalic">SUZ12</em> may even be found in the same AML case [<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>]; however, they may affect different clones. <em xmlns="" class="EmphasisTypeItalic">RUNX1</em> mutations are frequently associated with <em xmlns="" class="EmphasisTypeItalic">ASXL1</em> defects in MDSs [<span class="CitationRef"><a href="#CR100" data-toggle="citation" data-target="CR100">100</a></span>]. Mutations in <em xmlns="" class="EmphasisTypeItalic">ASXL1</em> and <em xmlns="" class="EmphasisTypeItalic">TET2</em> can be concomitant (Figure <span class="InternalRef"><a href="#Fig1">1</a></span>), and each can co-occur with mutations in signaling molecules [<span class="CitationRef"><a href="#CR58" data-toggle="citation" data-target="CR58">58</a></span>, <span class="CitationRef"><a href="#CR100" data-toggle="citation" data-target="CR100">100</a></span>]. In MDSs, <em xmlns="" class="EmphasisTypeItalic">U2AF1</em> mutations are more frequent in <em xmlns="" class="EmphasisTypeItalic">ASXL1</em>-mutated than in <em xmlns="" class="EmphasisTypeItalic">ASXL1</em>-wildtype cases [<span class="CitationRef"><a href="#CR38" data-toggle="citation" data-target="CR38">38</a></span>, <span class="CitationRef"><a href="#CR42" data-toggle="citation" data-target="CR42">42</a></span>]. <em xmlns="" class="EmphasisTypeItalic">TP53</em> mutations and losses, likely associated with genetic instability, are found in MDSs with karyotypic alterations but not in cases with normal karyotype [<span class="CitationRef"><a href="#CR58" data-toggle="citation" data-target="CR58">58</a></span>]. <em xmlns="" class="EmphasisTypeItalic">DNMT3A</em> mutations are more frequent in AML with <em xmlns="" class="EmphasisTypeItalic">NPM1</em> and <em xmlns="" class="EmphasisTypeItalic">FLT3</em> mutations, infrequently found in <em xmlns="" class="EmphasisTypeItalic">ASXL1</em>-mutated cases, and very rare in cases with translocations [<span class="CitationRef"><a href="#CR24" data-toggle="citation" data-target="CR24">24</a></span>, <span class="CitationRef"><a href="#CR101" data-toggle="citation" data-target="CR101">101</a></span>]. Overall, while <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> and <em xmlns="" class="EmphasisTypeItalic">TET2</em> mutations are equally distributed, there seem to be two major associations in AMLs with intermediate cytogenetic risk, <em xmlns="" class="EmphasisTypeItalic">ASXL1/RUNX1</em> on the one hand (secondary, dysplastic AMLs), <em xmlns="" class="EmphasisTypeItalic">NPM1/FLT3/DNMT3A</em> on the other hand (primary, non-dysplastic AMLs) [<span class="CitationRef"><a href="#CR99" data-toggle="citation" data-target="CR99">99</a></span>]. These and other associations and exclusions not described here or yet to be discovered will help understand the major leukemogenic pathways. An important issue is to demonstrate that mutations found in the same case are actually cooperating mutations that co-occur in the same cell progeny and not in different clones.</p>
                </section>
                <section id="Sec11" class="Section3 RenderAsSection3">
                  <h4 class="Heading">How many hits are necessary to trigger a malignant myeloid disease?</h4>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Early studies of chronic and acute hematopoietic malignant diseases have shown that some cases may display a single mutational event whereas others harbor several hits [<span class="CitationRef"><a href="#CR100" data-toggle="citation" data-target="CR100">100</a></span>]. This difference may just be due to the low mutational frequency of many driver genes (e.g. <em xmlns="" class="EmphasisTypeItalic">NF1A, EED</em>) [<span class="CitationRef"><a href="#CR102" data-toggle="citation" data-target="CR102">102</a></span>] and to our current ignorance of other targets. Actually, NGS studies have shown that the general rule is to find several altered genes in each case [<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>, <span class="CitationRef"><a href="#CR26" data-toggle="citation" data-target="CR26">26</a></span>, <span class="CitationRef"><a href="#CR59" data-toggle="citation" data-target="CR59">59</a></span>, <span class="CitationRef"><a href="#CR103" data-toggle="citation" data-target="CR103">103</a></span>] and murine models have shown that single alterations are, except in rare cases, not sufficient to cause AML [<span class="CitationRef"><a href="#CR104" data-toggle="citation" data-target="CR104">104</a></span>, <span class="CitationRef"><a href="#CR105" data-toggle="citation" data-target="CR105">105</a></span>]. In the years to come mouse models will have to challenge many combinations of mutations.</p>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The study of matched chronic and acute stages has shown that progression is associated with additional alterations. However, the chronic stages are already characterized by the presence of several mutations. We found that many cases of CMML have already four mutations [<span class="CitationRef"><a href="#CR36" data-toggle="citation" data-target="CR36">36</a></span>], and this was without counting mutations in splicing factors. <em xmlns="" class="EmphasisTypeItalic">JAK2</em> and <em xmlns="" class="EmphasisTypeItalic">TET2</em> concomitant mutations are frequent in MPNs [<span class="CitationRef"><a href="#CR16" data-toggle="citation" data-target="CR16">16</a></span>, <span class="CitationRef"><a href="#CR37" data-toggle="citation" data-target="CR37">37</a></span>]. Whether they are both necessary for the various phases of the disease and their order of appearance are a matter of debate [<span class="CitationRef"><a href="#CR106" data-toggle="citation" data-target="CR106">106</a></span>]. An NGS study indeed showed that the ten mutations identified in an MDS patient can be detected together in most studied single cells, suggesting a linear evolution of the disease and the existence of a dominant clone [<span class="CitationRef"><a href="#CR103" data-toggle="citation" data-target="CR103">103</a></span>]. Regarding evolution of AML after therapy, a recent NGS study has revealed two major patterns at relapse [<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>]; the first pattern is the persistence of a dominant clone and the second pattern is the selection and expansion of a minor clone; in both cases the relapse clone had gained additional mutations. Another recent NGS study showed that genetic evolution of secondary AML is a dynamic process shaped by multiple cycles of mutation acquisition and clonal selection. MDS are oligoclonal with founding clones; these clones persist in secondary AML, which shows at least an additional subclone with new progression mutations [<span class="CitationRef"><a href="#CR107" data-toggle="citation" data-target="CR107">107</a></span>]. Founding mutations may occur in various genes, such as <em xmlns="" class="EmphasisTypeItalic">U2AF1</em>[<span class="CitationRef"><a href="#CR39" data-toggle="citation" data-target="CR39">39</a></span>] or <em xmlns="" class="EmphasisTypeItalic">TET2</em>. Many different genes may be involved in progression. Thus, several steps are necessary to trigger a myeloid disease, even a so-called chronic one, and progression involves additional hits.</p>
                </section>
                <section id="Sec12" class="Section3 RenderAsSection3">
                  <h4 class="Heading">How many of these steps are there?</h4>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">A first step in the leukemogenic process is likely to be a mere clonal expansion. Several gene mutations may play a role at this stage. Their identity may depend on whether they target a hematopoietic stem cell or a progenitor. In the first case the initial hit should provide a proliferation boost, in the second the hit should bestow self-renewal on the proliferating progenitor [<span class="CitationRef"><a href="#CR108" data-toggle="citation" data-target="CR108">108</a></span>]. Mutations in a TSG, splicing gene, or in some ERs such as <em xmlns="" class="EmphasisTypeItalic">TET2,</em> could occur at this initial step. It is also possible that, in a susceptible background, several clones emerge independently early on [<span class="CitationRef"><a href="#CR12" data-toggle="citation" data-target="CR12">12</a></span>, <span class="CitationRef"><a href="#CR109" data-toggle="citation" data-target="CR109">109</a></span>].</p>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Then, because of increasing proliferation and genetic instability, a cell from the affected clone (or clones) undergoes various additional mutations (including many background mutations), leading to an oligoclonal malignant tumor. Some of the early mutations may not be present in the clone that eventually becomes leukemic. Thus, for each case, only the determination of all potential mutations and the reconstitution of the mutation profile and clonal evolution will help understand the pathophysiology of the disease. This is now achievable by using NGS. How many steps can eventually be individualized may depend on how many clones are initially expanded, on the level of genetic instability that results from the initial hits, and on the impact of the mutations on self-renewal, differentiation and proliferation. Some mutations in epigenetic regulators may have a milder effect on genetic reprogramming than a gene fusion involving a master transcription factor, which will induce a strong block of differentiation in a hematopoietic precursor [<span class="CitationRef"><a href="#CR92" data-toggle="citation" data-target="CR92">92</a></span>]. The latter event is prominent in <em xmlns="" class="EmphasisTypeItalic">de novo</em> AMLs, which accordingly display only few or none of the other recently-discovered mutated genes.</p>
                  <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">A previous scheme of leukemogenesis [<span class="CitationRef"><a href="#CR110" data-toggle="citation" data-target="CR110">110</a></span>] was based on the minimal cooperation of two oncogene classes, proliferation-drivers (kinases, RAS) and differentiation-blockers (mostly transcription factors), to trigger AML. The ever-increasing molecular complexity of myeloid malignancies is now obvious and calls for an update of this model. First, it is now routinely possible to observe the cooperation, already at the chronic stage, of three, four or more mutated genes (to speak only of known or suspected drivers), whose products belong to at least five classes, class I signaling molecules class II TFs, class III ERs, class IV TSGs and class V splicing factors [<span class="CitationRef"><a href="#CR100" data-toggle="citation" data-target="CR100">100</a></span>]. Second, not all mutations of a class are equivalent; mutations in <em xmlns="" class="EmphasisTypeItalic">ASXL1, RUNX1</em> or <em xmlns="" class="EmphasisTypeItalic">TET2</em> occur almost as frequently at the chronic stages as in AML whereas mutations of <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> or <em xmlns="" class="EmphasisTypeItalic">DNMT3A</em> are preferentially found at the acute stage. The reason for this remains obscure but may have to do with the different intensities in the differentiation block induced by the mutations. Third, the classes are not well individualized. For example, <em xmlns="" class="EmphasisTypeItalic">EZH2, RUNX1</em> and <em xmlns="" class="EmphasisTypeItalic">TET2</em> are both TSGs and TF/ERs. <em xmlns="" class="EmphasisTypeItalic">NF1</em> is both a TSG and a regulator of signaling pathways. Because it induces phosphorylation of histone H3 and PRMT5 arginine methyltransferase, JAK2V617F may also be an ER [<span class="CitationRef"><a href="#CR111" data-toggle="citation" data-target="CR111">111</a></span>]. Fourth, all classes may not be systematically affected in each case. Fifth, if classes I and V are relatively well individualized, with genes whose mutations are generally mutually exclusive, the definition of the other classes may evolve. However, despite all this, the initial schematic model might not be so far off. The two key processes of differentiation and self-renewal seem to be always altered and proliferation is frequently affected. It may just be that the oncogenic hits required to achieve each step might be more numerous than initially expected. This model will apply to cases with intermediate or normal cytogenetic risk; a different leukemogenesis pathway linked to genetic instability may be involved in cases with <em xmlns="" class="EmphasisTypeItalic">TP53</em> mutation and complex karyotype [<span class="CitationRef"><a href="#CR112" data-toggle="citation" data-target="CR112">112</a></span>].</p>
                  <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Considering all this, several pathways to leukemia can be envisaged (Figure <span class="InternalRef"><a href="#Fig4">4</a></span>). The first pathway could be direct and trigger <em xmlns="" class="EmphasisTypeItalic">de novo</em> AML with a gene fusion as the major event and few other alterations. The second pathway is characterized by <em xmlns="" class="EmphasisTypeItalic">NPM1</em> mutations, which are rarely associated with mutations in other known TFs or ERs except in <em xmlns="" class="EmphasisTypeItalic">DNMT3A</em> and <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em>[<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>, <span class="CitationRef"><a href="#CR101" data-toggle="citation" data-target="CR101">101</a></span>]. AML with complex karyotype can derive from genetic instability, with or without <em xmlns="" class="EmphasisTypeItalic">TP53</em> mutations. A fourth pathway would be the accumulation of several hits in signaling molecules, TFs, ERs and splicing factors, which induce either secondary AML after a chronic phase (Figure <span class="InternalRef"><a href="#Fig5">5</a></span>) or <em xmlns="" class="EmphasisTypeItalic">de novo</em> AML; however, some so-called <em xmlns="" class="EmphasisTypeItalic">de novo</em> AMLs with several ER mutations could actually be secondary to a non-detected chronic phase. Mutations in TFs and ERs are not major events in chronic myeloid leukemia (CML), which is triggered by the <em xmlns="" class="EmphasisTypeItalic">BCR-ABL1</em> fusion; however, mutations in ERs such as <em xmlns="" class="EmphasisTypeItalic">ASXL1, IDH1/2</em> and <em xmlns="" class="EmphasisTypeItalic">TET2</em> may participate to CML progression to AML [<span class="CitationRef"><a href="#CR113" data-toggle="citation" data-target="CR113">113</a></span>, <span class="CitationRef"><a href="#CR114" data-toggle="citation" data-target="CR114">114</a></span>].<figure xmlns="" class="Figure" id="Fig4"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                        <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_Article_3221_Fig4_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_Article_3221_Fig4_HTML.jpg"></img></a>
                      </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 4</span>
                          <p xmlns="" class="SimplePara">
<strong class="EmphasisTypeBold">Schematic representation of pathways leading to acute myeloid leukemia (AML) from hematopoietic stem cell (HSC) or progenitors (PG).</strong> Gene fusions and <em class="EmphasisTypeItalic">NPM1</em> mutation are major events in the induction of primary AMLs with favorable and intermediate cytogenetic risk (they correspond respectively to mutation groups A and B of Ley et al [<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR24" data-toggle="citation" data-target="CR24">24</a></span>], and to mutation groups 2+3 and 1 of Shen et al. [<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR101" data-toggle="citation" data-target="CR101">101</a></span>]. Secondary AML following MPN or MDS (see Figure <span xmlns="http://www.w3.org/1999/xhtml" class="InternalRef"><a href="#Fig1">1</a></span>) could occur after a series of gene mutations in transcription factors and epigenetic regulators combined with a mutation in a signaling pathway (see Figure <span xmlns="http://www.w3.org/1999/xhtml" class="InternalRef"><a href="#Fig3">3</a></span>), after TP53 mutation and a series of mutations and karyotype alterations due to genetic instability, or after additional mutations in BCR-ABL chronic myeloid leukemia.</p>
                        </div></figcaption></figure>
<figure xmlns="" class="Figure" id="Fig5"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                        <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_Article_3221_Fig5_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_Article_3221_Fig5_HTML.jpg"></img></a>
                      </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 5</span>
                          <p xmlns="" class="SimplePara">
<strong class="EmphasisTypeBold">Schematic representation of a case of malignant myeloid disease evolving in four stages along one pathway.</strong> Clones with different gene mutations (color squares in cells) represent various ratios of the oligoclonal leukemia. The order and nature of the mutations (or genome alterations) is given as an example and may differ from one case to another. However, in contrast to JAK2V617F, which has a mild effect on hematopoietic stem cell (HSC) [<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR16" data-toggle="citation" data-target="CR16">16</a></span>], <em class="EmphasisTypeItalic">TET2</em> mutation has the property to initiate the amplification of HSC and to pave the way to secondary mutations [<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR77" data-toggle="citation" data-target="CR77">77</a></span>]. Mutations in signaling molecules, which have a major impact on the disease phenotype, will vary with the type of chronic stage, for example it could affect <em class="EmphasisTypeItalic">JAK2</em> in case of MPN, <em class="EmphasisTypeItalic">RAS</em> in case of MP-CMML and be absent in case of MDS. MF: myelofibrosis, RAEB: refractory anemia with excess of blasts, AML: acute myeloid leukemia.</p>
                        </div></figcaption></figure>
</div>
                  <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Overall, the development of an AML may follow a slot machine model (Figure <span class="InternalRef"><a href="#Fig6">6</a></span>), in which the late steps would be, to some point, constrained by the initial ones (clonal dominance, cooperations/exclusions). Oligoclonality would be due to several possible draws at each step. It is important that we determine the exact number of reels (hits) and symbols (genes) and the possible combinations.<figure xmlns="" class="Figure" id="Fig6"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                        <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_Article_3221_Fig6_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_Article_3221_Fig6_HTML.jpg"></img></a>
                      </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 6</span>
                          <p xmlns="" class="SimplePara">
<strong class="EmphasisTypeBold">Slot machine model of leukemogenesis.</strong> Alterations in signaling molecules, transcription factors (TFs), epigenetic regulators (ERs), tumor suppressors (TSG), spliceosome components and various genome abnormalities (examples are given) fall into (at least) four reels (steps) that combine to induce a malignant myeloid disease. Acute myeloid leukemia (AML) results from one of the allowed combinations of four (at least) cooperating alterations. At chronic stages, the steps are variably combined, some may be absent (e.g. signaling), some may be specific (e.g. <em class="EmphasisTypeItalic">SF3B1</em> splicing mutations in RARS). Each step can be achieved by alterations in one of several genes. The initial step leads to expansion of a founding clone. Two examples of draw (plain and dotted lines) leading to AML are shown.</p>
                        </div></figcaption></figure>
</div>
                </section>
              </section><section id="Sec13" class="Section2 RenderAsSection2">
                <h3 class="Heading">Utilizing molecular leukemogenesis</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Understanding and modeling leukemogenesis will have a major impact on the management and treatment of hematopoietic malignancies. Molecular biology already helps establish the diagnosis (<em xmlns="" class="EmphasisTypeItalic">JAK2</em>), classification (<em xmlns="" class="EmphasisTypeItalic">BCR-ABL1, FGFR1, PDGFRs</em>), prognosis (<em xmlns="" class="EmphasisTypeItalic">FLT3, NPM1, CEBPA</em>) and treatment (BCR-ABL, 5q-, JAK2) of myeloid diseases. Due to the increasing simplification and accessibility to clinical laboratories of NGS equipment, the repertoire of all genetic alterations will soon be determined for any new case as a routine practice.</p>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The establishment of a precise taxonomy comprising homogeneous pathophysiological entities is a major goal in hematology. It relies heavily on molecular data. It started with the karyotype and has continued with gene expression profiles [<span class="CitationRef"><a href="#CR115" data-toggle="citation" data-target="CR115">115</a></span>, <span class="CitationRef"><a href="#CR116" data-toggle="citation" data-target="CR116">116</a></span>]. Gene mutations will nicely complete the picture. Other factors such as microRNAs and long non-coding RNAs status [<span class="CitationRef"><a href="#CR1" data-toggle="citation" data-target="CR1">1</a></span>], methylation profiles [<span class="CitationRef"><a href="#CR117" data-toggle="citation" data-target="CR117">117</a></span>] and histone marks may have to be integrated too.</p>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Several studies have shown that gene mutations have indeed a major impact on prognosis of myeloid diseases. This is the case in MDSs for mutations in five genes, <em xmlns="" class="EmphasisTypeItalic">ASXL1, ETV6, EZH2, TP53</em> and <em xmlns="" class="EmphasisTypeItalic">RUNX1</em>[<span class="CitationRef"><a href="#CR58" data-toggle="citation" data-target="CR58">58</a></span>]. Mutations in <em xmlns="" class="EmphasisTypeItalic">ASXL1</em> seem to be associated with an aggressive phenotype in all myeloid malignancies [<span class="CitationRef"><a href="#CR8" data-toggle="citation" data-target="CR8">8</a></span>]: they are frequent in high-risk MDSs and correlate with poor prognosis in MDSs [<span class="CitationRef"><a href="#CR118" data-toggle="citation" data-target="CR118">118</a></span><span class="CitationRef"><a href="#CR120" data-toggle="citation" data-target="CR120">120</a></span>] and with acute progression in CMML [<span class="CitationRef"><a href="#CR36" data-toggle="citation" data-target="CR36">36</a></span>], they are more frequent in myelofibrosis than in other MPNs [<span class="CitationRef"><a href="#CR37" data-toggle="citation" data-target="CR37">37</a></span>, <span class="CitationRef"><a href="#CR121" data-toggle="citation" data-target="CR121">121</a></span>], and characterize secondary AML. <em xmlns="" class="EmphasisTypeItalic">DNMT3A</em> mutations are frequent in younger patients with AML and are associated with an unfavorable prognosis in MDS and AML [<span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>, <span class="CitationRef"><a href="#CR24" data-toggle="citation" data-target="CR24">24</a></span>, <span class="CitationRef"><a href="#CR30" data-toggle="citation" data-target="CR30">30</a></span>, <span class="CitationRef"><a href="#CR101" data-toggle="citation" data-target="CR101">101</a></span>]. Among splicing gene mutations, those in <em xmlns="" class="EmphasisTypeItalic">U2AF1</em> and <em xmlns="" class="EmphasisTypeItalic">SRSF2</em> seem to be associated with aggressive forms of myeloid diseases and those in <em xmlns="" class="EmphasisTypeItalic">SF3B1</em> with good prognosis [<span class="CitationRef"><a href="#CR38" data-toggle="citation" data-target="CR38">38</a></span>, <span class="CitationRef"><a href="#CR39" data-toggle="citation" data-target="CR39">39</a></span>, <span class="CitationRef"><a href="#CR41" data-toggle="citation" data-target="CR41">41</a></span>, <span class="CitationRef"><a href="#CR42" data-toggle="citation" data-target="CR42">42</a></span>]. Molecular data will allow the establishment of an upgraded index of prognosis. For example, in MDSs, it is highly conceivable that the current prognostic index used for the evaluation of the disease (IPSS), which already includes karyotypic data, can be improved by a molecular index regrouping the mutations that impact on the patients outcome [<span class="CitationRef"><a href="#CR112" data-toggle="citation" data-target="CR112">112</a></span>]. Whether <em xmlns="" class="EmphasisTypeItalic">TET2</em> mutations are to be included is a matter of debate [<span class="CitationRef"><a href="#CR122" data-toggle="citation" data-target="CR122">122</a></span><span class="CitationRef"><a href="#CR124" data-toggle="citation" data-target="CR124">124</a></span>]. In AML, a thorough study of 18 genes, including <em xmlns="" class="EmphasisTypeItalic">ASXL1</em> and <em xmlns="" class="EmphasisTypeItalic">DNMT3A</em>, proposed an updated and precise risk stratification based on gene mutations [<span class="CitationRef"><a href="#CR125" data-toggle="citation" data-target="CR125">125</a></span>].</p>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">New therapeutic targets can be found in two of the five major classes of leukemogenic genes. Following the successful use of imatinib in CML, abnormal signaling pathways associated with myeloproliferation, be it the JAK-STAT pathway [<span class="CitationRef"><a href="#CR126" data-toggle="citation" data-target="CR126">126</a></span><span class="CitationRef"><a href="#CR128" data-toggle="citation" data-target="CR128">128</a></span>] or another pathway, represent appealing targets. Drugs targeting epigenetic modifications, i.e. epidrugs, such as histone deacetylase inhibitors and hypomethylating agents (DNMT inhibitors), are currently developed or used in clinics, and many new ones are studied in preclinical assays and clinical trials [<span class="CitationRef"><a href="#CR1" data-toggle="citation" data-target="CR1">1</a></span>]. Targeting histone methyltransferases (e.g. MLL) or lysine acetyltransferases (e.g. P300) [<span class="CitationRef"><a href="#CR129" data-toggle="citation" data-target="CR129">129</a></span>] is also a promising area of development. The determination of gene mutations and their consequence on gene regulation and cell programming will help treat myeloid malignancies in providing a rationale for the use and development of new epidrugs, in directing the choice of the drug cocktails, and in allowing the design of drug delivery and the monitoring of drug response and disease progression. For example, agents directed against TET2-, IDH- and DNMT3A-associated methylation defects may represent a new area of development. To date, the use of <em xmlns="" class="EmphasisTypeItalic">TET2</em> mutations status to evaluate the response to DNMT inhibitors is still debated [<span class="CitationRef"><a href="#CR130" data-toggle="citation" data-target="CR130">130</a></span>, <span class="CitationRef"><a href="#CR131" data-toggle="citation" data-target="CR131">131</a></span>]. Because many mutations compromise PRC2 function drugs antagonizing this defect hold great promise.</p>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Proteins of two other leukemogenic classes may also serve as therapeutic targets. For example, the antitumor macrolide pladienolide targets SF3B1 [<span class="CitationRef"><a href="#CR132" data-toggle="citation" data-target="CR132">132</a></span>] opening new opportunities to develop treatments against RARS. Compounds aiming at restoring a normal P53 pathway are in development [<span class="CitationRef"><a href="#CR133" data-toggle="citation" data-target="CR133">133</a></span>, <span class="CitationRef"><a href="#CR134" data-toggle="citation" data-target="CR134">134</a></span>].</p>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The existence of concomitant mutations is an incentive for combinatorial therapies; for example, therapeutic synergy may be obtained by the combined use of signaling inhibitors and epidrugs.</p>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Finally, the complete determination of the mutation repertoire will provide novel therapeutic targets. For some diseases, such as CMML, it is already possible to identify at least one target for nearly nine cases out of ten [<span class="CitationRef"><a href="#CR33" data-toggle="citation" data-target="CR33">33</a></span>, <span class="CitationRef"><a href="#CR36" data-toggle="citation" data-target="CR36">36</a></span>]. However, the development of resistance, as observed with imatinib [<span class="CitationRef"><a href="#CR135" data-toggle="citation" data-target="CR135">135</a></span>], is a critical issue. Hopefully, target identification will allow for the development of new combinatorial strategies, such as the one based on synthetic lethality [<span class="CitationRef"><a href="#CR136" data-toggle="citation" data-target="CR136">136</a></span>, <span class="CitationRef"><a href="#CR137" data-toggle="citation" data-target="CR137">137</a></span>]. If two mutations never occur together it may mean that their combined effect is deleterious. Thus, opportunities for deriving synthetic lethality drugs could stem from the observation of exclusions in mutations patterns.</p>
              </section></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec14" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Conclusions</h2><div class="js-CollapseSection"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Thus, mutations and models (M and Ms) will help manage myeloid malignancies. The eventual comprehensive determination in any given case and at diagnosis, of the set of altered genes, underlying affected pathways and disease stage, will guide towards an optimal treatment based on an appropriate combination of drugs targeting the various affected processes of the disease. Clinically-oriented laboratories should already be preparing for that challenge. Meanwhile, there is much to mull over the M and Ms of myeloid malignancies.</p></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec15" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Authors contributions</h2><div class="js-CollapseSection"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">All authors have contributed ideas, discussions, and have participated in the writing of the manuscript. All authors read and approved the final manuscript.</p></div></section>
          <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1" id="Declarations"><h2 class="Heading js-ToggleCollapseSection">
              Declarations
            </h2><div class="js-CollapseSection"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Acknowledgments"><h3 xmlns="" class="Heading">Acknowledgements</h3><p xmlns="" class="SimplePara">We are grateful to O. Bernard for his critical reading of the manuscript. Work in our laboratory on this subject is supported by Inserm, Institut Paoli-Calmettes and grants from the Association pour la Recherche contre le Cancer (DB) and Association Laurette Fugain (MJM).</p></div><aside class="Appendix" id="App1">
              
                <h3 class="Heading">Authors' original submitted files for images</h3><div id="widgetContainer"></div>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Below are the links to the authors original submitted files for images.<div class="MediaObject" id="MOESM1">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_3221_MOESM1_ESM.pdf">12885_2011_3221_MOESM1_ESM.pdf</a>
                          <span xmlns="" class="SimplePara">Authors original file for figure 1</span>
                        </div></div>
                  </div>
<div class="MediaObject" id="MOESM2">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_3221_MOESM2_ESM.pdf">12885_2011_3221_MOESM2_ESM.pdf</a>
                          <span xmlns="" class="SimplePara">Authors original file for figure 2</span>
                        </div></div>
                  </div>
<div class="MediaObject" id="MOESM3">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_3221_MOESM3_ESM.pdf">12885_2011_3221_MOESM3_ESM.pdf</a>
                          <span xmlns="" class="SimplePara">Authors original file for figure 3</span>
                        </div></div>
                  </div>
<div class="MediaObject" id="MOESM4">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_3221_MOESM4_ESM.pdf">12885_2011_3221_MOESM4_ESM.pdf</a>
                          <span xmlns="" class="SimplePara">Authors original file for figure 4</span>
                        </div></div>
                  </div>
<div class="MediaObject" id="MOESM5">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_3221_MOESM5_ESM.pdf">12885_2011_3221_MOESM5_ESM.pdf</a>
                          <span xmlns="" class="SimplePara">Authors original file for figure 5</span>
                        </div></div>
                  </div>
<div class="MediaObject" id="MOESM6">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2F1471-2407-12-304/MediaObjects/12885_2011_3221_MOESM6_ESM.pdf">12885_2011_3221_MOESM6_ESM.pdf</a>
                          <span xmlns="" class="SimplePara">Authors original file for figure 6</span>
                        </div></div>
                  </div>
</div>
              
            </aside><aside xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ArticleNote ArticleNoteMisc"><h3 xmlns="" class="Heading">Competing interests</h3><p xmlns="" class="SimplePara">The authors have no competing interests.</p></aside></div></section></div>
                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1 Affiliations" id="Aff"><h2 class="Heading js-ToggleCollapseSection">Authors Affiliations</h2><div class="js-CollapseSection"><div class="Affiliation" id="Aff1"><span class="AffiliationNumber">(1)</span><div class="AffiliationText">Centre de Recherche en Cancrologie de Marseille, laboratoire dOncologie Molculaire; UMR1068 Inserm, Institut Paoli-Calmettes</div></div></div></section></div>
                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1 SectionTypeMaterialsAndMethods" id="Bib1"><h2 class="Heading js-ToggleCollapseSection">References</h2><div class="js-CollapseSection"><ol class="BibliographyWrapper"><li class="Citation"><cite class="CitationContent" id="CR1">Chen J, Odenike O, Rowley JD: Leukaemogenesis: more than mutant genes. Nat Rev Cancer. 2010, 10: 23-36.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20029422"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972637"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Leukaemogenesis%3A%20more%20than%20mutant%20genes&amp;author=J.%20Chen&amp;author=O.%20Odenike&amp;author=JD.%20Rowley&amp;journal=Nat%20Rev%20Cancer&amp;volume=10&amp;pages=23-36&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR2">Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005, 365: 1054-1061.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15781101"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Acquired%20mutation%20of%20the%20tyrosine%20kinase%20JAK2%20in%20human%20myeloproliferative%20disorders&amp;author=EJ.%20Baxter&amp;author=LM.%20Scott&amp;author=PJ.%20Campbell&amp;author=C.%20East&amp;author=N.%20Fourouclas&amp;author=S.%20Swanton&amp;author=GS.%20Vassiliou&amp;author=AJ.%20Bench&amp;author=EM.%20Boyd&amp;author=N.%20Curtin&amp;author=MA.%20Scott&amp;author=WN.%20Erber&amp;author=AR.%20Green&amp;journal=Lancet&amp;volume=365&amp;pages=1054-1061&amp;publication_year=2005"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR3">James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005, 434: 1144-1148.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15793561"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=A%20unique%20clonal%20JAK2%20mutation%20leading%20to%20constitutive%20signalling%20causes%20polycythaemia%20vera&amp;author=C.%20James&amp;author=V.%20Ugo&amp;author=JP.%20Le%20Couedic&amp;author=J.%20Staerk&amp;author=F.%20Delhommeau&amp;author=C.%20Lacout&amp;author=L.%20Garcon&amp;author=H.%20Raslova&amp;author=R.%20Berger&amp;author=A.%20Bennaceur-Griscelli&amp;author=JL.%20Villeval&amp;author=SN.%20Constantinescu&amp;author=N.%20Casadevall&amp;author=W.%20Vainchenker&amp;journal=Nature&amp;volume=434&amp;pages=1144-1148&amp;publication_year=2005"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR4">Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005, 352: 1779-1790.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15858187"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=A%20gain-of-function%20mutation%20of%20JAK2%20in%20myeloproliferative%20disorders&amp;author=R.%20Kralovics&amp;author=F.%20Passamonti&amp;author=AS.%20Buser&amp;author=SS.%20Teo&amp;author=R.%20Tiedt&amp;author=JR.%20Passweg&amp;author=A.%20Tichelli&amp;author=M.%20Cazzola&amp;author=RC.%20Skoda&amp;journal=N%20Engl%20J%20Med&amp;volume=352&amp;pages=1779-1790&amp;publication_year=2005"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR5">Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005, 7: 387-397.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15837627"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Activating%20mutation%20in%20the%20tyrosine%20kinase%20JAK2%20in%20polycythemia%20vera%2C%20essential%20thrombocythemia%2C%20and%20myeloid%20metaplasia%20with%20myelofibrosis&amp;author=RL.%20Levine&amp;author=M.%20Wadleigh&amp;author=J.%20Cools&amp;author=BL.%20Ebert&amp;author=G.%20Wernig&amp;author=BJ.%20Huntly&amp;author=TJ.%20Boggon&amp;author=I.%20Wlodarska&amp;author=JJ.%20Clark&amp;author=S.%20Moore&amp;author=J.%20Adelsperger&amp;author=S.%20Koo&amp;author=JC.%20Lee&amp;author=S.%20Gabriel&amp;author=T.%20Mercher&amp;author=A.%20D%27Andrea&amp;author=S.%20Frohling&amp;author=K.%20Dohner&amp;author=P.%20Marynen&amp;author=P.%20Vandenberghe&amp;author=RA.%20Mesa&amp;author=A.%20Tefferi&amp;author=JD.%20Griffin&amp;author=MJ.%20Eck&amp;author=WR.%20Sellers&amp;author=M.%20Meyerson&amp;author=TR.%20Golub&amp;author=SJ.%20Lee&amp;author=DG.%20Gilliland&amp;journal=Cancer%20Cell&amp;volume=7&amp;pages=387-397&amp;publication_year=2005"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR6">Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996, 2: 561-566.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8616716"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Effects%20of%20a%20selective%20inhibitor%20of%20the%20Abl%20tyrosine%20kinase%20on%20the%20growth%20of%20Bcr-Abl%20positive%20cells&amp;author=BJ.%20Druker&amp;author=S.%20Tamura&amp;author=E.%20Buchdunger&amp;author=S.%20Ohno&amp;author=GM.%20Segal&amp;author=S.%20Fanning&amp;author=J.%20Zimmermann&amp;author=NB.%20Lydon&amp;journal=Nat%20Med&amp;volume=2&amp;pages=561-566&amp;publication_year=1996"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR7">Fathi AT, Abdel-Wahab O: Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol. 2012, 2012: 469592-<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21811504"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutations%20in%20epigenetic%20modifiers%20in%20myeloid%20malignancies%20and%20the%20prospect%20of%20novel%20epigenetic-targeted%20therapy&amp;author=AT.%20Fathi&amp;author=O.%20Abdel-Wahab&amp;journal=Adv%20Hematol&amp;volume=2012&amp;pages=469592&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR8">Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D: Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012, 5: 12-<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22436456"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355025"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutations%20in%20ASXL1%20are%20associated%20with%20poor%20prognosis%20across%20the%20spectrum%20of%20malignant%20myeloid%20diseases&amp;author=V.%20Gelsi-Boyer&amp;author=M.%20Brecqueville&amp;author=R.%20Devillier&amp;author=A.%20Murati&amp;author=MJ.%20Mozziconacci&amp;author=D.%20Birnbaum&amp;journal=J%20Hematol%20Oncol&amp;volume=5&amp;pages=12&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR9">Graubert TA, Walter MJ: Genetics of Myelodysplastic Syndromes: New Insights. Hematology Am Soc Hematol Educ Program. 2011, 1: 543-549.<span class="Occurrences"><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Genetics%20of%20Myelodysplastic%20Syndromes%3A%20New%20Insights&amp;author=TA.%20Graubert&amp;author=MJ.%20Walter&amp;journal=Hematology%20Am%20Soc%20Hematol%20Educ%20Program&amp;volume=1&amp;pages=543-549&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR10">Marcucci G, Haferlach T, Dohner H: Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011, 29: 475-486.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21220609"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Molecular%20genetics%20of%20adult%20acute%20myeloid%20leukemia%3A%20prognostic%20and%20therapeutic%20implications&amp;author=G.%20Marcucci&amp;author=T.%20Haferlach&amp;author=H.%20Dohner&amp;journal=J%20Clin%20Oncol&amp;volume=29&amp;pages=475-486&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR11">Mercher T, Quivoron C, Couronne L, Bastard C, Vainchenker W, Bernard OA: TET2, a tumor suppressor in hematological disorders. Biochim Biophys Acta. 2012, 1825: 173-177.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22240200"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=TET2%2C%20a%20tumor%20suppressor%20in%20hematological%20disorders&amp;author=T.%20Mercher&amp;author=C.%20Quivoron&amp;author=L.%20Couronne&amp;author=C.%20Bastard&amp;author=W.%20Vainchenker&amp;author=OA.%20Bernard&amp;journal=Biochim%20Biophys%20Acta&amp;volume=1825&amp;pages=173-177&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR12">Schaub FX, Jager R, Looser R, Hao-Shen H, Hermouet S, Girodon F, Tichelli A, Gisslinger H, Kralovics R, Skoda RC: Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 2009, 113: 2022-2027.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19047681"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Clonal%20analysis%20of%20deletions%20on%20chromosome%2020q%20and%20JAK2-V617F%20in%20MPD%20suggests%20that%20del20q%20acts%20independently%20and%20is%20not%20one%20of%20the%20predisposing%20mutations%20for%20JAK2-V617F&amp;author=FX.%20Schaub&amp;author=R.%20Jager&amp;author=R.%20Looser&amp;author=H.%20Hao-Shen&amp;author=S.%20Hermouet&amp;author=F.%20Girodon&amp;author=A.%20Tichelli&amp;author=H.%20Gisslinger&amp;author=R.%20Kralovics&amp;author=RC.%20Skoda&amp;journal=Blood&amp;volume=113&amp;pages=2022-2027&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR13">Takahashi S: Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol. 2011, 4: 36-<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21917154"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180439"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Current%20findings%20for%20recurring%20mutations%20in%20acute%20myeloid%20leukemia&amp;author=S.%20Takahashi&amp;journal=J%20Hematol%20Oncol&amp;volume=4&amp;pages=36&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR14">Tefferi A: Mutations galore in myeloproliferative neoplasms: Would the real Spartacus please stand up?. Leukemia. 2011, 25: 1059-1063.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21750560"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutations%20galore%20in%20myeloproliferative%20neoplasms%3A%20Would%20the%20real%20Spartacus%20please%20stand%20up%3F&amp;author=A.%20Tefferi&amp;journal=Leukemia&amp;volume=25&amp;pages=1059-1063&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR15">Thol F, Damm F, Ludeking A, Winschel C, Wagner K, Morgan M, Yun H, Gohring G, Schlegelberger B, Hoelzer D, Lubbert M, Kanz L, Fiedler W, Kirchner H, Heil G, Krauter J, Ganser A, Heuser M: Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia. J Clin Oncol. 2011, 29: 2889-2896.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21670448"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Incidence%20and%20Prognostic%20Influence%20of%20DNMT3A%20Mutations%20in%20Acute%20Myeloid%20Leukemia&amp;author=F.%20Thol&amp;author=F.%20Damm&amp;author=A.%20Ludeking&amp;author=C.%20Winschel&amp;author=K.%20Wagner&amp;author=M.%20Morgan&amp;author=H.%20Yun&amp;author=G.%20Gohring&amp;author=B.%20Schlegelberger&amp;author=D.%20Hoelzer&amp;author=M.%20Lubbert&amp;author=L.%20Kanz&amp;author=W.%20Fiedler&amp;author=H.%20Kirchner&amp;author=G.%20Heil&amp;author=J.%20Krauter&amp;author=A.%20Ganser&amp;author=M.%20Heuser&amp;journal=J%20Clin%20Oncol&amp;volume=29&amp;pages=2889-2896&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR16">Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA: New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011, 118: 1723-1735.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21653328"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=New%20mutations%20and%20pathogenesis%20of%20myeloproliferative%20neoplasms&amp;author=W.%20Vainchenker&amp;author=F.%20Delhommeau&amp;author=SN.%20Constantinescu&amp;author=OA.%20Bernard&amp;journal=Blood&amp;volume=118&amp;pages=1723-1735&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR17">Brecqueville M, Cervera N, Adlaide J, Rey J, Carbuccia N, Chaffanet M, Vey N, Birnbaum D, Murati A: Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer Journal. 2011, 1: e18-<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22829153"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255259"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutations%20and%20deletions%20of%20the%20SUZ12%20polycomb%20gene%20in%20myeloproliferative%20neoplasms&amp;author=M.%20Brecqueville&amp;author=N.%20Cervera&amp;author=J.%20Ad%C3%A9laide&amp;author=J.%20Rey&amp;author=N.%20Carbuccia&amp;author=M.%20Chaffanet&amp;author=N.%20Vey&amp;author=D.%20Birnbaum&amp;author=A.%20Murati&amp;journal=Blood%20Cancer%20Journal&amp;volume=1&amp;pages=e18&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR18">Delhommeau F, Dupont S, Della VV, James C, Trannoy S, Masse A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lecluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguie F, Fontenay M, Vainchenker W, Bernard OA: Mutation in TET2 in myeloid cancers. N Engl J Med. 2009, 360: 2289-2301.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19474426"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutation%20in%20TET2%20in%20myeloid%20cancers&amp;author=F.%20Delhommeau&amp;author=S.%20Dupont&amp;author=VV.%20Della&amp;author=C.%20James&amp;author=S.%20Trannoy&amp;author=A.%20Masse&amp;author=O.%20Kosmider&amp;author=JP.%20Le%20Couedic&amp;author=F.%20Robert&amp;author=A.%20Alberdi&amp;author=Y.%20Lecluse&amp;author=I.%20Plo&amp;author=FJ.%20Dreyfus&amp;author=C.%20Marzac&amp;author=N.%20Casadevall&amp;author=C.%20Lacombe&amp;author=SP.%20Romana&amp;author=P.%20Dessen&amp;author=J.%20Soulier&amp;author=F.%20Viguie&amp;author=M.%20Fontenay&amp;author=W.%20Vainchenker&amp;author=OA.%20Bernard&amp;journal=N%20Engl%20J%20Med&amp;volume=360&amp;pages=2289-2301&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR19">Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H, Sekeres MA, Wang XF, McDevitt MA, Maciejewski JP: 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008, 68: 10349-10357.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19074904"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668538"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=250%E2%80%89K%20single%20nucleotide%20polymorphism%20array%20karyotyping%20identifies%20acquired%20uniparental%20disomy%20and%20homozygous%20mutations%2C%20including%20novel%20missense%20substitutions%20of%20c-Cbl%2C%20in%20myeloid%20malignancies&amp;author=AJ.%20Dunbar&amp;author=LP.%20Gondek&amp;author=CL.%20O%27Keefe&amp;author=H.%20Makishima&amp;author=MS.%20Rataul&amp;author=H.%20Szpurka&amp;author=MA.%20Sekeres&amp;author=XF.%20Wang&amp;author=MA.%20McDevitt&amp;author=JP.%20Maciejewski&amp;journal=Cancer%20Res&amp;volume=68&amp;pages=10349-10357&amp;publication_year=2008"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR20">Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, Hochhaus A, Drexler HG, Duncombe A, Cervantes F, Oscier D, Boultwood J, Grand FH, Cross NC: Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010, 42: 722-726.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20601953"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Inactivating%20mutations%20of%20the%20histone%20methyltransferase%20gene%20EZH2%20in%20myeloid%20disorders&amp;author=T.%20Ernst&amp;author=AJ.%20Chase&amp;author=J.%20Score&amp;author=CE.%20Hidalgo-Curtis&amp;author=C.%20Bryant&amp;author=AV.%20Jones&amp;author=K.%20Waghorn&amp;author=K.%20Zoi&amp;author=FM.%20Ross&amp;author=A.%20Reiter&amp;author=A.%20Hochhaus&amp;author=HG.%20Drexler&amp;author=A.%20Duncombe&amp;author=F.%20Cervantes&amp;author=D.%20Oscier&amp;author=J.%20Boultwood&amp;author=FH.%20Grand&amp;author=NC.%20Cross&amp;journal=Nat%20Genet&amp;volume=42&amp;pages=722-726&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR21">Gelsi-Boyer V, Trouplin V, Adlaide J, Bonansea J, Cervera N, Carbuccia N, Lagarde A, Prebet T, Nezri M, Sainty D, Olschwang S, Xerri L, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D: Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009, 145: 788-800.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19388938"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutations%20of%20polycomb-associated%20gene%20ASXL1%20in%20myelodysplastic%20syndromes%20and%20chronic%20myelomonocytic%20leukaemia&amp;author=V.%20Gelsi-Boyer&amp;author=V.%20Trouplin&amp;author=J.%20Ad%C3%A9laide&amp;author=J.%20Bonansea&amp;author=N.%20Cervera&amp;author=N.%20Carbuccia&amp;author=A.%20Lagarde&amp;author=T.%20Prebet&amp;author=M.%20Nezri&amp;author=D.%20Sainty&amp;author=S.%20Olschwang&amp;author=L.%20Xerri&amp;author=M.%20Chaffanet&amp;author=MJ.%20Mozziconacci&amp;author=N.%20Vey&amp;author=D.%20Birnbaum&amp;journal=Br%20J%20Haematol&amp;volume=145&amp;pages=788-800&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR22">Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER, van der Heijden A, Scheele TN, Vandenberghe P: de WT, van der Reijden BA, Jansen JH: Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010, 42: 665-667.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20601954"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=de%20WT%2C%20van%20der%20Reijden%20BA%2C%20Jansen%20JH%3A%20Somatic%20mutations%20of%20the%20histone%20methyltransferase%20gene%20EZH2%20in%20myelodysplastic%20syndromes&amp;author=G.%20Nikoloski&amp;author=SM.%20Langemeijer&amp;author=RP.%20Kuiper&amp;author=R.%20Knops&amp;author=M.%20Massop&amp;author=ER.%20Tonnissen&amp;author=A.%20van%20der%20Heijden&amp;author=TN.%20Scheele&amp;author=P.%20Vandenberghe&amp;journal=Nat%20Genet&amp;volume=42&amp;pages=665-667&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR23">Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF: Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012, 481: 506-510.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22237025"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267864"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Clonal%20evolution%20in%20relapsed%20acute%20myeloid%20leukaemia%20revealed%20by%20whole-genome%20sequencing&amp;author=L.%20Ding&amp;author=TJ.%20Ley&amp;author=DE.%20Larson&amp;author=CA.%20Miller&amp;author=DC.%20Koboldt&amp;author=JS.%20Welch&amp;author=JK.%20Ritchey&amp;author=MA.%20Young&amp;author=T.%20Lamprecht&amp;author=MD.%20McLellan&amp;author=JF.%20McMichael&amp;author=JW.%20Wallis&amp;author=C.%20Lu&amp;author=D.%20Shen&amp;author=CC.%20Harris&amp;author=DJ.%20Dooling&amp;author=RS.%20Fulton&amp;author=LL.%20Fulton&amp;author=K.%20Chen&amp;author=H.%20Schmidt&amp;author=J.%20Kalicki-Veizer&amp;author=VJ.%20Magrini&amp;author=L.%20Cook&amp;author=SD.%20McGrath&amp;author=TL.%20Vickery&amp;author=MC.%20Wendl&amp;author=S.%20Heath&amp;author=MA.%20Watson&amp;author=DC.%20Link&amp;author=MH.%20Tomasson&amp;author=WD.%20Shannon&amp;author=JE.%20Payton&amp;author=S.%20Kulkarni&amp;author=P.%20Westervelt&amp;author=MJ.%20Walter&amp;author=TA.%20Graubert&amp;author=ER.%20Mardis&amp;author=RK.%20Wilson&amp;author=JF.%20DiPersio&amp;journal=Nature&amp;volume=481&amp;pages=506-510&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR24">Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, Schmidt H, Zhang Q, Osborne JR, Lin L, O'Laughlin M, McMichael JF, Delehaunty KD, McGrath SD, Fulton LA, Magrini VJ, Vickery TL, Hundal J, Cook LL, Conyers JJ, Swift GW, Reed JP, Alldredge PA, Wylie T, Walker J, Kalicki J, Watson MA, Heath S, Shannon WD, Varghese N, Nagarajan R, Westervelt P, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Wilson RK: DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010, 363: 2424-2433.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21067377"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201818"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=DNMT3A%20mutations%20in%20acute%20myeloid%20leukemia&amp;author=TJ.%20Ley&amp;author=L.%20Ding&amp;author=MJ.%20Walter&amp;author=MD.%20McLellan&amp;author=T.%20Lamprecht&amp;author=DE.%20Larson&amp;author=C.%20Kandoth&amp;author=JE.%20Payton&amp;author=J.%20Baty&amp;author=J.%20Welch&amp;author=CC.%20Harris&amp;author=CF.%20Lichti&amp;author=RR.%20Townsend&amp;author=RS.%20Fulton&amp;author=DJ.%20Dooling&amp;author=DC.%20Koboldt&amp;author=H.%20Schmidt&amp;author=Q.%20Zhang&amp;author=JR.%20Osborne&amp;author=L.%20Lin&amp;author=M.%20O%27Laughlin&amp;author=JF.%20McMichael&amp;author=KD.%20Delehaunty&amp;author=SD.%20McGrath&amp;author=LA.%20Fulton&amp;author=VJ.%20Magrini&amp;author=TL.%20Vickery&amp;author=J.%20Hundal&amp;author=LL.%20Cook&amp;author=JJ.%20Conyers&amp;author=GW.%20Swift&amp;author=JP.%20Reed&amp;author=PA.%20Alldredge&amp;author=T.%20Wylie&amp;author=J.%20Walker&amp;author=J.%20Kalicki&amp;author=MA.%20Watson&amp;author=S.%20Heath&amp;author=WD.%20Shannon&amp;author=N.%20Varghese&amp;author=R.%20Nagarajan&amp;author=P.%20Westervelt&amp;author=MH.%20Tomasson&amp;author=DC.%20Link&amp;author=TA.%20Graubert&amp;author=JF.%20DiPersio&amp;author=ER.%20Mardis&amp;author=RK.%20Wilson&amp;journal=N%20Engl%20J%20Med&amp;volume=363&amp;pages=2424-2433&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR25">Li M, Collins R, Jiao Y, Ouillette P, Bixby D, Erba H, Vogelstein B, Kinzler KW, Papadopoulos N, Malek SN: Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia. Blood. 2011, 118: 5914-5917.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21989985"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228503"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Somatic%20mutations%20in%20the%20transcriptional%20corepressor%20gene%20BCORL1%20in%20adult%20acute%20myelogenous%20leukemia&amp;author=M.%20Li&amp;author=R.%20Collins&amp;author=Y.%20Jiao&amp;author=P.%20Ouillette&amp;author=D.%20Bixby&amp;author=H.%20Erba&amp;author=B.%20Vogelstein&amp;author=KW.%20Kinzler&amp;author=N.%20Papadopoulos&amp;author=SN.%20Malek&amp;journal=Blood&amp;volume=118&amp;pages=5914-5917&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR26">Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK, Pohl CS, Wallis JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME, Ivy JV, Kalicki J, Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson MA, Baty J, Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ, Graubert TA, DiPersio JF, Wilson RK, Ley TJ: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009, 361: 1058-1066.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19657110"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201812"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Recurring%20mutations%20found%20by%20sequencing%20an%20acute%20myeloid%20leukemia%20genome&amp;author=ER.%20Mardis&amp;author=L.%20Ding&amp;author=DJ.%20Dooling&amp;author=DE.%20Larson&amp;author=MD.%20McLellan&amp;author=K.%20Chen&amp;author=DC.%20Koboldt&amp;author=RS.%20Fulton&amp;author=KD.%20Delehaunty&amp;author=SD.%20McGrath&amp;author=LA.%20Fulton&amp;author=DP.%20Locke&amp;author=VJ.%20Magrini&amp;author=RM.%20Abbott&amp;author=TL.%20Vickery&amp;author=JS.%20Reed&amp;author=JS.%20Robinson&amp;author=T.%20Wylie&amp;author=SM.%20Smith&amp;author=L.%20Carmichael&amp;author=JM.%20Eldred&amp;author=CC.%20Harris&amp;author=J.%20Walker&amp;author=JB.%20Peck&amp;author=F.%20Du&amp;author=AF.%20Dukes&amp;author=GE.%20Sanderson&amp;author=AM.%20Brummett&amp;author=E.%20Clark&amp;author=JF.%20McMichael&amp;author=RJ.%20Meyer&amp;author=JK.%20Schindler&amp;author=CS.%20Pohl&amp;author=JW.%20Wallis&amp;author=X.%20Shi&amp;author=L.%20Lin&amp;author=H.%20Schmidt&amp;author=Y.%20Tang&amp;author=C.%20Haipek&amp;author=ME.%20Wiechert&amp;author=JV.%20Ivy&amp;author=J.%20Kalicki&amp;author=G.%20Elliott&amp;author=RE.%20Ries&amp;author=JE.%20Payton&amp;author=P.%20Westervelt&amp;author=MH.%20Tomasson&amp;author=MA.%20Watson&amp;author=J.%20Baty&amp;author=S.%20Heath&amp;author=WD.%20Shannon&amp;author=R.%20Nagarajan&amp;author=DC.%20Link&amp;author=MJ.%20Walter&amp;author=TA.%20Graubert&amp;author=JF.%20DiPersio&amp;author=RK.%20Wilson&amp;author=TJ.%20Ley&amp;journal=N%20Engl%20J%20Med&amp;volume=361&amp;pages=1058-1066&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR27">Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagati A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Cross JR, Green AR, Futreal PA, Stratton MR, Campbell PJ: Somatic mutation of SF3B1 in myelodysplasia with ring sideroblasts and other cancers. N Engl J Med. 2011, 365: 1384-1395.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21995386"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322589"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Somatic%20mutation%20of%20SF3B1%20in%20myelodysplasia%20with%20ring%20sideroblasts%20and%20other%20cancers&amp;author=E.%20Papaemmanuil&amp;author=M.%20Cazzola&amp;author=J.%20Boultwood&amp;author=L.%20Malcovati&amp;author=P.%20Vyas&amp;author=D.%20Bowen&amp;author=A.%20Pellagati&amp;author=JS.%20Wainscoat&amp;author=E.%20Hellstrom-Lindberg&amp;author=C.%20Gambacorti-Passerini&amp;author=AL.%20Godfrey&amp;author=JR.%20Cross&amp;author=AR.%20Green&amp;author=PA.%20Futreal&amp;author=MR.%20Stratton&amp;author=PJ.%20Campbell&amp;journal=N%20Engl%20J%20Med&amp;volume=365&amp;pages=1384-1395&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR28">Van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C, Edkins S, Hardy C, O'Meara S, Teague J, Butler A, Hinton J, Latimer C, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Cole J, Forbes S, Jia M, Jones D, Kok CY, Leroy C, Lin ML, McBride DJ, Maddison M, Maquire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, Pleasance E, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turner R, Turrell K, Varian J, West S, Widaa S, Wray P, Collins VP, Ichimura K, Law S, Wong J, Yuen ST, Leung SY, Tonon G, DePinho RA, Tai YT, Anderson KC, Kahnoski RJ, Massie A, Khoo SK, Teh BT, Stratton MR, Futreal PA: Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet. 2009, 41: 521-523.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19330029"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873835"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Somatic%20mutations%20of%20the%20histone%20H3K27%20demethylase%20gene%20UTX%20in%20human%20cancer&amp;author=G.%20Van%20Haaften&amp;author=GL.%20Dalgliesh&amp;author=H.%20Davies&amp;author=L.%20Chen&amp;author=G.%20Bignell&amp;author=C.%20Greenman&amp;author=S.%20Edkins&amp;author=C.%20Hardy&amp;author=S.%20O%27Meara&amp;author=J.%20Teague&amp;author=A.%20Butler&amp;author=J.%20Hinton&amp;author=C.%20Latimer&amp;author=J.%20Andrews&amp;author=S.%20Barthorpe&amp;author=D.%20Beare&amp;author=G.%20Buck&amp;author=PJ.%20Campbell&amp;author=J.%20Cole&amp;author=S.%20Forbes&amp;author=M.%20Jia&amp;author=D.%20Jones&amp;author=CY.%20Kok&amp;author=C.%20Leroy&amp;author=ML.%20Lin&amp;author=DJ.%20McBride&amp;author=M.%20Maddison&amp;author=S.%20Maquire&amp;author=K.%20McLay&amp;author=A.%20Menzies&amp;author=T.%20Mironenko&amp;author=L.%20Mulderrig&amp;author=L.%20Mudie&amp;author=E.%20Pleasance&amp;author=R.%20Shepherd&amp;author=R.%20Smith&amp;author=L.%20Stebbings&amp;author=P.%20Stephens&amp;author=G.%20Tang&amp;author=PS.%20Tarpey&amp;author=R.%20Turner&amp;author=K.%20Turrell&amp;author=J.%20Varian&amp;author=S.%20West&amp;author=S.%20Widaa&amp;author=P.%20Wray&amp;author=VP.%20Collins&amp;author=K.%20Ichimura&amp;author=S.%20Law&amp;author=J.%20Wong&amp;author=ST.%20Yuen&amp;author=SY.%20Leung&amp;author=G.%20Tonon&amp;author=RA.%20DePinho&amp;author=YT.%20Tai&amp;author=KC.%20Anderson&amp;author=RJ.%20Kahnoski&amp;author=A.%20Massie&amp;author=SK.%20Khoo&amp;author=BT.%20Teh&amp;author=MR.%20Stratton&amp;author=PA.%20Futreal&amp;journal=Nat%20Genet&amp;volume=41&amp;pages=521-523&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR29">Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A, O'Keefe C, Rogers HJ, Sekeres MA, Maciejewski JP, Tiu RV: SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2011, 26: 542-545.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21886174"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=SF3B1%2C%20a%20splicing%20factor%20is%20frequently%20mutated%20in%20refractory%20anemia%20with%20ring%20sideroblasts&amp;author=V.%20Visconte&amp;author=H.%20Makishima&amp;author=A.%20Jankowska&amp;author=H.%20Szpurka&amp;author=F.%20Traina&amp;author=A.%20Jerez&amp;author=C.%20O%27Keefe&amp;author=HJ.%20Rogers&amp;author=MA.%20Sekeres&amp;author=JP.%20Maciejewski&amp;author=RV.%20Tiu&amp;journal=Leukemia&amp;volume=26&amp;pages=542-545&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR30">Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, Shi JY, Zhu YM, Tang L, Zhang XW, Liang WX, Mi JQ, Song HD, Li KQ, Chen Z, Chen SJ: Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011, 43: 309-315.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21399634"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Exome%20sequencing%20identifies%20somatic%20mutations%20of%20DNA%20methyltransferase%20gene%20DNMT3A%20in%20acute%20monocytic%20leukemia&amp;author=XJ.%20Yan&amp;author=J.%20Xu&amp;author=ZH.%20Gu&amp;author=CM.%20Pan&amp;author=G.%20Lu&amp;author=Y.%20Shen&amp;author=JY.%20Shi&amp;author=YM.%20Zhu&amp;author=L.%20Tang&amp;author=XW.%20Zhang&amp;author=WX.%20Liang&amp;author=JQ.%20Mi&amp;author=HD.%20Song&amp;author=KQ.%20Li&amp;author=Z.%20Chen&amp;author=SJ.%20Chen&amp;journal=Nat%20Genet&amp;volume=43&amp;pages=309-315&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR31">Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, Chalkidis G, Suzuki Y, Shiosaka M, Kawahata R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Ishiyama K, Mori H, Nolte F, Hofmann WK, Miyawaki S, Sugano S, Haferlach C, Koeffler HP, Shih LY, Haferlach T, Chiba S, Nakauchi H, Miyano S, Ogawa S: Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011, 478: 64-69.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21909114"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Frequent%20pathway%20mutations%20of%20splicing%20machinery%20in%20myelodysplasia&amp;author=K.%20Yoshida&amp;author=M.%20Sanada&amp;author=Y.%20Shiraishi&amp;author=D.%20Nowak&amp;author=Y.%20Nagata&amp;author=R.%20Yamamoto&amp;author=Y.%20Sato&amp;author=A.%20Sato-Otsubo&amp;author=A.%20Kon&amp;author=M.%20Nagasaki&amp;author=G.%20Chalkidis&amp;author=Y.%20Suzuki&amp;author=M.%20Shiosaka&amp;author=R.%20Kawahata&amp;author=T.%20Yamaguchi&amp;author=M.%20Otsu&amp;author=N.%20Obara&amp;author=M.%20Sakata-Yanagimoto&amp;author=K.%20Ishiyama&amp;author=H.%20Mori&amp;author=F.%20Nolte&amp;author=WK.%20Hofmann&amp;author=S.%20Miyawaki&amp;author=S.%20Sugano&amp;author=C.%20Haferlach&amp;author=HP.%20Koeffler&amp;author=LY.%20Shih&amp;author=T.%20Haferlach&amp;author=S.%20Chiba&amp;author=H.%20Nakauchi&amp;author=S.%20Miyano&amp;author=S.%20Ogawa&amp;journal=Nature&amp;volume=478&amp;pages=64-69&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR32">Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL, Ueno T, Soda M, Hamada T, Haruta H, Takada S, Miyazaki Y, Kiyoi H, Ito E, Naoe T, Tomonaga M, Toyota M, Tajima S, Iwama A, Mano H: Array-based genomic resequencing of human leukemia. Oncogene. 2010, 29: 3723-3731.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20400977"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Array-based%20genomic%20resequencing%20of%20human%20leukemia&amp;author=Y.%20Yamashita&amp;author=J.%20Yuan&amp;author=I.%20Suetake&amp;author=H.%20Suzuki&amp;author=Y.%20Ishikawa&amp;author=YL.%20Choi&amp;author=T.%20Ueno&amp;author=M.%20Soda&amp;author=T.%20Hamada&amp;author=H.%20Haruta&amp;author=S.%20Takada&amp;author=Y.%20Miyazaki&amp;author=H.%20Kiyoi&amp;author=E.%20Ito&amp;author=T.%20Naoe&amp;author=M.%20Tomonaga&amp;author=M.%20Toyota&amp;author=S.%20Tajima&amp;author=A.%20Iwama&amp;author=H.%20Mano&amp;journal=Oncogene&amp;volume=29&amp;pages=3723-3731&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR33">Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, Maciejewski JP: Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A. Blood. 2011, 118: 3932-3941.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21828135"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193268"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutational%20spectrum%20analysis%20of%20chronic%20myelomonocytic%20leukemia%20includes%20genes%20associated%20with%20epigenetic%20regulation%3A%20UTX%2C%20EZH2%20and%20DNMT3A&amp;author=AM.%20Jankowska&amp;author=H.%20Makishima&amp;author=RV.%20Tiu&amp;author=H.%20Szpurka&amp;author=Y.%20Huang&amp;author=F.%20Traina&amp;author=V.%20Visconte&amp;author=Y.%20Sugimoto&amp;author=C.%20Prince&amp;author=C.%20O%27Keefe&amp;author=ED.%20Hsi&amp;author=A.%20List&amp;author=MA.%20Sekeres&amp;author=A.%20Rao&amp;author=MA.%20McDevitt&amp;author=JP.%20Maciejewski&amp;journal=Blood&amp;volume=118&amp;pages=3932-3941&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR34">Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P, Gilliland DG, Busque L: X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood. 2006, 107: 4139-4141.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16434490"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895292"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=X-inactivation-based%20clonality%20analysis%20and%20quantitative%20JAK2V617F%20assessment%20reveal%20a%20strong%20association%20between%20clonality%20and%20JAK2V617F%20in%20PV%20but%20not%20ET%2FMMM%2C%20and%20identifies%20a%20subset%20of%20JAK2V617F-negative%20ET%20and%20MMM%20patients%20with%20clonal%20hematopoiesis&amp;author=RL.%20Levine&amp;author=C.%20Belisle&amp;author=M.%20Wadleigh&amp;author=D.%20Zahrieh&amp;author=S.%20Lee&amp;author=P.%20Chagnon&amp;author=DG.%20Gilliland&amp;author=L.%20Busque&amp;journal=Blood&amp;volume=107&amp;pages=4139-4141&amp;publication_year=2006"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR35">Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, Boiret-Dupre N, Skoda RC, Hermouet S: The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006, 108: 1865-1867.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16728702"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20JAK2-V617F%20mutation%20is%20frequently%20present%20at%20diagnosis%20in%20patients%20with%20essential%20thrombocythemia%20and%20polycythemia%20vera&amp;author=E.%20Lippert&amp;author=M.%20Boissinot&amp;author=R.%20Kralovics&amp;author=F.%20Girodon&amp;author=I.%20Dobo&amp;author=V.%20Praloran&amp;author=N.%20Boiret-Dupre&amp;author=RC.%20Skoda&amp;author=S.%20Hermouet&amp;journal=Blood&amp;volume=108&amp;pages=1865-1867&amp;publication_year=2006"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR36">Gelsi-Boyer V, Trouplin V, Roquain J, Adlaide J, Carbuccia N, Esterni B, Finetti P, Murati A, Arnoulet C, Zerazhi H, Fezoui H, Tadrist Z, Nezri M, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D: ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010, 151: 365-375.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20880116"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=ASXL1%20mutation%20is%20associated%20with%20poor%20prognosis%20and%20acute%20transformation%20in%20chronic%20myelomonocytic%20leukaemia&amp;author=V.%20Gelsi-Boyer&amp;author=V.%20Trouplin&amp;author=J.%20Roquain&amp;author=J.%20Ad%C3%A9laide&amp;author=N.%20Carbuccia&amp;author=B.%20Esterni&amp;author=P.%20Finetti&amp;author=A.%20Murati&amp;author=C.%20Arnoulet&amp;author=H.%20Zerazhi&amp;author=H.%20Fezoui&amp;author=Z.%20Tadrist&amp;author=M.%20Nezri&amp;author=M.%20Chaffanet&amp;author=MJ.%20Mozziconacci&amp;author=N.%20Vey&amp;author=D.%20Birnbaum&amp;journal=Br%20J%20Haematol&amp;volume=151&amp;pages=365-375&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR37">Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi-Boyer V, Arnoulet C, Gisserot O, Verrot D, Slama B, Vey N, Mozziconacci MJ, Birnbaum D, Murati A: Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer. 2012, 51: 743-755.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22489043"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutation%20analysis%20of%20ASXL1%2C%20CBL%2C%20DNMT3A%2C%20IDH1%2C%20IDH2%2C%20JAK2%2C%20MPL%2C%20NF1%2C%20SF3B1%2C%20SUZ12%2C%20and%20TET2%20in%20myeloproliferative%20neoplasms&amp;author=M.%20Brecqueville&amp;author=J.%20Rey&amp;author=F.%20Bertucci&amp;author=E.%20Coppin&amp;author=P.%20Finetti&amp;author=N.%20Carbuccia&amp;author=N.%20Cervera&amp;author=V.%20Gelsi-Boyer&amp;author=C.%20Arnoulet&amp;author=O.%20Gisserot&amp;author=D.%20Verrot&amp;author=B.%20Slama&amp;author=N.%20Vey&amp;author=MJ.%20Mozziconacci&amp;author=D.%20Birnbaum&amp;author=A.%20Murati&amp;journal=Genes%20Chromosomes%20Cancer&amp;volume=51&amp;pages=743-755&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR38">Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Curtis CH, Della-Valle V, Couronne L, Scourzic L, Chesnais V, Guerci-Bresler A, Slama B, Beyne-Rauzy O, Schmidt-Tanguy A, Stamatoullas-Bastard A, Dreyfus F, Prebet T, De Botton S, Vey N, Morgan M, Cross JR, Preudhomme C, Birnbaum D, Bernard O, Fontenay M: Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood. 2012, 119: 3211-3218.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22343920"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutations%20affecting%20mRNA%20splicing%20define%20distinct%20clinical%20phenotypes%20and%20correlate%20with%20patient%20outcome%20in%20myelodysplastic%20syndromes&amp;author=F.%20Damm&amp;author=O.%20Kosmider&amp;author=V.%20Gelsi-Boyer&amp;author=A.%20Renneville&amp;author=N.%20Carbuccia&amp;author=CH.%20Curtis&amp;author=V.%20Della-Valle&amp;author=L.%20Couronne&amp;author=L.%20Scourzic&amp;author=V.%20Chesnais&amp;author=A.%20Guerci-Bresler&amp;author=B.%20Slama&amp;author=O.%20Beyne-Rauzy&amp;author=A.%20Schmidt-Tanguy&amp;author=A.%20Stamatoullas-Bastard&amp;author=F.%20Dreyfus&amp;author=T.%20Prebet&amp;author=S.%20De%20Botton&amp;author=N.%20Vey&amp;author=M.%20Morgan&amp;author=JR.%20Cross&amp;author=C.%20Preudhomme&amp;author=D.%20Birnbaum&amp;author=O.%20Bernard&amp;author=M.%20Fontenay&amp;journal=Blood&amp;volume=119&amp;pages=3211-3218&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR39">Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, Krysiak K, Harris CC, Koboldt DC, Larson DE, McLellan MD, Dooling DJ, Abbott RM, Fulton RS, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Grillot M, Baty J, Heath S, Frater JL, Nasim T, Link DC, Tomasson MH, Westervelt P, DiPersio JF, Mardis ER, Ley TJ, Wilson RK, Walter MJ: Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2011, 44: 53-57.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22158538"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247063"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Recurrent%20mutations%20in%20the%20U2AF1%20splicing%20factor%20in%20myelodysplastic%20syndromes&amp;author=TA.%20Graubert&amp;author=D.%20Shen&amp;author=L.%20Ding&amp;author=T.%20Okeyo-Owuor&amp;author=CL.%20Lunn&amp;author=J.%20Shao&amp;author=K.%20Krysiak&amp;author=CC.%20Harris&amp;author=DC.%20Koboldt&amp;author=DE.%20Larson&amp;author=MD.%20McLellan&amp;author=DJ.%20Dooling&amp;author=RM.%20Abbott&amp;author=RS.%20Fulton&amp;author=H.%20Schmidt&amp;author=J.%20Kalicki-Veizer&amp;author=M.%20O%27Laughlin&amp;author=M.%20Grillot&amp;author=J.%20Baty&amp;author=S.%20Heath&amp;author=JL.%20Frater&amp;author=T.%20Nasim&amp;author=DC.%20Link&amp;author=MH.%20Tomasson&amp;author=P.%20Westervelt&amp;author=JF.%20DiPersio&amp;author=ER.%20Mardis&amp;author=TJ.%20Ley&amp;author=RK.%20Wilson&amp;author=MJ.%20Walter&amp;journal=Nat%20Genet&amp;volume=44&amp;pages=53-57&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR40">Lasho TL, Finke CM, Hanson CA, Jimma T, Knudson RA, Ketterling RP, Pardanani A, Tefferi A: SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia. 2011, 26: 1135-1137.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22064353"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=SF3B1%20mutations%20in%20primary%20myelofibrosis%3A%20clinical%2C%20histopathology%20and%20genetic%20correlates%20among%20155%20patients&amp;author=TL.%20Lasho&amp;author=CM.%20Finke&amp;author=CA.%20Hanson&amp;author=T.%20Jimma&amp;author=RA.%20Knudson&amp;author=RP.%20Ketterling&amp;author=A.%20Pardanani&amp;author=A.%20Tefferi&amp;journal=Leukemia&amp;volume=26&amp;pages=1135-1137&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR41">Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu KS, Jerez A, Przychodzen B, Bupathi M, Guinta K, Afable MG, Sekeres MA, Padgett RA, Tiu RV, Maciejewski JP: Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012, 119: 3203-3210.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22323480"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321850"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutations%20in%20the%20spliceosome%20machinery%2C%20a%20novel%20and%20ubiquitous%20pathway%20in%20leukemogenesis&amp;author=H.%20Makishima&amp;author=V.%20Visconte&amp;author=H.%20Sakaguchi&amp;author=AM.%20Jankowska&amp;author=KS.%20Abu&amp;author=A.%20Jerez&amp;author=B.%20Przychodzen&amp;author=M.%20Bupathi&amp;author=K.%20Guinta&amp;author=MG.%20Afable&amp;author=MA.%20Sekeres&amp;author=RA.%20Padgett&amp;author=RV.%20Tiu&amp;author=JP.%20Maciejewski&amp;journal=Blood&amp;volume=119&amp;pages=3203-3210&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR42">Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J, Wlodarski MW, Kolking B, Wichmann M, Gorlich K, Gohring G, Bug G, Ottmann O, Niemeyer CM, Hofmann WK, Schlegelberger B, Ganser A, Heuser M: Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012, 119: 3578-3584.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22389253"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Frequency%20and%20prognostic%20impact%20of%20mutations%20in%20SRSF2%2C%20U2AF1%2C%20and%20ZRSR2%20in%20patients%20with%20myelodysplastic%20syndromes&amp;author=F.%20Thol&amp;author=S.%20Kade&amp;author=C.%20Schlarmann&amp;author=P.%20Loffeld&amp;author=M.%20Morgan&amp;author=J.%20Krauter&amp;author=MW.%20Wlodarski&amp;author=B.%20Kolking&amp;author=M.%20Wichmann&amp;author=K.%20Gorlich&amp;author=G.%20Gohring&amp;author=G.%20Bug&amp;author=O.%20Ottmann&amp;author=CM.%20Niemeyer&amp;author=WK.%20Hofmann&amp;author=B.%20Schlegelberger&amp;author=A.%20Ganser&amp;author=M.%20Heuser&amp;journal=Blood&amp;volume=119&amp;pages=3578-3584&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR43">Jankowska AM, Szpurka H: Mutational determinants of epigenetic instability in myeloid malignancies. Semin Oncol. 2012, 39: 80-96.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22289495"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutational%20determinants%20of%20epigenetic%20instability%20in%20myeloid%20malignancies&amp;author=AM.%20Jankowska&amp;author=H.%20Szpurka&amp;journal=Semin%20Oncol&amp;volume=39&amp;pages=80-96&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR44">Haferlach C, Grossmann V, Kohlmann A, Schindela S, Kern W, Schnittger S, Haferlach T: Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases. Leukemia. 2011, 26: 834-839.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22015770"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Deletion%20of%20the%20tumor-suppressor%20gene%20NF1%20occurs%20in%205%E2%80%89%25%20of%20myeloid%20malignancies%20and%20is%20accompanied%20by%20a%20mutation%20in%20the%20remaining%20allele%20in%20half%20of%20the%20cases&amp;author=C.%20Haferlach&amp;author=V.%20Grossmann&amp;author=A.%20Kohlmann&amp;author=S.%20Schindela&amp;author=W.%20Kern&amp;author=S.%20Schnittger&amp;author=T.%20Haferlach&amp;journal=Leukemia&amp;volume=26&amp;pages=834-839&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR45">Parkin B, Ouillette P, Wang Y, Liu Y, Wright W, Roulston D, Purkayastha A, Dressel A, Karp J, Bockenstedt P, Al-Zoubi A, Talpaz M, Kujawski L, Liu Y, Shedden K, Shakhan S, Li C, Erba H, Malek SN: NF1 inactivation in adult acute myelogenous leukemia. Clin Cancer Res. 2010, 16: 4135-4147.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20505189"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921448"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=NF1%20inactivation%20in%20adult%20acute%20myelogenous%20leukemia&amp;author=B.%20Parkin&amp;author=P.%20Ouillette&amp;author=Y.%20Wang&amp;author=Y.%20Liu&amp;author=W.%20Wright&amp;author=D.%20Roulston&amp;author=A.%20Purkayastha&amp;author=A.%20Dressel&amp;author=J.%20Karp&amp;author=P.%20Bockenstedt&amp;author=A.%20Al-Zoubi&amp;author=M.%20Talpaz&amp;author=L.%20Kujawski&amp;author=Y.%20Liu&amp;author=K.%20Shedden&amp;author=S.%20Shakhan&amp;author=C.%20Li&amp;author=H.%20Erba&amp;author=SN.%20Malek&amp;journal=Clin%20Cancer%20Res&amp;volume=16&amp;pages=4135-4147&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR46">Gelsi-Boyer V, Trouplin V, Adlaide J, Aceto N, Remy V, Pinson S, Houdayer C, Arnoulet C, Sainty D, Bentires-Alj M, Olschwang S, Vey N, Mozziconacci MJ, Birnbaum D, Chaffanet M: Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer. 2008, 8: 299-314.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18925961"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2588460"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Genome%20profiling%20of%20chronic%20myelomonocytic%20leukemia%3A%20frequent%20alterations%20of%20RAS%20and%20RUNX1%20genes&amp;author=V.%20Gelsi-Boyer&amp;author=V.%20Trouplin&amp;author=J.%20Ad%C3%A9laide&amp;author=N.%20Aceto&amp;author=V.%20Remy&amp;author=S.%20Pinson&amp;author=C.%20Houdayer&amp;author=C.%20Arnoulet&amp;author=D.%20Sainty&amp;author=M.%20Bentires-Alj&amp;author=S.%20Olschwang&amp;author=N.%20Vey&amp;author=MJ.%20Mozziconacci&amp;author=D.%20Birnbaum&amp;author=M.%20Chaffanet&amp;journal=BMC%20Cancer&amp;volume=8&amp;pages=299-314&amp;publication_year=2008"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR47">Greif PA, Eck SH, Konstandin NP, Benet-Pages A, Ksienzyk B, Dufour A, Vetter AT, Popp HD, Lorenz-Depiereux B, Meitinger T, Bohlander SK, Strom TM: Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing. Leukemia. 2011, 25: 821-827.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21339757"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Identification%20of%20recurring%20tumor-specific%20somatic%20mutations%20in%20acute%20myeloid%20leukemia%20by%20transcriptome%20sequencing&amp;author=PA.%20Greif&amp;author=SH.%20Eck&amp;author=NP.%20Konstandin&amp;author=A.%20Benet-Pages&amp;author=B.%20Ksienzyk&amp;author=A.%20Dufour&amp;author=AT.%20Vetter&amp;author=HD.%20Popp&amp;author=B.%20Lorenz-Depiereux&amp;author=T.%20Meitinger&amp;author=SK.%20Bohlander&amp;author=TM.%20Strom&amp;journal=Leukemia&amp;volume=25&amp;pages=821-827&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR48">Adlaide J, Gelsi-Boyer V, Rocquain J, Carbuccia N, Birnbaum DJ, Finetti P, Bertucci F, Mozziconacci MJ, Vey N, Birnbaum D, Chaffanet M: Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies. Leukemia. 2010, 24: 1539-1541.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20555362"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Gain%20of%20CBL-interacting%20protein%2C%20a%20possible%20alternative%20to%20CBL%20mutations%20in%20myeloid%20malignancies&amp;author=J.%20Ad%C3%A9laide&amp;author=V.%20Gelsi-Boyer&amp;author=J.%20Rocquain&amp;author=N.%20Carbuccia&amp;author=DJ.%20Birnbaum&amp;author=P.%20Finetti&amp;author=F.%20Bertucci&amp;author=MJ.%20Mozziconacci&amp;author=N.%20Vey&amp;author=D.%20Birnbaum&amp;author=M.%20Chaffanet&amp;journal=Leukemia&amp;volume=24&amp;pages=1539-1541&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR49">Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, Kreil S, Jones A, Score J, Metzgeroth G, Oscier D, Hall A, Brandts C, Serve H, Reiter A, Chase AJ, Cross NC: Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009, 113: 6182-6192.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19387008"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Frequent%20CBL%20mutations%20associated%20with%2011q%20acquired%20uniparental%20disomy%20in%20myeloproliferative%20neoplasms&amp;author=FH.%20Grand&amp;author=CE.%20Hidalgo-Curtis&amp;author=T.%20Ernst&amp;author=K.%20Zoi&amp;author=C.%20Zoi&amp;author=C.%20McGuire&amp;author=S.%20Kreil&amp;author=A.%20Jones&amp;author=J.%20Score&amp;author=G.%20Metzgeroth&amp;author=D.%20Oscier&amp;author=A.%20Hall&amp;author=C.%20Brandts&amp;author=H.%20Serve&amp;author=A.%20Reiter&amp;author=AJ.%20Chase&amp;author=NC.%20Cross&amp;journal=Blood&amp;volume=113&amp;pages=6182-6192&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR50">Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, Muramatsu H, O'Keefe C, Hsi E, Paquette RL, Kojima S, List AF, Sekeres MA, McDevitt MA, Maciejewski JP: Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 2009, 27: 6109-6116.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19901108"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040009"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutations%20of%20e3%20ubiquitin%20ligase%20cbl%20family%20members%20constitute%20a%20novel%20common%20pathogenic%20lesion%20in%20myeloid%20malignancies&amp;author=H.%20Makishima&amp;author=H.%20Cazzolli&amp;author=H.%20Szpurka&amp;author=A.%20Dunbar&amp;author=R.%20Tiu&amp;author=J.%20Huh&amp;author=H.%20Muramatsu&amp;author=C.%20O%27Keefe&amp;author=E.%20Hsi&amp;author=RL.%20Paquette&amp;author=S.%20Kojima&amp;author=AF.%20List&amp;author=MA.%20Sekeres&amp;author=MA.%20McDevitt&amp;author=JP.%20Maciejewski&amp;journal=J%20Clin%20Oncol&amp;volume=27&amp;pages=6109-6116&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR51">Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D, Zoi K, Ernst T, Stegelmann F, Dohner K, Chase A, Cross NC: Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood. 2011, 119: 1208-1213.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22053108"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Inactivation%20of%20polycomb%20repressive%20complex%202%20components%20in%20myeloproliferative%20and%20myelodysplastic%2Fmyeloproliferative%20neoplasms&amp;author=J.%20Score&amp;author=C.%20Hidalgo-Curtis&amp;author=AV.%20Jones&amp;author=N.%20Winkelmann&amp;author=A.%20Skinner&amp;author=D.%20Ward&amp;author=K.%20Zoi&amp;author=T.%20Ernst&amp;author=F.%20Stegelmann&amp;author=K.%20Dohner&amp;author=A.%20Chase&amp;author=NC.%20Cross&amp;journal=Blood&amp;volume=119&amp;pages=1208-1213&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR52">Haferlach C, Bacher U, Schnittger S, Alpermann T, Zenger M, Kern W, Haferlach T: ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer. 2012, 51: 328-337.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22162288"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=ETV6%20rearrangements%20are%20recurrent%20in%20myeloid%20malignancies%20and%20are%20frequently%20associated%20with%20other%20genetic%20events&amp;author=C.%20Haferlach&amp;author=U.%20Bacher&amp;author=S.%20Schnittger&amp;author=T.%20Alpermann&amp;author=M.%20Zenger&amp;author=W.%20Kern&amp;author=T.%20Haferlach&amp;journal=Genes%20Chromosomes%20Cancer&amp;volume=51&amp;pages=328-337&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR53">Cechova H, Lassuthova P, Novakova L, Belickova M, Stemberkova R, Jencik J, Stankova M, Hrabakova P, Pegova K, Zizkova H, Cermak J: Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia. Neoplasma. 2012, 59: 168-174.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22248274"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Monitoring%20of%20methylation%20changes%20in%209p21%20region%20in%20patients%20with%20myelodysplastic%20syndromes%20and%20acute%20myeloid%20leukemia&amp;author=H.%20Cechova&amp;author=P.%20Lassuthova&amp;author=L.%20Novakova&amp;author=M.%20Belickova&amp;author=R.%20Stemberkova&amp;author=J.%20Jencik&amp;author=M.%20Stankova&amp;author=P.%20Hrabakova&amp;author=K.%20Pegova&amp;author=H.%20Zizkova&amp;author=J.%20Cermak&amp;journal=Neoplasma&amp;volume=59&amp;pages=168-174&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR54">Aucagne R, Droin N, Paggetti J, Lagrange B, Largeot A, Hammann A, Bataille A, Martin L, Yan KP, Fenaux P, Losson R, Solary E, Bastie JN, Delva L: Transcription intermediary factor 1gamma is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest. 2011, 121: 2361-2370.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21537084"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104753"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Transcription%20intermediary%20factor%201gamma%20is%20a%20tumor%20suppressor%20in%20mouse%20and%20human%20chronic%20myelomonocytic%20leukemia&amp;author=R.%20Aucagne&amp;author=N.%20Droin&amp;author=J.%20Paggetti&amp;author=B.%20Lagrange&amp;author=A.%20Largeot&amp;author=A.%20Hammann&amp;author=A.%20Bataille&amp;author=L.%20Martin&amp;author=KP.%20Yan&amp;author=P.%20Fenaux&amp;author=R.%20Losson&amp;author=E.%20Solary&amp;author=JN.%20Bastie&amp;author=L.%20Delva&amp;journal=J%20Clin%20Invest&amp;volume=121&amp;pages=2361-2370&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR55">Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N, Hsu K, Bloomfield CD, Stone RM, DeAngelo DJ, Galinsky IA, Issa JP, Clarke MF, Look AT: Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007, 13: 78-83.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17159988"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Chromosome%205q%20deletion%20and%20epigenetic%20suppression%20of%20the%20gene%20encoding%20alpha-catenin%20%28CTNNA1%29%20in%20myeloid%20cell%20transformation&amp;author=TX.%20Liu&amp;author=MW.%20Becker&amp;author=J.%20Jelinek&amp;author=WS.%20Wu&amp;author=M.%20Deng&amp;author=N.%20Mikhalkevich&amp;author=K.%20Hsu&amp;author=CD.%20Bloomfield&amp;author=RM.%20Stone&amp;author=DJ.%20DeAngelo&amp;author=IA.%20Galinsky&amp;author=JP.%20Issa&amp;author=MF.%20Clarke&amp;author=AT.%20Look&amp;journal=Nat%20Med&amp;volume=13&amp;pages=78-83&amp;publication_year=2007"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR56">Brakensiek K, Langer F, Schlegelberger B, Kreipe H, Lehmann U: Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J Haematol. 2005, 130: 209-217.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16029449"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Hypermethylation%20of%20the%20suppressor%20of%20cytokine%20signalling-1%20%28SOCS-1%29%20in%20myelodysplastic%20syndrome&amp;author=K.%20Brakensiek&amp;author=F.%20Langer&amp;author=B.%20Schlegelberger&amp;author=H.%20Kreipe&amp;author=U.%20Lehmann&amp;journal=Br%20J%20Haematol&amp;volume=130&amp;pages=209-217&amp;publication_year=2005"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR57">McDevitt MA: Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies. Semin Oncol. 2012, 39: 109-122.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22289497"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Clinical%20applications%20of%20epigenetic%20markers%20and%20epigenetic%20profiling%20in%20myeloid%20malignancies&amp;author=MA.%20McDevitt&amp;journal=Semin%20Oncol&amp;volume=39&amp;pages=109-122&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR58">Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL: Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011, 364: 2496-2506.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21714648"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159042"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Clinical%20effect%20of%20point%20mutations%20in%20myelodysplastic%20syndromes&amp;author=R.%20Bejar&amp;author=K.%20Stevenson&amp;author=O.%20Abdel-Wahab&amp;author=N.%20Galili&amp;author=B.%20Nilsson&amp;author=G.%20Garcia-Manero&amp;author=H.%20Kantarjian&amp;author=A.%20Raza&amp;author=RL.%20Levine&amp;author=D.%20Neuberg&amp;author=BL.%20Ebert&amp;journal=N%20Engl%20J%20Med&amp;volume=364&amp;pages=2496-2506&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR59">Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M, Cook L, Abbott R, Larson DE, Koboldt DC, Pohl C, Smith S, Hawkins A, Abbott S, Locke D, Hillier LW, Miner T, Fulton L, Magrini V, Wylie T, Glasscock J, Conyers J, Sander N, Shi X, Osborne JR, Minx P, Gordon D, Chinwalla A, Zhao Y, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson M, Baty J, Ivanovich J, Heath S, Shannon WD, Nagarajan R, Walter MJ, Link DC, Graubert TA, DiPersio JF, Wilson RK: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008, 456: 66-72.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18987736"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2603574"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=DNA%20sequencing%20of%20a%20cytogenetically%20normal%20acute%20myeloid%20leukaemia%20genome&amp;author=TJ.%20Ley&amp;author=ER.%20Mardis&amp;author=L.%20Ding&amp;author=B.%20Fulton&amp;author=MD.%20McLellan&amp;author=K.%20Chen&amp;author=D.%20Dooling&amp;author=BH.%20Dunford-Shore&amp;author=S.%20McGrath&amp;author=M.%20Hickenbotham&amp;author=L.%20Cook&amp;author=R.%20Abbott&amp;author=DE.%20Larson&amp;author=DC.%20Koboldt&amp;author=C.%20Pohl&amp;author=S.%20Smith&amp;author=A.%20Hawkins&amp;author=S.%20Abbott&amp;author=D.%20Locke&amp;author=LW.%20Hillier&amp;author=T.%20Miner&amp;author=L.%20Fulton&amp;author=V.%20Magrini&amp;author=T.%20Wylie&amp;author=J.%20Glasscock&amp;author=J.%20Conyers&amp;author=N.%20Sander&amp;author=X.%20Shi&amp;author=JR.%20Osborne&amp;author=P.%20Minx&amp;author=D.%20Gordon&amp;author=A.%20Chinwalla&amp;author=Y.%20Zhao&amp;author=RE.%20Ries&amp;author=JE.%20Payton&amp;author=P.%20Westervelt&amp;author=MH.%20Tomasson&amp;author=M.%20Watson&amp;author=J.%20Baty&amp;author=J.%20Ivanovich&amp;author=S.%20Heath&amp;author=WD.%20Shannon&amp;author=R.%20Nagarajan&amp;author=MJ.%20Walter&amp;author=DC.%20Link&amp;author=TA.%20Graubert&amp;author=JF.%20DiPersio&amp;author=RK.%20Wilson&amp;journal=Nature&amp;volume=456&amp;pages=66-72&amp;publication_year=2008"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR60">Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K, Olcaydu D, Passamonti F, Rumi E, Pietra D, Jager R, Pieri L, Guglielmelli P, Iacobucci I, Martinelli G, Cazzola M, Vannucchi AM, Gisslinger H, Kralovics R: Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood. 2011, 118: 167-176.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21531982"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Genome%20integrity%20of%20myeloproliferative%20neoplasms%20in%20chronic%20phase%20and%20during%20disease%20progression&amp;author=T.%20Klampfl&amp;author=A.%20Harutyunyan&amp;author=T.%20Berg&amp;author=B.%20Gisslinger&amp;author=M.%20Schalling&amp;author=K.%20Bagienski&amp;author=D.%20Olcaydu&amp;author=F.%20Passamonti&amp;author=E.%20Rumi&amp;author=D.%20Pietra&amp;author=R.%20Jager&amp;author=L.%20Pieri&amp;author=P.%20Guglielmelli&amp;author=I.%20Iacobucci&amp;author=G.%20Martinelli&amp;author=M.%20Cazzola&amp;author=AM.%20Vannucchi&amp;author=H.%20Gisslinger&amp;author=R.%20Kralovics&amp;journal=Blood&amp;volume=118&amp;pages=167-176&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR61">Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat CV, Balbin M, Nicolas C, Payer AR, Fernandez HF, Tallman MS, Paietta E, Melnick A, Vandenberghe P, Speleman F, Aifantis I, Cools J, Levine R, Ferrando A: PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2011, 25: 130-134.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21030981"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=PHF6%20mutations%20in%20adult%20acute%20myeloid%20leukemia&amp;author=P.%20Van%20Vlierberghe&amp;author=J.%20Patel&amp;author=O.%20Abdel-Wahab&amp;author=C.%20Lobry&amp;author=CV.%20Hedvat&amp;author=M.%20Balbin&amp;author=C.%20Nicolas&amp;author=AR.%20Payer&amp;author=HF.%20Fernandez&amp;author=MS.%20Tallman&amp;author=E.%20Paietta&amp;author=A.%20Melnick&amp;author=P.%20Vandenberghe&amp;author=F.%20Speleman&amp;author=I.%20Aifantis&amp;author=J.%20Cools&amp;author=R.%20Levine&amp;author=A.%20Ferrando&amp;journal=Leukemia&amp;volume=25&amp;pages=130-134&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR62">Damm F, Bunke T, Thol F, Markus B, Wagner K, Gohring G, Schlegelberger B, Heil G, Reuter CW, Pullmann K, Schlenk RF, Dohner K, Heuser M, Krauter J, Dohner H, Ganser A, Morgan MA: Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia. Leukemia. 2012, 26: 289-295.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21826063"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Prognostic%20implications%20and%20molecular%20associations%20of%20NADH%20dehydrogenase%20subunit%204%20%28ND4%29%20mutations%20in%20acute%20myeloid%20leukemia&amp;author=F.%20Damm&amp;author=T.%20Bunke&amp;author=F.%20Thol&amp;author=B.%20Markus&amp;author=K.%20Wagner&amp;author=G.%20Gohring&amp;author=B.%20Schlegelberger&amp;author=G.%20Heil&amp;author=CW.%20Reuter&amp;author=K.%20Pullmann&amp;author=RF.%20Schlenk&amp;author=K.%20Dohner&amp;author=M.%20Heuser&amp;author=J.%20Krauter&amp;author=H.%20Dohner&amp;author=A.%20Ganser&amp;author=MA.%20Morgan&amp;journal=Leukemia&amp;volume=26&amp;pages=289-295&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR63">Rocquain J, Gelsi-Boyer V, Adlaide J, Murati A, Carbuccia N, Vey N, Birnbaum D, Mozziconacci MJ, Chaffanet M: Alteration of cohesin genes in myeloid diseases. Am J Hematol. 2010, 85: 717-719.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20687102"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Alteration%20of%20cohesin%20genes%20in%20myeloid%20diseases&amp;author=J.%20Rocquain&amp;author=V.%20Gelsi-Boyer&amp;author=J.%20Ad%C3%A9laide&amp;author=A.%20Murati&amp;author=N.%20Carbuccia&amp;author=N.%20Vey&amp;author=D.%20Birnbaum&amp;author=MJ.%20Mozziconacci&amp;author=M.%20Chaffanet&amp;journal=Am%20J%20Hematol&amp;volume=85&amp;pages=717-719&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR64">Cheung N, So CW: Transcriptional and epigenetic networks in haematological malignancy. FEBS Lett. 2011, 585: 2100-2111.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21477587"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Transcriptional%20and%20epigenetic%20networks%20in%20haematological%20malignancy&amp;author=N.%20Cheung&amp;author=CW.%20So&amp;journal=FEBS%20Lett&amp;volume=585&amp;pages=2100-2111&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR65">Peters AH, Schwaller J: Epigenetic mechanisms in acute myeloid leukemia. Prog Drug Res. 2011, 67: 197-219.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21141731"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Epigenetic%20mechanisms%20in%20acute%20myeloid%20leukemia&amp;author=AH.%20Peters&amp;author=J.%20Schwaller&amp;journal=Prog%20Drug%20Res&amp;volume=67&amp;pages=197-219&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR66">Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O'Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnoski RJ, Teh BT, Stratton MR, Futreal PA: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010, 463: 360-363.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20054297"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820242"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Systematic%20sequencing%20of%20renal%20carcinoma%20reveals%20inactivation%20of%20histone%20modifying%20genes&amp;author=GL.%20Dalgliesh&amp;author=K.%20Furge&amp;author=C.%20Greenman&amp;author=L.%20Chen&amp;author=G.%20Bignell&amp;author=A.%20Butler&amp;author=H.%20Davies&amp;author=S.%20Edkins&amp;author=C.%20Hardy&amp;author=C.%20Latimer&amp;author=J.%20Teague&amp;author=J.%20Andrews&amp;author=S.%20Barthorpe&amp;author=D.%20Beare&amp;author=G.%20Buck&amp;author=PJ.%20Campbell&amp;author=S.%20Forbes&amp;author=M.%20Jia&amp;author=D.%20Jones&amp;author=H.%20Knott&amp;author=CY.%20Kok&amp;author=KW.%20Lau&amp;author=C.%20Leroy&amp;author=ML.%20Lin&amp;author=DJ.%20McBride&amp;author=M.%20Maddison&amp;author=S.%20Maguire&amp;author=K.%20McLay&amp;author=A.%20Menzies&amp;author=T.%20Mironenko&amp;author=L.%20Mulderrig&amp;author=L.%20Mudie&amp;author=S.%20O%27Meara&amp;author=E.%20Pleasance&amp;author=A.%20Rajasingham&amp;author=R.%20Shepherd&amp;author=R.%20Smith&amp;author=L.%20Stebbings&amp;author=P.%20Stephens&amp;author=G.%20Tang&amp;author=PS.%20Tarpey&amp;author=K.%20Turrell&amp;author=KJ.%20Dykema&amp;author=SK.%20Khoo&amp;author=D.%20Petillo&amp;author=B.%20Wondergem&amp;author=J.%20Anema&amp;author=RJ.%20Kahnoski&amp;author=BT.%20Teh&amp;author=MR.%20Stratton&amp;author=PA.%20Futreal&amp;journal=Nature&amp;volume=463&amp;pages=360-363&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR67">Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LF, Richard S, Kahnoski RJ, Anema J, Tuveson DA, Perez-Mancera PA, Mustonen V, Fischer A, Adams DJ, Rust A, Chan-on W, Subimerb C, Dykema K, Furge K, Campbell PJ, Teh BT, Stratton MR, Futreal PA: Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011, 469: 539-542.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21248752"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3030920"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Exome%20sequencing%20identifies%20frequent%20mutation%20of%20the%20SWI%2FSNF%20complex%20gene%20PBRM1%20in%20renal%20carcinoma&amp;author=I.%20Varela&amp;author=P.%20Tarpey&amp;author=K.%20Raine&amp;author=D.%20Huang&amp;author=CK.%20Ong&amp;author=P.%20Stephens&amp;author=H.%20Davies&amp;author=D.%20Jones&amp;author=ML.%20Lin&amp;author=J.%20Teague&amp;author=G.%20Bignell&amp;author=A.%20Butler&amp;author=J.%20Cho&amp;author=GL.%20Dalgliesh&amp;author=D.%20Galappaththige&amp;author=C.%20Greenman&amp;author=C.%20Hardy&amp;author=M.%20Jia&amp;author=C.%20Latimer&amp;author=KW.%20Lau&amp;author=J.%20Marshall&amp;author=S.%20McLaren&amp;author=A.%20Menzies&amp;author=L.%20Mudie&amp;author=L.%20Stebbings&amp;author=DA.%20Largaespada&amp;author=LF.%20Wessels&amp;author=S.%20Richard&amp;author=RJ.%20Kahnoski&amp;author=J.%20Anema&amp;author=DA.%20Tuveson&amp;author=PA.%20Perez-Mancera&amp;author=V.%20Mustonen&amp;author=A.%20Fischer&amp;author=DJ.%20Adams&amp;author=A.%20Rust&amp;author=W.%20Chan-on&amp;author=C.%20Subimerb&amp;author=K.%20Dykema&amp;author=K.%20Furge&amp;author=PJ.%20Campbell&amp;author=BT.%20Teh&amp;author=MR.%20Stratton&amp;author=PA.%20Futreal&amp;journal=Nature&amp;volume=469&amp;pages=539-542&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR68">Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Lowenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010, 18: 553-567.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21130701"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105845"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Leukemic%20IDH1%20and%20IDH2%20mutations%20result%20in%20a%20hypermethylation%20phenotype%2C%20disrupt%20TET2%20function%2C%20and%20impair%20hematopoietic%20differentiation&amp;author=ME.%20Figueroa&amp;author=O.%20Abdel-Wahab&amp;author=C.%20Lu&amp;author=PS.%20Ward&amp;author=J.%20Patel&amp;author=A.%20Shih&amp;author=Y.%20Li&amp;author=N.%20Bhagwat&amp;author=A.%20Vasanthakumar&amp;author=HF.%20Fernandez&amp;author=MS.%20Tallman&amp;author=Z.%20Sun&amp;author=K.%20Wolniak&amp;author=JK.%20Peeters&amp;author=W.%20Liu&amp;author=SE.%20Choe&amp;author=VR.%20Fantin&amp;author=E.%20Paietta&amp;author=B.%20Lowenberg&amp;author=JD.%20Licht&amp;author=LA.%20Godley&amp;author=R.%20Delwel&amp;author=PJ.%20Valk&amp;author=CB.%20Thompson&amp;author=RL.%20Levine&amp;author=A.%20Melnick&amp;journal=Cancer%20Cell&amp;volume=18&amp;pages=553-567&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR69">Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB: Vander Heiden MG, Su SM: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2010, 465: 966-<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20559394"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766976"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Vander%20Heiden%20MG%2C%20Su%20SM%3A%20Cancer-associated%20IDH1%20mutations%20produce%202-hydroxyglutarate&amp;author=L.%20Dang&amp;author=DW.%20White&amp;author=S.%20Gross&amp;author=BD.%20Bennett&amp;author=MA.%20Bittinger&amp;author=EM.%20Driggers&amp;author=VR.%20Fantin&amp;author=HG.%20Jang&amp;author=S.%20Jin&amp;author=MC.%20Keenan&amp;author=KM.%20Marks&amp;author=RM.%20Prins&amp;author=PS.%20Ward&amp;author=KE.%20Yen&amp;author=LM.%20Liau&amp;author=JD.%20Rabinowitz&amp;author=LC.%20Cantley&amp;author=CB.%20Thompson&amp;journal=Nature&amp;volume=465&amp;pages=966&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR70">Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010, 17: 225-234.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20171147"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2849316"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20common%20feature%20of%20leukemia-associated%20IDH1%20and%20IDH2%20mutations%20is%20a%20neomorphic%20enzyme%20activity%20converting%20alpha-ketoglutarate%20to%202-hydroxyglutarate&amp;author=PS.%20Ward&amp;author=J.%20Patel&amp;author=DR.%20Wise&amp;author=O.%20Abdel-Wahab&amp;author=BD.%20Bennett&amp;author=HA.%20Coller&amp;author=JR.%20Cross&amp;author=VR.%20Fantin&amp;author=CV.%20Hedvat&amp;author=AE.%20Perl&amp;author=JD.%20Rabinowitz&amp;author=M.%20Carroll&amp;author=SM.%20Su&amp;author=KA.%20Sharp&amp;author=RL.%20Levine&amp;author=CB.%20Thompson&amp;journal=Cancer%20Cell&amp;volume=17&amp;pages=225-234&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR71">Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009, 324: 930-935.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19372391"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715015"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Conversion%20of%205-methylcytosine%20to%205-hydroxymethylcytosine%20in%20mammalian%20DNA%20by%20MLL%20partner%20TET1&amp;author=M.%20Tahiliani&amp;author=KP.%20Koh&amp;author=Y.%20Shen&amp;author=WA.%20Pastor&amp;author=H.%20Bandukwala&amp;author=Y.%20Brudno&amp;author=S.%20Agarwal&amp;author=LM.%20Iyer&amp;author=DR.%20Liu&amp;author=L.%20Aravind&amp;author=A.%20Rao&amp;journal=Science&amp;volume=324&amp;pages=930-935&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR72">Cimmino L, Abdel-Wahab O, Levine RL, Aifantis I: TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell. 2011, 9: 193-204.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21885017"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244690"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=TET%20family%20proteins%20and%20their%20role%20in%20stem%20cell%20differentiation%20and%20transformation&amp;author=L.%20Cimmino&amp;author=O.%20Abdel-Wahab&amp;author=RL.%20Levine&amp;author=I.%20Aifantis&amp;journal=Cell%20Stem%20Cell&amp;volume=9&amp;pages=193-204&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR73">Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y: Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine. Science. 2011, 233: 1300-1303.<span class="Occurrences"><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Tet%20Proteins%20Can%20Convert%205-Methylcytosine%20to%205-Formylcytosine%20and%205-Carboxylcytosine&amp;author=S.%20Ito&amp;author=L.%20Shen&amp;author=Q.%20Dai&amp;author=SC.%20Wu&amp;author=LB.%20Collins&amp;author=JA.%20Swenberg&amp;author=C.%20He&amp;author=Y.%20Zhang&amp;journal=Science&amp;volume=233&amp;pages=1300-1303&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR74">Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, Rappsilber J, Helin K: TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature. 2011, 473: 343-348.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21490601"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408592"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=TET1%20and%20hydroxymethylcytosine%20in%20transcription%20and%20DNA%20methylation%20fidelity&amp;author=K.%20Williams&amp;author=J.%20Christensen&amp;author=MT.%20Pedersen&amp;author=JV.%20Johansen&amp;author=PA.%20Cloos&amp;author=J.%20Rappsilber&amp;author=K.%20Helin&amp;journal=Nature&amp;volume=473&amp;pages=343-348&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR75">Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P, Zhang Y: Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006, 439: 811-816.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16362057"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Histone%20demethylation%20by%20a%20family%20of%20JmjC%20domain-containing%20proteins&amp;author=Y.%20Tsukada&amp;author=J.%20Fang&amp;author=H.%20Erdjument-Bromage&amp;author=ME.%20Warren&amp;author=CH.%20Borchers&amp;author=P.%20Tempst&amp;author=Y.%20Zhang&amp;journal=Nature&amp;volume=439&amp;pages=811-816&amp;publication_year=2006"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR76">Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa ME, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, He C, Ibrahim S, Beran M, Zavadil J, Nimer SD, Melnick A, Godley LA, Aifantis I, Levine RL: Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011, 20: 11-24.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21723200"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194039"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Tet2%20loss%20leads%20to%20increased%20hematopoietic%20stem%20cell%20self-renewal%20and%20myeloid%20transformation&amp;author=K.%20Moran-Crusio&amp;author=L.%20Reavie&amp;author=A.%20Shih&amp;author=O.%20Abdel-Wahab&amp;author=D.%20Ndiaye-Lobry&amp;author=C.%20Lobry&amp;author=ME.%20Figueroa&amp;author=A.%20Vasanthakumar&amp;author=J.%20Patel&amp;author=X.%20Zhao&amp;author=F.%20Perna&amp;author=S.%20Pandey&amp;author=J.%20Madzo&amp;author=C.%20Song&amp;author=Q.%20Dai&amp;author=C.%20He&amp;author=S.%20Ibrahim&amp;author=M.%20Beran&amp;author=J.%20Zavadil&amp;author=SD.%20Nimer&amp;author=A.%20Melnick&amp;author=LA.%20Godley&amp;author=I.%20Aifantis&amp;author=RL.%20Levine&amp;journal=Cancer%20Cell&amp;volume=20&amp;pages=11-24&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR77">Quivoron C, Couronne L, Della VV, Lopez CK, Plo I, Wagner-Ballon O, Do CM, Delhommeau F, Arnulf B, Stern MH, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard OA: TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis. Cancer Cell. 2011, 20: 25-38.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21723201"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=TET2%20Inactivation%20Results%20in%20Pleiotropic%20Hematopoietic%20Abnormalities%20in%20Mouse%20and%20Is%20a%20Recurrent%20Event%20during%20Human%20Lymphomagenesis&amp;author=C.%20Quivoron&amp;author=L.%20Couronne&amp;author=VV.%20Della&amp;author=CK.%20Lopez&amp;author=I.%20Plo&amp;author=O.%20Wagner-Ballon&amp;author=CM.%20Do&amp;author=F.%20Delhommeau&amp;author=B.%20Arnulf&amp;author=MH.%20Stern&amp;author=L.%20Godley&amp;author=P.%20Opolon&amp;author=H.%20Tilly&amp;author=E.%20Solary&amp;author=Y.%20Duffourd&amp;author=P.%20Dessen&amp;author=H.%20Merle-Beral&amp;author=F.%20Nguyen-Khac&amp;author=M.%20Fontenay&amp;author=W.%20Vainchenker&amp;author=C.%20Bastard&amp;author=T.%20Mercher&amp;author=OA.%20Bernard&amp;journal=Cancer%20Cell&amp;volume=20&amp;pages=25-38&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR78">Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van EA, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di CL: de LY, Fuks F: The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006, 439: 871-874.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16357870"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=de%20LY%2C%20Fuks%20F%3A%20The%20Polycomb%20group%20protein%20EZH2%20directly%20controls%20DNA%20methylation&amp;author=E.%20Vire&amp;author=C.%20Brenner&amp;author=R.%20Deplus&amp;author=L.%20Blanchon&amp;author=M.%20Fraga&amp;author=C.%20Didelot&amp;author=L.%20Morey&amp;author=EA.%20Van&amp;author=D.%20Bernard&amp;author=JM.%20Vanderwinden&amp;author=M.%20Bollen&amp;author=M.%20Esteller&amp;author=CL.%20Di&amp;journal=Nature&amp;volume=439&amp;pages=871-874&amp;publication_year=2006"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR79">Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, Bock C, Vasanthakumar A, Gu H, Xi Y, Liang S, Lu Y, Darlington GJ, Meissner A, Issa JP, Godley LA, Li W, Goodell MA: Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2012, 44: 23-31.<span class="Occurrences"><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Dnmt3a%20is%20essential%20for%20hematopoietic%20stem%20cell%20differentiation&amp;author=GA.%20Challen&amp;author=D.%20Sun&amp;author=M.%20Jeong&amp;author=M.%20Luo&amp;author=J.%20Jelinek&amp;author=JS.%20Berg&amp;author=C.%20Bock&amp;author=A.%20Vasanthakumar&amp;author=H.%20Gu&amp;author=Y.%20Xi&amp;author=S.%20Liang&amp;author=Y.%20Lu&amp;author=GJ.%20Darlington&amp;author=A.%20Meissner&amp;author=JP.%20Issa&amp;author=LA.%20Godley&amp;author=W.%20Li&amp;author=MA.%20Goodell&amp;journal=Nat%20Genet&amp;volume=44&amp;pages=23-31&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR80">Ficz G, Branco MR, Seisenberger S, Santos F, Krueger F, Hore TA, Marques CJ, Andrews S, Reik W: Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature. 2011, 473: 398-402.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21460836"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Dynamic%20regulation%20of%205-hydroxymethylcytosine%20in%20mouse%20ES%20cells%20and%20during%20differentiation&amp;author=G.%20Ficz&amp;author=MR.%20Branco&amp;author=S.%20Seisenberger&amp;author=F.%20Santos&amp;author=F.%20Krueger&amp;author=TA.%20Hore&amp;author=CJ.%20Marques&amp;author=S.%20Andrews&amp;author=W.%20Reik&amp;journal=Nature&amp;volume=473&amp;pages=398-402&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR81">Wu H, D'Alessio AC, Ito S, Xia K, Wang Z, Cui K, Zhao K, Sun YE, Zhang Y: Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature. 2011, 473: 389-393.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21451524"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539771"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Dual%20functions%20of%20Tet1%20in%20transcriptional%20regulation%20in%20mouse%20embryonic%20stem%20cells&amp;author=H.%20Wu&amp;author=AC.%20D%27Alessio&amp;author=S.%20Ito&amp;author=K.%20Xia&amp;author=Z.%20Wang&amp;author=K.%20Cui&amp;author=K.%20Zhao&amp;author=YE.%20Sun&amp;author=Y.%20Zhang&amp;journal=Nature&amp;volume=473&amp;pages=389-393&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR82">Li T, Hu JF, Qiu X, Ling J, Chen H, Wang S, Hou A, Vu TH, Hoffman AR: CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop. Mol Cell Biol. 2008, 28: 6473-6482.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18662993"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577414"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=CTCF%20regulates%20allelic%20expression%20of%20Igf2%20by%20orchestrating%20a%20promoter-polycomb%20repressive%20complex%202%20intrachromosomal%20loop&amp;author=T.%20Li&amp;author=JF.%20Hu&amp;author=X.%20Qiu&amp;author=J.%20Ling&amp;author=H.%20Chen&amp;author=S.%20Wang&amp;author=A.%20Hou&amp;author=TH.%20Vu&amp;author=AR.%20Hoffman&amp;journal=Mol%20Cell%20Biol&amp;volume=28&amp;pages=6473-6482&amp;publication_year=2008"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR83">Abdel-Wahab O, Adli M, Saunders L, Gao J, Shih A, Pandey S, Jaffe J, Zhao X, Perna F, Caroll M, Melnick A, Nimer SD, Aifantis I, Bernstein B, Levine R: ASXL1 Mutations Promote Myeloid Transformation Through Inhibition of PRC2-Mediated Gene Repression. ASH Annual Meeting Abstracts. 2011, 118: 405-<span class="Occurrences"><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=ASXL1%20Mutations%20Promote%20Myeloid%20Transformation%20Through%20Inhibition%20of%20PRC2-Mediated%20Gene%20Repression&amp;author=O.%20Abdel-Wahab&amp;author=M.%20Adli&amp;author=L.%20Saunders&amp;author=J.%20Gao&amp;author=A.%20Shih&amp;author=S.%20Pandey&amp;author=J.%20Jaffe&amp;author=X.%20Zhao&amp;author=F.%20Perna&amp;author=M.%20Caroll&amp;author=A.%20Melnick&amp;author=SD.%20Nimer&amp;author=I.%20Aifantis&amp;author=B.%20Bernstein&amp;author=R.%20Levine&amp;journal=ASH%20Annual%20Meeting%20Abstracts&amp;volume=118&amp;pages=405&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR84">Beisel C, Paro R: Silencing chromatin: comparing modes and mechanisms. Nat Rev Genet. 2011, 12: 123-135.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21221116"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Silencing%20chromatin%3A%20comparing%20modes%20and%20mechanisms&amp;author=C.%20Beisel&amp;author=R.%20Paro&amp;journal=Nat%20Rev%20Genet&amp;volume=12&amp;pages=123-135&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR85">Ntziachristos P, Tsirigos A, Vlierberghe PV, Nedjic J, Trimarchi T, Flaherty MS, Ferres-Marco D: da RV, Tang Z, Siegle J, Asp P, Hadler M, Rigo I, Keersmaecker KD, Patel J, Huynh T, Utro F, Poglio S, Samon JB, Paietta E, Racevskis J, Rowe JM, Rabadan R, Levine RL, Brown S, Pflumio F, Dominguez M, Ferrando A, Aifantis I: Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med. 2012, 18: 298-303.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22237151"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274628"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=da%20RV%2C%20Tang%20Z%2C%20Siegle%20J%2C%20Asp%20P%2C%20Hadler%20M%2C%20Rigo%20I%2C%20Keersmaecker%20KD%2C%20Patel%20J%2C%20Huynh%20T%2C%20Utro%20F%2C%20Poglio%20S%2C%20Samon%20JB%2C%20Paietta%20E%2C%20Racevskis%20J%2C%20Rowe%20JM%2C%20Rabadan%20R%2C%20Levine%20RL%2C%20Brown%20S%2C%20Pflumio%20F%2C%20Dominguez%20M%2C%20Ferrando%20A%2C%20Aifantis%20I%3A%20Genetic%20inactivation%20of%20the%20polycomb%20repressive%20complex%202%20in%20T%20cell%20acute%20lymphoblastic%20leukemia&amp;author=P.%20Ntziachristos&amp;author=A.%20Tsirigos&amp;author=PV.%20Vlierberghe&amp;author=J.%20Nedjic&amp;author=T.%20Trimarchi&amp;author=MS.%20Flaherty&amp;author=D.%20Ferres-Marco&amp;journal=Nat%20Med&amp;volume=18&amp;pages=298-303&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR86">Oguro H, Yuan J, Tanaka S, Miyagi S, Mochizuki-Kashio M, Ichikawa H, Yamazaki S, Koseki H, Nakauchi H, Iwama A: Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes. J Exp Med. 2012, 209: 445-454.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22351929"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302226"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Lethal%20myelofibrosis%20induced%20by%20Bmi1-deficient%20hematopoietic%20cells%20unveils%20a%20tumor%20suppressor%20function%20of%20the%20polycomb%20group%20genes&amp;author=H.%20Oguro&amp;author=J.%20Yuan&amp;author=S.%20Tanaka&amp;author=S.%20Miyagi&amp;author=M.%20Mochizuki-Kashio&amp;author=H.%20Ichikawa&amp;author=S.%20Yamazaki&amp;author=H.%20Koseki&amp;author=H.%20Nakauchi&amp;author=A.%20Iwama&amp;journal=J%20Exp%20Med&amp;volume=209&amp;pages=445-454&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR87">Brecqueville M, Adlaide J, Bertucci F, Finetti P, Chaffanet M, Birnbaum D, Murati A: Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms. Cell Cycle. 2012, in press: in press-in press<span class="Occurrences"><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Alterations%20of%20polycomb%20gene%20BMI1%20in%20human%20myeloproliferative%20neoplasms&amp;author=M.%20Brecqueville&amp;author=J.%20Ad%C3%A9laide&amp;author=F.%20Bertucci&amp;author=P.%20Finetti&amp;author=M.%20Chaffanet&amp;author=D.%20Birnbaum&amp;author=A.%20Murati&amp;journal=Cell%20Cycle&amp;volume=in%20press&amp;pages=in%20press&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR88">Simon JA, Kingston RE: Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol. 2009, 10: 697-708.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19738629"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mechanisms%20of%20polycomb%20gene%20silencing%3A%20knowns%20and%20unknowns&amp;author=JA.%20Simon&amp;author=RE.%20Kingston&amp;journal=Nat%20Rev%20Mol%20Cell%20Biol&amp;volume=10&amp;pages=697-708&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR89">Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA: Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N: DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011, 331: 1199-1203.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21252315"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144496"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Vogelstein%20B%2C%20Kinzler%20KW%2C%20Hruban%20RH%2C%20Papadopoulos%20N%3A%20DAXX%2FATRX%2C%20MEN1%2C%20and%20mTOR%20pathway%20genes%20are%20frequently%20altered%20in%20pancreatic%20neuroendocrine%20tumors&amp;author=Y.%20Jiao&amp;author=C.%20Shi&amp;author=BH.%20Edil&amp;author=RF.%20de%20Wilde&amp;author=DS.%20Klimstra&amp;author=A.%20Maitra&amp;author=RD.%20Schulick&amp;author=LH.%20Tang&amp;author=CL.%20Wolfgang&amp;author=MA.%20Choti&amp;author=VE.%20Velculescu&amp;author=LA.%20Diaz&amp;journal=Science&amp;volume=331&amp;pages=1199-1203&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR90">Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jager N, Rausch T, Ryzhova M, Korbel JO, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann MU, Scheurlen W, Pekrun A, Fruhwald MC, Roggendorf W, Kramm C, Durken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel P, Kulozik AE, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G: von DA, Ichimura K, Collins VP, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister SM, Jabado N: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012, 482: 226-231.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22286061"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=von%20DA%2C%20Ichimura%20K%2C%20Collins%20VP%2C%20Witt%20H%2C%20Milde%20T%2C%20Witt%20O%2C%20Zhang%20C%2C%20Castelo-Branco%20P%2C%20Lichter%20P%2C%20Faury%20D%2C%20Tabori%20U%2C%20Plass%20C%2C%20Majewski%20J%2C%20Pfister%20SM%2C%20Jabado%20N%3A%20Driver%20mutations%20in%20histone%20H3.3%20and%20chromatin%20remodelling%20genes%20in%20paediatric%20glioblastoma&amp;author=J.%20Schwartzentruber&amp;author=A.%20Korshunov&amp;author=XY.%20Liu&amp;author=DT.%20Jones&amp;author=E.%20Pfaff&amp;author=K.%20Jacob&amp;author=D.%20Sturm&amp;author=AM.%20Fontebasso&amp;author=DA.%20Quang&amp;author=M.%20Tonjes&amp;author=V.%20Hovestadt&amp;author=S.%20Albrecht&amp;author=M.%20Kool&amp;author=A.%20Nantel&amp;author=C.%20Konermann&amp;author=A.%20Lindroth&amp;author=N.%20Jager&amp;author=T.%20Rausch&amp;author=M.%20Ryzhova&amp;author=JO.%20Korbel&amp;author=T.%20Hielscher&amp;author=P.%20Hauser&amp;author=M.%20Garami&amp;author=A.%20Klekner&amp;author=L.%20Bognar&amp;author=M.%20Ebinger&amp;author=MU.%20Schuhmann&amp;author=W.%20Scheurlen&amp;author=A.%20Pekrun&amp;author=MC.%20Fruhwald&amp;author=W.%20Roggendorf&amp;author=C.%20Kramm&amp;author=M.%20Durken&amp;author=J.%20Atkinson&amp;author=P.%20Lepage&amp;author=A.%20Montpetit&amp;author=M.%20Zakrzewska&amp;author=K.%20Zakrzewski&amp;author=PP.%20Liberski&amp;author=Z.%20Dong&amp;author=P.%20Siegel&amp;author=AE.%20Kulozik&amp;author=M.%20Zapatka&amp;author=A.%20Guha&amp;author=D.%20Malkin&amp;author=J.%20Felsberg&amp;author=G.%20Reifenberger&amp;journal=Nature&amp;volume=482&amp;pages=226-231&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR91">Berger AH, Pandolfi PP: Haplo-insufficiency: a driving force in cancer. J Pathol. 2011, 223: 137-146.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21125671"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Haplo-insufficiency%3A%20a%20driving%20force%20in%20cancer&amp;author=AH.%20Berger&amp;author=PP.%20Pandolfi&amp;journal=J%20Pathol&amp;volume=223&amp;pages=137-146&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR92">Acquaviva C, Gelsi-Boyer V, Birnbaum D: Myelodysplastic syndromes: lost between two states?. Leukemia. 2010, 24: 1-5.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20068572"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Myelodysplastic%20syndromes%3A%20lost%20between%20two%20states%3F&amp;author=C.%20Acquaviva&amp;author=V.%20Gelsi-Boyer&amp;author=D.%20Birnbaum&amp;journal=Leukemia&amp;volume=24&amp;pages=1-5&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR93">Isono K, Mizutani-Koseki Y, Komori T, Schmidt-Zachmann MS, Koseki H: Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1. Genes Dev. 2005, 19: 536-541.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15741318"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC551574"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mammalian%20polycomb-mediated%20repression%20of%20Hox%20genes%20requires%20the%20essential%20spliceosomal%20protein%20Sf3b1&amp;author=K.%20Isono&amp;author=Y.%20Mizutani-Koseki&amp;author=T.%20Komori&amp;author=MS.%20Schmidt-Zachmann&amp;author=H.%20Koseki&amp;journal=Genes%20Dev&amp;volume=19&amp;pages=536-541&amp;publication_year=2005"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR94">Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T: Regulation of alternative splicing by histone modifications. Science. 2010, 327: 996-1000.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20133523"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913848"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Regulation%20of%20alternative%20splicing%20by%20histone%20modifications&amp;author=RF.%20Luco&amp;author=Q.%20Pan&amp;author=K.%20Tominaga&amp;author=BJ.%20Blencowe&amp;author=OM.%20Pereira-Smith&amp;author=T.%20Misteli&amp;journal=Science&amp;volume=327&amp;pages=996-1000&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR95">Kralovics R: Genetic complexity of myeloproliferative neoplasms. Leukemia. 2008, 22: 1841-1848.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18754034"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?&amp;author=R.%20Kralovics&amp;journal=Genetic%20complexity%20of%20myeloproliferative%20neoplasms.%20Leukemia&amp;volume=22&amp;pages=1841-1848&amp;publication_year=2008"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR96">Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A: LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010, 24: 1713-1718.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20724988"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=LNK%20mutation%20studies%20in%20blast-phase%20myeloproliferative%20neoplasms%2C%20and%20in%20chronic-phase%20disease%20with%20TET2%2C%20IDH%2C%20JAK2%20or%20MPL%20mutations&amp;author=A.%20Pardanani&amp;author=T.%20Lasho&amp;author=C.%20Finke&amp;author=ST.%20Oh&amp;author=J.%20Gotlib&amp;author=A.%20Tefferi&amp;journal=Leukemia&amp;volume=24&amp;pages=1713-1718&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR97">Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006, 108: 3472-3476.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16868251"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=MPL515%20mutations%20in%20myeloproliferative%20and%20other%20myeloid%20disorders%3A%20a%20study%20of%201182%20patients&amp;author=AD.%20Pardanani&amp;author=RL.%20Levine&amp;author=T.%20Lasho&amp;author=Y.%20Pikman&amp;author=RA.%20Mesa&amp;author=M.%20Wadleigh&amp;author=DP.%20Steensma&amp;author=MA.%20Elliott&amp;author=AP.%20Wolanskyj&amp;author=WJ.%20Hogan&amp;author=RF.%20McClure&amp;author=MR.%20Litzow&amp;author=DG.%20Gilliland&amp;author=A.%20Tefferi&amp;journal=Blood&amp;volume=108&amp;pages=3472-3476&amp;publication_year=2006"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR98">Abbas S, Rotmans G, Lowenberg B, Valk PJ: Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias. Haematologica. 2008, 93: 1595-1597.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18698078"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Exon%208%20splice%20site%20mutations%20in%20the%20gene%20encoding%20the%20E3-ligase%20CBL%20are%20associated%20with%20core%20binding%20factor%20acute%20myeloid%20leukemias&amp;author=S.%20Abbas&amp;author=G.%20Rotmans&amp;author=B.%20Lowenberg&amp;author=PJ.%20Valk&amp;journal=Haematologica&amp;volume=93&amp;pages=1595-1597&amp;publication_year=2008"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR99">Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adlaide J, Olschwang S, Xerri L, Vey N, Chaffanet M, Birnbaum D, Mozziconacci MJ: Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia. 2010, 24: 469-473.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19865112"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutual%20exclusion%20of%20ASXL1%20and%20NPM1%20mutations%20in%20a%20series%20of%20acute%20myeloid%20leukemias&amp;author=N.%20Carbuccia&amp;author=V.%20Trouplin&amp;author=V.%20Gelsi-Boyer&amp;author=A.%20Murati&amp;author=J.%20Rocquain&amp;author=J.%20Ad%C3%A9laide&amp;author=S.%20Olschwang&amp;author=L.%20Xerri&amp;author=N.%20Vey&amp;author=M.%20Chaffanet&amp;author=D.%20Birnbaum&amp;author=MJ.%20Mozziconacci&amp;journal=Leukemia&amp;volume=24&amp;pages=469-473&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR100">Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, Tadrist Z, Olschwang S, Vey N, Birnbaum D, Gelsi-Boyer V, Mozziconacci MJ: Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer. 2010, 10: 401-405.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20678218"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923633"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Combined%20mutations%20of%20ASXL1%2C%20CBL%2C%20FLT3%2C%20IDH1%2C%20IDH2%2C%20JAK2%2C%20KRAS%2C%20NPM1%2C%20NRAS%2C%20RUNX1%2C%20TET2%20and%20WT1%20genes%20in%20myelodysplastic%20syndromes%20and%20acute%20myeloid%20leukemias&amp;author=J.%20Rocquain&amp;author=N.%20Carbuccia&amp;author=V.%20Trouplin&amp;author=S.%20Raynaud&amp;author=A.%20Murati&amp;author=M.%20Nezri&amp;author=Z.%20Tadrist&amp;author=S.%20Olschwang&amp;author=N.%20Vey&amp;author=D.%20Birnbaum&amp;author=V.%20Gelsi-Boyer&amp;author=MJ.%20Mozziconacci&amp;journal=BMC%20Cancer&amp;volume=10&amp;pages=401-405&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR101">Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ, Gu ZH, Wang YY, Chen B, Jiang CL, Yan H, Chen FF, Chen HM, Chen Z, Jin J, Chen SJ: Gene mutation patterns and their prognostic impact in a cohort of 1,185 patients with acute myeloid leukemia. Blood. 2011, 118: 5593-5603.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21881046"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Gene%20mutation%20patterns%20and%20their%20prognostic%20impact%20in%20a%20cohort%20of%201%2C185%20patients%20with%20acute%20myeloid%20leukemia&amp;author=Y.%20Shen&amp;author=YM.%20Zhu&amp;author=X.%20Fan&amp;author=JY.%20Shi&amp;author=QR.%20Wang&amp;author=XJ.%20Yan&amp;author=ZH.%20Gu&amp;author=YY.%20Wang&amp;author=B.%20Chen&amp;author=CL.%20Jiang&amp;author=H.%20Yan&amp;author=FF.%20Chen&amp;author=HM.%20Chen&amp;author=Z.%20Chen&amp;author=J.%20Jin&amp;author=SJ.%20Chen&amp;journal=Blood&amp;volume=118&amp;pages=5593-5603&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR102">Bernard F, Gelsi-Boyer V, Murati A, Giraudier S, Trouplin V, Adlaide J, Rey J, Olschwang S, Vainchenker W, Chaffanet M, Vey N, Mozziconacci MJ, Birnbaum D: Alterations of NFIA in chronic malignant myeloid diseases. Leukemia. 2009, 23: 583-585.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18754024"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Alterations%20of%20NFIA%20in%20chronic%20malignant%20myeloid%20diseases&amp;author=F.%20Bernard&amp;author=V.%20Gelsi-Boyer&amp;author=A.%20Murati&amp;author=S.%20Giraudier&amp;author=V.%20Trouplin&amp;author=J.%20Ad%C3%A9laide&amp;author=J.%20Rey&amp;author=S.%20Olschwang&amp;author=W.%20Vainchenker&amp;author=M.%20Chaffanet&amp;author=N.%20Vey&amp;author=MJ.%20Mozziconacci&amp;author=D.%20Birnbaum&amp;journal=Leukemia&amp;volume=23&amp;pages=583-585&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR103">Damm F, Fontenay M, Bernard OA: Point mutations in myelodysplastic syndromes. N Engl J Med. 2011, 365: 1154-1155.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21992131"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Point%20mutations%20in%20myelodysplastic%20syndromes&amp;author=F.%20Damm&amp;author=M.%20Fontenay&amp;author=OA.%20Bernard&amp;journal=N%20Engl%20J%20Med&amp;volume=365&amp;pages=1154-1155&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR104">Fortier JM, Graubert TA: Murine models of human acute myeloid leukemia. Cancer Treat Res. 2010, 145: 183-196.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20306252"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Murine%20models%20of%20human%20acute%20myeloid%20leukemia&amp;author=JM.%20Fortier&amp;author=TA.%20Graubert&amp;journal=Cancer%20Treat%20Res&amp;volume=145&amp;pages=183-196&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR105">McCormack E, Bruserud O, Gjertsen BT: Animal models of acute myelogenous leukaemia - development, application and future perspectives. Leukemia. 2005, 19: 687-706.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15759039"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Animal%20models%20of%20acute%20myelogenous%20leukaemia%20-%20development%2C%20application%20and%20future%20perspectives&amp;author=E.%20McCormack&amp;author=O.%20Bruserud&amp;author=BT.%20Gjertsen&amp;journal=Leukemia&amp;volume=19&amp;pages=687-706&amp;publication_year=2005"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR106">Pronier E, Quivoron C, Bernard OA, Villeval JL: JAK2V(1)F/TET2 mutations: does the order matter?. Haematologica. 2011, 96: 638-640.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21531945"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084907"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=JAK2V%281%29F%2FTET2%20mutations%3A%20does%20the%20order%20matter%3F&amp;author=E.%20Pronier&amp;author=C.%20Quivoron&amp;author=OA.%20Bernard&amp;author=JL.%20Villeval&amp;journal=Haematologica&amp;volume=96&amp;pages=638-640&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR107">Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, Larson DE, McLellan MD, Dooling D, Abbott R, Fulton R, Magrini V, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Fan X, Grillot M, Witowski S, Heath S, Frater JL, Eades W, Tomasson M, Westervelt P, DiPersio JF, Link DC, Mardis ER, Ley TJ, Wilson RK, Graubert TA: Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012, 366: 1090-1098.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22417201"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320218"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Clonal%20architecture%20of%20secondary%20acute%20myeloid%20leukemia&amp;author=MJ.%20Walter&amp;author=D.%20Shen&amp;author=L.%20Ding&amp;author=J.%20Shao&amp;author=DC.%20Koboldt&amp;author=K.%20Chen&amp;author=DE.%20Larson&amp;author=MD.%20McLellan&amp;author=D.%20Dooling&amp;author=R.%20Abbott&amp;author=R.%20Fulton&amp;author=V.%20Magrini&amp;author=H.%20Schmidt&amp;author=J.%20Kalicki-Veizer&amp;author=M.%20O%27Laughlin&amp;author=X.%20Fan&amp;author=M.%20Grillot&amp;author=S.%20Witowski&amp;author=S.%20Heath&amp;author=JL.%20Frater&amp;author=W.%20Eades&amp;author=M.%20Tomasson&amp;author=P.%20Westervelt&amp;author=JF.%20DiPersio&amp;author=DC.%20Link&amp;author=ER.%20Mardis&amp;author=TJ.%20Ley&amp;author=RK.%20Wilson&amp;author=TA.%20Graubert&amp;journal=N%20Engl%20J%20Med&amp;volume=366&amp;pages=1090-1098&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR108">Passegue E, Jamieson CH, Ailles LE, Weissman IL: Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. Proc Natl Acad Sci U S A. 2003, 100 (Suppl 1): 11842-11849.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=14504387"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC304096"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Normal%20and%20leukemic%20hematopoiesis%3A%20are%20leukemias%20a%20stem%20cell%20disorder%20or%20a%20reacquisition%20of%20stem%20cell%20characteristics%3F&amp;author=E.%20Passegue&amp;author=CH.%20Jamieson&amp;author=LE.%20Ailles&amp;author=IL.%20Weissman&amp;journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;volume=100&amp;issue=Suppl%201&amp;pages=11842-11849&amp;publication_year=2003"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR109">Lambert JR, Everington T, Linch DC, Gale RE: In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood. 2009, 114: 3018-3023.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19541820"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=In%20essential%20thrombocythemia%2C%20multiple%20JAK2-V617F%20clones%20are%20present%20in%20most%20mutant-positive%20patients%3A%20a%20new%20disease%20paradigm&amp;author=JR.%20Lambert&amp;author=T.%20Everington&amp;author=DC.%20Linch&amp;author=RE.%20Gale&amp;journal=Blood&amp;volume=114&amp;pages=3018-3023&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR110">Gilliland DG: Molecular genetics of human leukemias: new insights into therapy. Semin Hematol. 2002, 39: 6-11.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12447846"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Molecular%20genetics%20of%20human%20leukemias%3A%20new%20insights%20into%20therapy&amp;author=DG.%20Gilliland&amp;journal=Semin%20Hematol&amp;volume=39&amp;pages=6-11&amp;publication_year=2002"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR111">Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green AR, Kouzarides T: JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009, 461: 819-822.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19783980"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785147"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=JAK2%20phosphorylates%20histone%20H3Y41%20and%20excludes%20HP1alpha%20from%20chromatin&amp;author=MA.%20Dawson&amp;author=AJ.%20Bannister&amp;author=B.%20Gottgens&amp;author=SD.%20Foster&amp;author=T.%20Bartke&amp;author=AR.%20Green&amp;author=T.%20Kouzarides&amp;journal=Nature&amp;volume=461&amp;pages=819-822&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR112">Bejar R, Levine R, Ebert BL: Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011, 29: 504-515.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21220588"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969457"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Unraveling%20the%20molecular%20pathophysiology%20of%20myelodysplastic%20syndromes&amp;author=R.%20Bejar&amp;author=R.%20Levine&amp;author=BL.%20Ebert&amp;journal=J%20Clin%20Oncol&amp;volume=29&amp;pages=504-515&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR113">Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, Dujardin S, Cazzolli H, Przychodzen B, Prince C, Nicoll J, Siddaiah H, Shaik M, Szpurka H, Hsi E, Advani A, Paquette R, Maciejewski JP: CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011, 117: e198-e206.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21346257"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110035"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=CBL%2C%20CBLB%2C%20TET2%2C%20ASXL1%2C%20and%20IDH1%2F2%20mutations%20and%20additional%20chromosomal%20aberrations%20constitute%20molecular%20events%20in%20chronic%20myelogenous%20leukemia&amp;author=H.%20Makishima&amp;author=AM.%20Jankowska&amp;author=MA.%20McDevitt&amp;author=C.%20O%27Keefe&amp;author=S.%20Dujardin&amp;author=H.%20Cazzolli&amp;author=B.%20Przychodzen&amp;author=C.%20Prince&amp;author=J.%20Nicoll&amp;author=H.%20Siddaiah&amp;author=M.%20Shaik&amp;author=H.%20Szpurka&amp;author=E.%20Hsi&amp;author=A.%20Advani&amp;author=R.%20Paquette&amp;author=JP.%20Maciejewski&amp;journal=Blood&amp;volume=117&amp;pages=e198-e206&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR114">Roche-Lestienne C, Marceau A, Labis E, Nibourel O, Coiteux V, Guilhot J, Legros L, Nicolini F, Rousselot P, Gardembas M, Helevaut N, Frimat C, Mahon FX, Guilhot F, Preudhomme C: Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia. 2011, 25: 1661-1664.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21637286"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutation%20analysis%20of%20TET2%2C%20IDH1%2C%20IDH2%20and%20ASXL1%20in%20chronic%20myeloid%20leukemia&amp;author=C.%20Roche-Lestienne&amp;author=A.%20Marceau&amp;author=E.%20Labis&amp;author=O.%20Nibourel&amp;author=V.%20Coiteux&amp;author=J.%20Guilhot&amp;author=L.%20Legros&amp;author=F.%20Nicolini&amp;author=P.%20Rousselot&amp;author=M.%20Gardembas&amp;author=N.%20Helevaut&amp;author=C.%20Frimat&amp;author=FX.%20Mahon&amp;author=F.%20Guilhot&amp;author=C.%20Preudhomme&amp;journal=Leukemia&amp;volume=25&amp;pages=1661-1664&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR115">Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Bene MC, De VJ, Hernandez JM, Hofmann WK, Mills KI, Gilkes A, Chiaretti S, Shurtleff SA, Kipps TJ, Rassenti LZ, Yeoh AE, Papenhausen PR, Liu WM, Williams PM, Foa R: Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010, 28: 2529-2537.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20406941"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Clinical%20utility%20of%20microarray-based%20gene%20expression%20profiling%20in%20the%20diagnosis%20and%20subclassification%20of%20leukemia%3A%20report%20from%20the%20International%20Microarray%20Innovations%20in%20Leukemia%20Study%20Group&amp;author=T.%20Haferlach&amp;author=A.%20Kohlmann&amp;author=L.%20Wieczorek&amp;author=G.%20Basso&amp;author=GT.%20Kronnie&amp;author=MC.%20Bene&amp;author=VJ.%20De&amp;author=JM.%20Hernandez&amp;author=WK.%20Hofmann&amp;author=KI.%20Mills&amp;author=A.%20Gilkes&amp;author=S.%20Chiaretti&amp;author=SA.%20Shurtleff&amp;author=TJ.%20Kipps&amp;author=LZ.%20Rassenti&amp;author=AE.%20Yeoh&amp;author=PR.%20Papenhausen&amp;author=WM.%20Liu&amp;author=PM.%20Williams&amp;author=R.%20Foa&amp;journal=J%20Clin%20Oncol&amp;volume=28&amp;pages=2529-2537&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR116">Vey N, Mozziconacci MJ, Groulet-Martinec A, Debono S, Finetti P, Carbuccia N, Beillard E, Devilard E, Arnoulet C, Coso D, Sainty D, Xerri L, Stoppa AM, Lafage-Pochitaloff M, Nguyen C, Houlgatte R, Blaise D, Maraninchi D, Birg F, Birnbaum D, Bertucci F: Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. Oncogene. 2004, 23: 9381-9391.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15543237"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Identification%20of%20new%20classes%20among%20acute%20myelogenous%20leukaemias%20with%20normal%20karyotype%20using%20gene%20expression%20profiling&amp;author=N.%20Vey&amp;author=MJ.%20Mozziconacci&amp;author=A.%20Groulet-Martinec&amp;author=S.%20Debono&amp;author=P.%20Finetti&amp;author=N.%20Carbuccia&amp;author=E.%20Beillard&amp;author=E.%20Devilard&amp;author=C.%20Arnoulet&amp;author=D.%20Coso&amp;author=D.%20Sainty&amp;author=L.%20Xerri&amp;author=AM.%20Stoppa&amp;author=M.%20Lafage-Pochitaloff&amp;author=C.%20Nguyen&amp;author=R.%20Houlgatte&amp;author=D.%20Blaise&amp;author=D.%20Maraninchi&amp;author=F.%20Birg&amp;author=D.%20Birnbaum&amp;author=F.%20Bertucci&amp;journal=Oncogene&amp;volume=23&amp;pages=9381-9391&amp;publication_year=2004"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR117">Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J: van PW, Skrabanek L, Campagne F, Mazumdar M, Greally JM, Valk PJ, Lowenberg B, Delwel R, Melnick A: DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010, 17: 13-27.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20060365"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008568"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=van%20PW%2C%20Skrabanek%20L%2C%20Campagne%20F%2C%20Mazumdar%20M%2C%20Greally%20JM%2C%20Valk%20PJ%2C%20Lowenberg%20B%2C%20Delwel%20R%2C%20Melnick%20A%3A%20DNA%20methylation%20signatures%20identify%20biologically%20distinct%20subtypes%20in%20acute%20myeloid%20leukemia&amp;author=ME.%20Figueroa&amp;author=S.%20Lugthart&amp;author=Y.%20Li&amp;author=C.%20Erpelinck-Verschueren&amp;author=X.%20Deng&amp;author=PJ.%20Christos&amp;author=E.%20Schifano&amp;author=J.%20Booth&amp;journal=Cancer%20Cell&amp;volume=17&amp;pages=13-27&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR118">Boultwood J, Perry J, Zaman R, Fernandez-Santamaria C, Littlewood T, Kusec R, Pellagatti A, Wang L, Clark RE, Wainscoat JS: High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia. 2010, 24: 1139-1145.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20410925"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=High-density%20single%20nucleotide%20polymorphism%20array%20analysis%20and%20ASXL1%20gene%20mutation%20screening%20in%20chronic%20myeloid%20leukemia%20during%20disease%20progression&amp;author=J.%20Boultwood&amp;author=J.%20Perry&amp;author=R.%20Zaman&amp;author=C.%20Fernandez-Santamaria&amp;author=T.%20Littlewood&amp;author=R.%20Kusec&amp;author=A.%20Pellagatti&amp;author=L.%20Wang&amp;author=RE.%20Clark&amp;author=JS.%20Wainscoat&amp;journal=Leukemia&amp;volume=24&amp;pages=1139-1145&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR119">Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY, Hsu SC, Chen YC, Huang YN, Chang YC, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF: Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood. 2010, 116: 4086-4094.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20693432"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Distinct%20clinical%20and%20biological%20features%20of%20de%20novo%20acute%20myeloid%20leukemia%20with%20additional%20sex%20comb-like%201%20%28ASXL1%29%20mutations&amp;author=WC.%20Chou&amp;author=HH.%20Huang&amp;author=HA.%20Hou&amp;author=CY.%20Chen&amp;author=JL.%20Tang&amp;author=M.%20Yao&amp;author=W.%20Tsay&amp;author=BS.%20Ko&amp;author=SJ.%20Wu&amp;author=SY.%20Huang&amp;author=SC.%20Hsu&amp;author=YC.%20Chen&amp;author=YN.%20Huang&amp;author=YC.%20Chang&amp;author=FY.%20Lee&amp;author=MC.%20Liu&amp;author=CW.%20Liu&amp;author=MH.%20Tseng&amp;author=CF.%20Huang&amp;author=HF.%20Tien&amp;journal=Blood&amp;volume=116&amp;pages=4086-4094&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR120">Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, Wagner K, Chaturvedi A, Sharma A, Wichmann M, Gohring G, Schumann C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Heuser M, Ganser A: Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes. J Clin Oncol. 2011, 29: 2499-2506.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21576631"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Prognostic%20Significance%20of%20ASXL1%20Mutations%20in%20Patients%20With%20Myelodysplastic%20Syndromes&amp;author=F.%20Thol&amp;author=I.%20Friesen&amp;author=F.%20Damm&amp;author=H.%20Yun&amp;author=EM.%20Weissinger&amp;author=J.%20Krauter&amp;author=K.%20Wagner&amp;author=A.%20Chaturvedi&amp;author=A.%20Sharma&amp;author=M.%20Wichmann&amp;author=G.%20Gohring&amp;author=C.%20Schumann&amp;author=G.%20Bug&amp;author=O.%20Ottmann&amp;author=WK.%20Hofmann&amp;author=B.%20Schlegelberger&amp;author=M.%20Heuser&amp;author=A.%20Ganser&amp;journal=J%20Clin%20Oncol&amp;volume=29&amp;pages=2499-2506&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR121">Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR: Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica. 2011, 96: 1462-1469.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21712540"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186307"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Disruption%20of%20the%20ASXL1%20gene%20is%20frequent%20in%20primary%2C%20post-essential%20thrombocytosis%20and%20post-polycythemia%20vera%20myelofibrosis%2C%20but%20not%20essential%20thrombocytosis%20or%20polycythemia%20vera%3A%20analysis%20of%20molecular%20genetics%20and%20clinical%20phenotypes&amp;author=BL.%20Stein&amp;author=DM.%20Williams&amp;author=C.%20O%27Keefe&amp;author=O.%20Rogers&amp;author=RG.%20Ingersoll&amp;author=JL.%20Spivak&amp;author=A.%20Verma&amp;author=JP.%20Maciejewski&amp;author=MA.%20McDevitt&amp;author=AR.%20Moliterno&amp;journal=Haematologica&amp;volume=96&amp;pages=1462-1469&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR122">Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Viguie F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De MV, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M: TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009, 114: 3285-3291.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19666869"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=TET2%20mutation%20is%20an%20independent%20favorable%20prognostic%20factor%20in%20myelodysplastic%20syndromes%20%28MDSs%29&amp;author=O.%20Kosmider&amp;author=V.%20Gelsi-Boyer&amp;author=M.%20Cheok&amp;author=S.%20Grabar&amp;author=V.%20Della-Valle&amp;author=F.%20Picard&amp;author=F.%20Viguie&amp;author=B.%20Quesnel&amp;author=O.%20Beyne-Rauzy&amp;author=E.%20Solary&amp;author=N.%20Vey&amp;author=M.%20Hunault-Berger&amp;author=P.%20Fenaux&amp;author=MV.%20Mansat-De&amp;author=E.%20Delabesse&amp;author=P.%20Guardiola&amp;author=C.%20Lacombe&amp;author=W.%20Vainchenker&amp;author=C.%20Preudhomme&amp;author=F.%20Dreyfus&amp;author=OA.%20Bernard&amp;author=D.%20Birnbaum&amp;author=M.%20Fontenay&amp;journal=Blood&amp;volume=114&amp;pages=3285-3291&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR123">Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD: TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011, 29: 1373-1381.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21343549"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084003"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=TET2%20mutations%20improve%20the%20new%20European%20LeukemiaNet%20risk%20classification%20of%20acute%20myeloid%20leukemia%3A%20a%20Cancer%20and%20Leukemia%20Group%20B%20study&amp;author=KH.%20Metzeler&amp;author=K.%20Maharry&amp;author=MD.%20Radmacher&amp;author=K.%20Mrozek&amp;author=D.%20Margeson&amp;author=H.%20Becker&amp;author=J.%20Curfman&amp;author=KB.%20Holland&amp;author=S.%20Schwind&amp;author=SP.%20Whitman&amp;author=YZ.%20Wu&amp;author=W.%20Blum&amp;author=BL.%20Powell&amp;author=TH.%20Carter&amp;author=M.%20Wetzler&amp;author=JO.%20Moore&amp;author=JE.%20Kolitz&amp;author=MR.%20Baer&amp;author=AJ.%20Carroll&amp;author=RA.%20Larson&amp;author=MA.%20Caligiuri&amp;author=G.%20Marcucci&amp;author=CD.%20Bloomfield&amp;journal=J%20Clin%20Oncol&amp;volume=29&amp;pages=1373-1381&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR124">Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, Dombret H, Dreyfus F, Quesnel B, Geffroy S, Quentin S, Roche-Lestienne C, Cayuela JM, Roumier C, Fenaux P, Vainchenker W, Bernard OA, Soulier J, Fontenay M, Preudhomme C: Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood. 2010, 116: 1132-1135.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20489055"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Incidence%20and%20prognostic%20value%20of%20TET2%20alterations%20in%20de%20novo%20acute%20myeloid%20leukemia%20achieving%20complete%20remission&amp;author=O.%20Nibourel&amp;author=O.%20Kosmider&amp;author=M.%20Cheok&amp;author=N.%20Boissel&amp;author=A.%20Renneville&amp;author=N.%20Philippe&amp;author=H.%20Dombret&amp;author=F.%20Dreyfus&amp;author=B.%20Quesnel&amp;author=S.%20Geffroy&amp;author=S.%20Quentin&amp;author=C.%20Roche-Lestienne&amp;author=JM.%20Cayuela&amp;author=C.%20Roumier&amp;author=P.%20Fenaux&amp;author=W.%20Vainchenker&amp;author=OA.%20Bernard&amp;author=J.%20Soulier&amp;author=M.%20Fontenay&amp;author=C.%20Preudhomme&amp;journal=Blood&amp;volume=116&amp;pages=1132-1135&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR125">Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van VP, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012, 366: 1079-1089.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22417203"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545649"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Prognostic%20relevance%20of%20integrated%20genetic%20profiling%20in%20acute%20myeloid%20leukemia&amp;author=JP.%20Patel&amp;author=M.%20Gonen&amp;author=ME.%20Figueroa&amp;author=H.%20Fernandez&amp;author=Z.%20Sun&amp;author=J.%20Racevskis&amp;author=VP.%20Van&amp;author=I.%20Dolgalev&amp;author=S.%20Thomas&amp;author=O.%20Aminova&amp;author=K.%20Huberman&amp;author=J.%20Cheng&amp;author=A.%20Viale&amp;author=ND.%20Socci&amp;author=A.%20Heguy&amp;author=A.%20Cherry&amp;author=G.%20Vance&amp;author=RR.%20Higgins&amp;author=RP.%20Ketterling&amp;author=RE.%20Gallagher&amp;author=M.%20Litzow&amp;author=MR.%20van%20den%20Brink&amp;author=HM.%20Lazarus&amp;author=JM.%20Rowe&amp;author=S.%20Luger&amp;author=A.%20Ferrando&amp;author=E.%20Paietta&amp;author=MS.%20Tallman&amp;author=A.%20Melnick&amp;author=O.%20Abdel-Wahab&amp;author=RL.%20Levine&amp;journal=N%20Engl%20J%20Med&amp;volume=366&amp;pages=1079-1089&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR126">Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012, 366: 787-798.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22375970"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=JAK%20inhibition%20with%20ruxolitinib%20versus%20best%20available%20therapy%20for%20myelofibrosis&amp;author=C.%20Harrison&amp;author=JJ.%20Kiladjian&amp;author=HK.%20Al-Ali&amp;author=H.%20Gisslinger&amp;author=R.%20Waltzman&amp;author=V.%20Stalbovskaya&amp;author=M.%20McQuitty&amp;author=DS.%20Hunter&amp;author=R.%20Levy&amp;author=L.%20Knoops&amp;author=F.%20Cervantes&amp;author=AM.%20Vannucchi&amp;author=T.%20Barbui&amp;author=G.%20Barosi&amp;journal=N%20Engl%20J%20Med&amp;volume=366&amp;pages=787-798&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR127">Pardanani A, Tefferi A: Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol. 2011, 18: 105-110.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21245760"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Targeting%20myeloproliferative%20neoplasms%20with%20JAK%20inhibitors&amp;author=A.%20Pardanani&amp;author=A.%20Tefferi&amp;journal=Curr%20Opin%20Hematol&amp;volume=18&amp;pages=105-110&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR128">Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH: Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012, 366: 799-807.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22375971"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822164"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Arcasoy%20MO%2C%20Hexner%20E%2C%20Lyons%20RM%2C%20Paquette%20R%2C%20Raza%20A%2C%20Vaddi%20K%2C%20Erickson-Viitanen%20S%2C%20Koumenis%20IL%2C%20Sun%20W%2C%20Sandor%20V%2C%20Kantarjian%20HM%3A%20A%20double-blind%2C%20placebo-controlled%20trial%20of%20ruxolitinib%20for%20myelofibrosis&amp;author=S.%20Verstovsek&amp;author=RA.%20Mesa&amp;author=J.%20Gotlib&amp;author=RS.%20Levy&amp;author=V.%20Gupta&amp;author=JF.%20DiPersio&amp;author=JV.%20Catalano&amp;author=M.%20Deininger&amp;author=C.%20Miller&amp;author=RT.%20Silver&amp;author=M.%20Talpaz&amp;author=EF.%20Winton&amp;author=JH.%20Harvey&amp;journal=N%20Engl%20J%20Med&amp;volume=366&amp;pages=799-807&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR129">Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen MA, Vu L, Liu F, Xu H, Asai T, Xu H, Deblasio T, Menendez S, Voza F, Jiang Y, Cole PA, Zhang J, Melnick A, Roeder RG, Nimer SD: The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation. Science. 2011, 333: 765-769.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21764752"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251012"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20Leukemogenicity%20of%20AML1-ETO%20Is%20Dependent%20on%20Site-Specific%20Lysine%20Acetylation&amp;author=L.%20Wang&amp;author=A.%20Gural&amp;author=XJ.%20Sun&amp;author=X.%20Zhao&amp;author=F.%20Perna&amp;author=G.%20Huang&amp;author=MA.%20Hatlen&amp;author=L.%20Vu&amp;author=F.%20Liu&amp;author=H.%20Xu&amp;author=T.%20Asai&amp;author=H.%20Xu&amp;author=T.%20Deblasio&amp;author=S.%20Menendez&amp;author=F.%20Voza&amp;author=Y.%20Jiang&amp;author=PA.%20Cole&amp;author=J.%20Zhang&amp;author=A.%20Melnick&amp;author=RG.%20Roeder&amp;author=SD.%20Nimer&amp;journal=Science&amp;volume=333&amp;pages=765-769&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR130">Itzykson R, Kosmider O, Cluzeau T, Mansat-De MV, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Ades L, Fenaux P, Fontenay M: Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011, 25: 1147-1152.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21494260"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Impact%20of%20TET2%20mutations%20on%20response%20rate%20to%20azacitidine%20in%20myelodysplastic%20syndromes%20and%20low%20blast%20count%20acute%20myeloid%20leukemias&amp;author=R.%20Itzykson&amp;author=O.%20Kosmider&amp;author=T.%20Cluzeau&amp;author=MV.%20Mansat-De&amp;author=F.%20Dreyfus&amp;author=O.%20Beyne-Rauzy&amp;author=B.%20Quesnel&amp;author=N.%20Vey&amp;author=V.%20Gelsi-Boyer&amp;author=S.%20Raynaud&amp;author=C.%20Preudhomme&amp;author=L.%20Ades&amp;author=P.%20Fenaux&amp;author=M.%20Fontenay&amp;journal=Leukemia&amp;volume=25&amp;pages=1147-1152&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR131">Pollyea DA, Raval A, Kusler B, Gotlib JR, Alizadeh AA, Mitchell BS: Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. Hematol Oncol. 2010, 29: 157-160.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21922510"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Impact%20of%20TET2%20mutations%20on%20mRNA%20expression%20and%20clinical%20outcomes%20in%20MDS%20patients%20treated%20with%20DNA%20methyltransferase%20inhibitors&amp;author=DA.%20Pollyea&amp;author=A.%20Raval&amp;author=B.%20Kusler&amp;author=JR.%20Gotlib&amp;author=AA.%20Alizadeh&amp;author=BS.%20Mitchell&amp;journal=Hematol%20Oncol&amp;volume=29&amp;pages=157-160&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR132">Yokoi A, Kotake Y, Takahashi K, Kadowaki T, Matsumoto Y, Minoshima Y, Sugi NH, Sagane K, Hamaguchi M, Iwata M, Mizui Y: Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS J. 2011, 278: 4870-4880.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21981285"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Biological%20validation%20that%20SF3b%20is%20a%20target%20of%20the%20antitumor%20macrolide%20pladienolide&amp;author=A.%20Yokoi&amp;author=Y.%20Kotake&amp;author=K.%20Takahashi&amp;author=T.%20Kadowaki&amp;author=Y.%20Matsumoto&amp;author=Y.%20Minoshima&amp;author=NH.%20Sugi&amp;author=K.%20Sagane&amp;author=M.%20Hamaguchi&amp;author=M.%20Iwata&amp;author=Y.%20Mizui&amp;journal=FEBS%20J&amp;volume=278&amp;pages=4870-4880&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR133">Amson R, Pece S, Lespagnol A, Vyas R, Mazzarol G, Tosoni D, Colaluca I, Viale G, Rodrigues-Ferreira S, Wynendaele J, Chaloin O, Hoebeke J, Marine JC, Di Fiore PP, Telerman A: Reciprocal repression between P53 and TCTP. Nat Med. 2012, 18: 91-99.<span class="Occurrences"><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Reciprocal%20repression%20between%20P53%20and%20TCTP&amp;author=R.%20Amson&amp;author=S.%20Pece&amp;author=A.%20Lespagnol&amp;author=R.%20Vyas&amp;author=G.%20Mazzarol&amp;author=D.%20Tosoni&amp;author=I.%20Colaluca&amp;author=G.%20Viale&amp;author=S.%20Rodrigues-Ferreira&amp;author=J.%20Wynendaele&amp;author=O.%20Chaloin&amp;author=J.%20Hoebeke&amp;author=JC.%20Marine&amp;author=PP.%20Di%20Fiore&amp;author=A.%20Telerman&amp;journal=Nat%20Med&amp;volume=18&amp;pages=91-99&amp;publication_year=2012"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR134">Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002, 8: 282-288.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11875500"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Restoration%20of%20the%20tumor%20suppressor%20function%20to%20mutant%20p53%20by%20a%20low-molecular-weight%20compound&amp;author=VJ.%20Bykov&amp;author=N.%20Issaeva&amp;author=A.%20Shilov&amp;author=M.%20Hultcrantz&amp;author=E.%20Pugacheva&amp;author=P.%20Chumakov&amp;author=J.%20Bergman&amp;author=KG.%20Wiman&amp;author=G.%20Selivanova&amp;journal=Nat%20Med&amp;volume=8&amp;pages=282-288&amp;publication_year=2002"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR135">Roychowdhury S, Talpaz M: Managing resistance in chronic myeloid leukemia. Blood Rev. 2011, 25: 279-290.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21982419"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Managing%20resistance%20in%20chronic%20myeloid%20leukemia&amp;author=S.%20Roychowdhury&amp;author=M.%20Talpaz&amp;journal=Blood%20Rev&amp;volume=25&amp;pages=279-290&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR136">Chan DA, Giaccia AJ: Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov. 2011, 10: 351-364.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21532565"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652585"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Harnessing%20synthetic%20lethal%20interactions%20in%20anticancer%20drug%20discovery&amp;author=DA.%20Chan&amp;author=AJ.%20Giaccia&amp;journal=Nat%20Rev%20Drug%20Discov&amp;volume=10&amp;pages=351-364&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR137">Eisinger F, Sobol H, Birnbaum D: Hypothesis: more mutations to cure cancer?. Oncol Rep. 1999, 6: 1189-1190.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10523678"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Hypothesis%3A%20more%20mutations%20to%20cure%20cancer%3F&amp;author=F.%20Eisinger&amp;author=H.%20Sobol&amp;author=D.%20Birnbaum&amp;journal=Oncol%20Rep&amp;volume=6&amp;pages=1189-1190&amp;publication_year=1999"><span><span>Google Scholar</span></span></a></span></span></cite></li><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="BibSection" id="BSec1"><h3 xmlns="" class="Heading">Pre-publication history</h3><ol class="BibliographyWrapper"><li xmlns="" class="Citation"><cite class="CitationContent" id="CR138">The pre-publication history for this paper can be accessed here:<span xmlns="http://www.w3.org/1999/xhtml" class="ExternalRef"><a href="http://www.biomedcentral.com/1471-2407/12/304/prepub"><span class="RefSource">http://www.biomedcentral.com/1471-2407/12/304/prepub</span></a></span>
<span class="Occurrences"></span></cite></li></ol></div></ol></div></section><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1" id="CopyrightMessage"><h2 class="Heading js-ToggleCollapseSection">Copyright</h2><div class="js-CollapseSection"><div xmlns="http://www.w3.org/1999/xhtml" class="ArticleCopyright">&nbsp;Murati et al.; licensee BioMed Central Ltd.&nbsp;2012<div class="CopyrightComment">
                <p xmlns="" class="SimplePara">This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ExternalRef"><a href="http://creativecommons.org/licenses/by/2.0"><span class="RefSource">http://creativecommons.org/licenses/by/2.0</span></a></span>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
              </div></div></div></section></div>
                            


                        </div>
                    </div>
                    <div class="layout__sidebar-right" id="main-sidebar">
                        
                        <div class="block">
                            <aside role="complementary">
                                <div class="SideBox">
                                    
    <p class="SideBox_action">
        <a class="SideBox_pdf" id="articlePdf" target="_blank" href="/track/pdf/10.1186/1471-2407-12-304?site&#x3D;bmccancer.biomedcentral.com" data-track-event="click" data-event-category="PDF Download"
           data-event-action="Click download article PDF"
           data-event-label="10.1186/1471-2407-12-304">Download PDF</a>
    </p>

                                    
                                    
    <h3 class="export-citations-button" data-toggle="collapse" data-target="js-exportCitations">Export citations</h3>
    <div id="js-exportCitations" class="export-citations-content panel">
        <div class="panel__section">
            <h4 class="panel__title">Citations & References</h4>
            <ul class="ListDownload" id="articleReferences">
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Papers, Zotero, Reference Manager, RefWorks citations and references"
                       data-event-label="10.1186/1471-2407-12-304"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1471-2407-12-304?format=refman&flavour=full">Papers, Zotero, Reference Manager, RefWorks <span>(.RIS)</span></a>
                </li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download EndNote citations and references" data-event-label="10.1186/1471-2407-12-304"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1471-2407-12-304?format=endnote&flavour=full">EndNote <span>(.ENW)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Mendeley, JabRef citations and references" data-event-label="10.1186/1471-2407-12-304"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1471-2407-12-304?format=bibtex&flavour=full">Mendeley, JabRef <span>(.BIB)</span></a></li>
            </ul>
        </div>
        <div class="panel__section">
            <h4 class="panel__title">Article citation</h4>
            <ul class="ListDownload">
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Papers, Zotero, Reference Manager, RefWorks article citations" data-event-label="10.1186/1471-2407-12-304"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1471-2407-12-304?format=refman&flavour=citation">Papers, Zotero, Reference Manager, RefWorks <span>(.RIS)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download EndNote article citations" data-event-label="10.1186/1471-2407-12-304"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1471-2407-12-304?format=endnote&flavour=citation">EndNote <span>(.ENW)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Mendeley, JabRef article citations" data-event-label="10.1186/1471-2407-12-304"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1471-2407-12-304?format=bibtex&flavour=citation">Mendeley, JabRef <span>(.BIB)</span></a></li>
            </ul>
        </div>
        <div class="panel__section">
            <h4 class="panel__title">References</h4>
            <ul class="ListDownload">
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Papers, Zotero, Reference Manager, RefWorks references" data-event-label="10.1186/1471-2407-12-304"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1471-2407-12-304?format=refman&flavour=references">Papers, Zotero, Reference Manager, RefWorks <span>(.RIS)</span></a>
                </li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download EndNote references" data-event-label="10.1186/1471-2407-12-304"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1471-2407-12-304?format=endnote&flavour=references">EndNote <span>(.ENW)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Mendeley, JabRef references" data-event-label="10.1186/1471-2407-12-304"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1471-2407-12-304?format=bibtex&flavour=references">Mendeley, JabRef <span>(.BIB)</span></a></li>
            </ul>
        </div>
    </div>

                                </div>
                                <div class="SideBox">
                                    <nav xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="ArticleNavigation" class="table-of-contents" aria-label="table of contents"><div class="table-of-contents__content" data-sticky="toc"><h3 class="table-of-contents__title is-open" data-toggle="collapse" data-target="tocMenu" data-event-category="Table of Contents" data-track-event="click" data-event-action="Toggle ToC" data-event-label="Toggle" data-toggle-disable-clickoff="true" aria-expanded="true">Table of Contents</h3><ul class="table-of-contents__menu is-open" role="menu" id="tocMenu" aria-expanded="true"><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Abs1" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Abstract">Abstract</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec1" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Introduction">Introduction</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec2" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Review">Review</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec14" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Conclusions">Conclusions</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec15" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Authors contributions">Authors contributions</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Declarations" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Declarations">
                        Declarations
                      </a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Bib1" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="References">References</a></li><li role="menuitem" class="table-of-contents__item is-hidden"><a class="table-of-contents__link" href="#comments" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Comments">Comments</a></li></ul></div></nav>
                                </div>
                                <div class="SideBox">
                                    <h3 class="SideBox_title">Metrics</h3>
                                    <ul class="SideBox_list list-stacked list-stacked--small list-stacked--2">
                                        <div id="article-access-count-loader" class="placeholder" data-replace="true" data-placeholder="/placeholder/v1/article/access-count/10.1186/1471-2407-12-304 #accessCount-container"></div>
                                        <div id="citation-count-loader" class="placeholder" data-replace="true" data-placeholder="/placeholder/v1/article/citation-count/10.1186/1471-2407-12-304 #count-container"></div>
                                        <div id="altmetric-loader" class="placeholder" data-replace="true" data-placeholder="/placeholder/v1/article/altmetric/10.1186/1471-2407-12-304 #altmetric-container"></div>
                                    </ul>
                                </div>
                                
    <div id="sociaMediaShare" class="SideBox">
        <h3 class="SideBox_title">Share this article</h3>
        <ul id="shareButtons" class="share">
            <li class="share__item">
                <button id="shareOnTwitter" class="js-btnShareOnTwitter share__button share__button--twitter" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Twitter" data-event-label="10.1186/1471-2407-12-304">
                    <span class="sr-only">Share on Twitter</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnFacebook" class="js-btnShareOnFacebook share__button share__button--facebook" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Facebook" data-event-label="10.1186/1471-2407-12-304">
                    <span class="sr-only">Share on Facebook</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnLinkedIn" class="js-btnShareOnLinkedIn share__button share__button--linkedin" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share LinkedIn" data-event-label="10.1186/1471-2407-12-304">
                    <span class="sr-only">Share on LinkedIn</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnWeibo" class="js-btnShareOnWeibo share__button share__button--weibo" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Weibo" data-event-label="10.1186/1471-2407-12-304">
                    <span class="sr-only">Share on Weibo</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnGooglePlus" class="js-btnShareOnGplus share__button share__button--gplus" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Google+" data-event-label="10.1186/1471-2407-12-304">
                    <span class="sr-only">Share on Google Plus</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnReddit" class="js-btnShareOnReddit share__button share__button--reddit" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Reddit" data-event-label="10.1186/1471-2407-12-304">
                    <span class="sr-only">Share on Reddit</span>
                </button>
            </li>
        </ul>
    </div>

                                
    

                                
    

                                
    

                                <div class="SideBox">
                                    <h3 class="SideBox_title">Other Actions</h3>
                                    <ul class="list-stacked list-stacked--2 list-stacked--small">
                                        <li class="list-stacked__item">
                                            
    <a data-track-event="click" data-event-category="Article Page" data-event-action="Order article reprints" data-event-label="10.1186/1471-2407-12-304" href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=738&doi=10.1186%2F1471-2407-12-304&volume=12&issue=1&title=Myeloid+malignancies%3A+mutations%2C+models+and+management&author_name=Anne+Murati&start_page=1&end_page=15">Order reprint</a>

                                        </li>
                                    </ul>
                                </div>
                                
        
        <div id="sociaMediaAccounts" class="SideBox">
            <h3 class="SideBox_title">Follow</h3>
            <ul class="follow follow--inline">
                
                <li class="follow__item">
                    <a class="follow__link follow__link--twitter-2" href="https://twitter.com/BMC_series" data-track-event="click" data-event-category="Social Media"
                       data-event-action="Click Follow Social Media" data-event-label="Twitter">
                        <span class="follow__label">Follow us on Twitter</span>
                    </a>
                </li>
                

                

                
            </ul>
        </div>
        
    
                            </aside>
                            
    <div id="FulltextAd" class="adsbox Ad Ad--skyscraper">
        <div class="Ad_content">
            <p class="Ad_label">Advertisement</p>
            <span id="pbgrd-43415139"></span>
        </div>
    </div>

                        </div>
                    </div>
                </div>
            </div>
        </main>
        
            <div class="journal-footer">
                <div class="journal-footer__inner">
                    <div class="journal-footer__summary">
                        <h4 class="journal-footer__title">
                            
                            <span class="journal-footer__title-text">BMC Cancer</span>
                        </h4>
                        <p class="journal-footer__issn">ISSN: 1471-2407</p>
                    </div>
                    
                        <div class="journal-footer__contact">
                            <h4 class="journal-footer__contact-title">Contact us</h4>
                            <ul class="journal-footer__contact-list">
                                
                                    <li class="journal-footer__contact-item">Editorial email: <a href="mailto:bmccancer@biomedcentral.com">bmccancer@biomedcentral.com</a></li>
                                
                                
                                    <li class="journal-footer__contact-item">Support email: <a href="mailto:info@biomedcentral.com">info@biomedcentral.com</a></li>
                                
                            </ul>
                        </div>
                    
                </div>
            </div>
        
         
    <footer>
        <div class="footer">
            <div class="footer__header">
                <img srcset="/static/images/biomed-central-logo-white-3c6c941205.svg" src="/static/images/biomed-central-logo-white-faac4202d5.png" class="logo__img footer__logo" alt="Biomed Central" />
                
                    <h2 class="footer__menu-title">Publisher Main Menu</h2>
                    <ul class="footer__primary-menu">
                        
                            <li class="footer__primary-item">
                                <a class="footer__link footer__primary-link" href="//www.biomedcentral.com/journals">Explore journals</a>
                            </li>
                        
                            <li class="footer__primary-item">
                                <a class="footer__link footer__primary-link" href="//www.biomedcentral.com/getpublished">Get published</a>
                            </li>
                        
                            <li class="footer__primary-item">
                                <a class="footer__link footer__primary-link" href="//www.biomedcentral.com/about">About BioMed Central</a>
                            </li>
                        
                    </ul>
                
            </div>
            <div id="Test-FooterExists" class="footer__content">
                <div class="footer__legal">
                    
                    <p class="footer__terms">By continuing to use this website, you agree to our <a class="footer__link footer__link--inline" href="//www.biomedcentral.com/terms-and-conditions">Terms and Conditions</a>, <a class="footer__link footer__link--inline"
                                                                                                                                                                                                                               href="//www.biomedcentral.com/terms-and-conditions/privacy-statement">Privacy
                        statement</a> and <a class="footer__link footer__link--inline" href="//www.biomedcentral.com/cookies">Cookies</a> policy.</p>
                </div>
                
    <nav id="publisherFooter" class="footer__nav">
        <h3 class="footer__menu-title">Publisher secondary menu</h3>
        <div class="footer__nav-inner">
            
            <div class="footer__menu">
                <ul class="footer__list">
                    
                    <li class="footer__item">
                        <a class="footer__link" href="http://blogs.biomedcentral.com/">Read more on our blogs</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/login">Receive BMC newsletters</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/account">Manage article alerts</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="http://authorservices.springernature.com/language-editing/">Language editing for authors</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="http://authorservices.springernature.com/scientific-editing/">Scientific editing for authors</a>
                        
                    </li>
                    
                </ul>
            </div>
            
            <div class="footer__menu">
                <ul class="footer__list">
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/policies">Policies</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/accessibility">Accessibility</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/press-centre">Press center</a>
                        
                    </li>
                    
                </ul>
            </div>
            
            <div class="footer__menu">
                <ul class="footer__list">
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/contact-us">Contact us</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="https://biomedcentral.typeform.com/to/VLXboo">Leave feedback</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/jobs">Careers</a>
                        
                    </li>
                    
                </ul>
            </div>
            
            <div class="footer__menu footer__menu--follow">
                <div class="footer__follow">
                    <h3 class="footer__follow-title">Follow BioMed Central</h3>
                    <ul class="follow follow--inline">
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--twitter" href="https://twitter.com/biomedcentral" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Twitter">
                                <span class="follow__label">Twitter</span>
                            </a>
                        </li>
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--facebook" href="https://www.facebook.com/BioMedCentral" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Facebook">
                                <span class="follow__label">Facebook</span>
                            </a>
                        </li>
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--gplus" href="https://plus.google.com/106226337984152901734/" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Google Plus">
                                <span class="follow__label">Google Plus</span>
                            </a>
                        </li>
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--weibo" href="http://www.weibo.com/biomedcentral" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Weibo">
                                <span class="follow__label">Weibo</span>
                            </a>
                        </li>
                    
                    </ul>
                </div>
            </div>
        </div>
    </nav>


            </div>
        </div>
        <div class="branding-bar">
            <div class="logo branding-bar__logo">
                <img srcset="/static/images/logo-springernature-4230d19d5c.svg" src="/static/images/logo-springernature-828f4f84c8.png" class="logo__img branding-bar-logo__img" alt="Springer Nature Logo" />
            </div>
            <p class="branding-bar__copyright">&#169; 2017 BioMed Central Ltd unless otherwise stated. Part of <a class="branding-bar__link" href="http://www.springernature.com">Springer Nature</a>.</p>
        </div>
    </footer>
    <noscript class="js-cookie-banner-noscript">
        <div class="cookie-banner js-cookie-banner">
            <div class="cookie-banner__inner">
                <p class="cookie-banner__message">
                    We use cookies to improve your experience with our site.
                    <a href="https://www.biomedcentral.com/cookies"
                       class="cookie-banner__link"
                       data-track-event="click"
                       data-event-category="EU Cookie Law Banner"
                       data-event-action="Find out more">More information <span class="sr-only">about our cookie policy</span>
                    </a>
                </p>
                <button hidden class="cookie-banner__dismiss js-cookie-banner-dismiss"
                        data-track-event="click"
                        data-event-category="EU Cookie Law Banner"
                        data-event-action="Close"><span class="cookie-banner__dismiss-text">Close</span>
                </button>
            </div>
        </div>
</noscript>


    </div>
    
    <img class='tracker' style='display:none' src='/track/article/10.1186/1471-2407-12-304' alt=""/>

    <div id="JFulltext"></div>

    
    <script type="text/javascript" src="//cdn.pbgrd.com/bmc.js" async="async"></script>

    

    
<script>
(function() {
    var linkEl = document.querySelector('.js-ctm');
    if (linkEl && window.matchMedia && window.matchMedia(linkEl.media)) {
        var vendorScript = document.createElement('script');
        vendorScript.src = '/static/js/oscar-vendor-67103b4f35.js';
        vendorScript.async = false;
        document.body.appendChild(vendorScript);
        var appScript = document.createElement('script');
        appScript.src = '/static/js/oscar-app-4e91ea0ef9.js';
        appScript.async = false;
        document.body.appendChild(appScript);
    }
})();
</script>



<script type="text/javascript">
    if (config) {
        (function (d) {
            Array.prototype.forEach.call(d.getElementsByClassName('RealMediaAd'), function (adElement) {
                var iframe = d.createElement('iframe');
                iframe.frameBorder = '0';
                iframe.scrolling = 'no';
                var position = adElement.getAttribute("data-position"),
                        iframeInDoc = adElement.getElementsByClassName('Ad_content')[0].appendChild(iframe),
                        doc = iframeInDoc.contentWindow.document;

                doc.open().write('<body onload="window.location.href = '
                        + '\'/placeholder/v1/advertising/realMedia?siteWithPath=' + encodeURIComponent(config.siteWithPath)
                        + '&placement=' + position + '\';">');
                doc.close();
            });
        })(document);
    }
</script>



    
        <script type="text/javascript">
            document.addEventListener('readystatechange', function () {
                if (document.readyState === 'complete') {
                    setTimeout(function () {
                        var script = document.createElement("script");
                        script.type = "text/javascript";
                        script.src = "https://recommendations.springernature.com/latest/entry-point.js";
                        document.getElementsByTagName("head")[0].appendChild(script);
                    }, 0);
                }
            });
        </script>
    


    <script type="text/javascript">
        var _kiq = _kiq || [];
        (function () {
            setTimeout(function () {
                var d = document, f = d.getElementsByTagName('script')[0], s = d.createElement('script');
                s.type = 'text/javascript';
                s.async = true;
                s.src = '//s3.amazonaws.com/ki.js/47412/9CC.js';
                f.parentNode.insertBefore(s, f);
            }, 1);
            setTimeout(function () {
                var d = document, f = d.getElementsByTagName('script')[0], s = d.createElement('script');
                s.type = 'text/javascript';
                s.async = true;
                s.src = '//s3.amazonaws.com/ki.js/47412/aC6.js';
                f.parentNode.insertBefore(s, f);
            }, 1);
        })();
    </script>


<noscript>
	<img hidden src="https://verify.nature.com/verify/nature.png" border="0" width="0" height="0" style="display: none">
</noscript>
</body>
</html>

